CCO Infectious Disease Podcast: Recent Episodes
Clinical Care Options
Weekly updates on new data and best practices in patient care for a variety of infectious diseases including COVID-19, HIV, and viral hepatitis, from Clinical Care Options. Gain practical strategies and earn CME/CE credit for selected episodes.
Mental health care is HIV care! It is reasonable and feasible to screen for and treat mild to moderate cases of substance use disorder, depression, and anxiety in HIV primary care. Featuring audio from a live webinar presented by experts Kathleen Page, MD, and Glenn Treisman, MD, PhD, this case-based virtual Grand Rounds series explores practical strategies for integrating mental health care into routine HIV clinical practice. Visit the program page to follow along with the downloadable slides and to view other related activities.
Topics covered include:
- Strategies for screening for mental health conditions as part of HIV care
- Deciding when to continue management vs refer
- Actionable ways to support engagement in care and ART adherence
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Kathleen Page, MD
Professor of Medicine
Division of Infectious Diseases
Johns Hopkins School of Medicine
Baltimore, Maryland
Glenn J. Treisman, MD, PhD
Eugene Meyer III Professor of Psychiatry and Medicine
Departments of Psychiatry and Behavioral Sciences and Internal Medicine
Johns Hopkins Hospital
Baltimore, Maryland
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
With this podcast, featuring audio from a Medical Minute webcast, expert faculty Maria Londoño, MD, PhD, discusses how recent clinical trial and real-world data can improve treatment plans for patients with PBC. Listen now and visit the program page to download the accompanying slides.
Topics covered include:
- Real-world Evidence for Treatment with PPAR Agonists
- PPAR Agonists for People With Prior Second-line Treatment
- PPARs Agonists for People With ALP 1.00-1.67x ULN
- Biochemical Response and Liver Stiffness
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Maria Londoño, MD, PhD
Consultant Hepatologist
Hospital Clinic Barcelona
Associate Professor
University of Barcelona
Barcelona, Spain
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Just as pneumonia isn’t “just a cold,” the pneumococcal vaccine does much more than just protect yourself or your child against pneumonia. Listen in and learn from experts Robert H. Hopkins, Jr., MD, and Brenda L. Tesini, MD, how to discuss the full benefits of pneumococcal vaccine.
Topics covered include:
- Burden of pneumococcal disease among pediatric and older adult populations in the United States
- Risk factors for severe pneumococcal disease
- Which pneumococcal vaccines to use for certain populations and why
- How pneumococcal vaccination protects from long-term sequelae and potential community benefits of vaccination
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Robert H. Hopkins, Jr., MD
Professor of Internal Medicine and Pediatrics
Division of General Internal Medicine
University of Arkansas for Medical Sciences, School of Medicine
Little Rock, Arkansas
Brenda L. Tesini, MD
Associate Professor of Medicine, Pediatrics, and Community Health
Division of Infectious Diseases
University of Rochester Medical Center
Rochester, New York
Link to program page:
https://bit.ly/3SuymiN
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In the final episode of a 3-part series, featuring audio from a live symposium, experts Mary Koslap-Petraco, DNP, PPCNP, CPNP, FAANP, Patricia Stinchfield, MS, RN, PNP, and Jennifer M. Walsh, DNP, CPNP-PC, CNE explore how to use “prebunking” strategies to inoculate patients and caregivers against vaccine misinformation and disinformation, as well as proven strategies to provide effective vaccine recommendations. Visit the program page to view the full on-demand webcast and download the accompanying slides.
Topics covered include:
- “Prebunking” Tactics
- Presumptive Recommendations
- Motivational Interviewing Principles
- Responding to Arguments Against Immunization
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Mary Koslap-Petraco, DNP, PPCNP, CPNP, FAANP
Clinical Assistant Professor
Stony Brook University School of Nursing
Nurse Consultant
Immunize.org
Owner/NP Pediatric Nurse Practitioner House Calls
Stony Brook, New York
Patricia Stinchfield, MS, RN, PNP
Independent Consultant
Victoria, Minnesota
(Retired) Senior Director, Infection Prevention & Control, Infectious Disease
Children’s Minnesota
Immediate Past President, National Foundation for Infectious Diseases
Minneapolis, Minnesota
Jennifer M. Walsh, DNP, CPNP-PC, CNE
Certified Pediatric Nurse Practitioner – Primary Care
Assistant Professor
School of Nursing
George Washington University
Washington, DC
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In the second episode of a 3-part series featuring audio from a live symposium, experts Mary Koslap-Petraco, DNP, PPCNP, CPNP, FAANP, Patricia Stinchfield, MS, RN, PNP, and Jennifer M. Walsh, DNP, CPNP-PC, CNE explore effective strategies to counter common myths and misconceptions about vaccines, including actionable methods to champion the benefits and safety of pediatric vaccines. Visit the program page to view the full on-demand webcast and download the accompanying slides.
Topics covered include:
- Debunking the Link Between Vaccines and Autism
- Reemergence of Previously Eliminated Diseases
- Building Trust With Parents and Caregivers
- Who and How to Debunk Vaccine Misinformation
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Mary Koslap-Petraco, DNP, PPCNP, CPNP, FAANP
Clinical Assistant Professor
Stony Brook University School of Nursing
Nurse Consultant
Immunize.org
Owner/NP Pediatric Nurse Practitioner House Calls
Stony Brook, New York
Patricia Stinchfield, MS, RN, PNP
Independent Consultant
Victoria, Minnesota
(Retired) Senior Director, Infection Prevention & Control, Infectious Disease
Children’s Minnesota
Immediate Past President, National Foundation for Infectious Diseases
Minneapolis, Minnesota
Jennifer M. Walsh, DNP, CPNP-PC, CNE
Certified Pediatric Nurse Practitioner – Primary Care
Assistant Professor
School of Nursing
George Washington University
Washington, DC
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Pneumococcal vaccine recommendations are constantly evolving to respond to shifting patterns of infections, which is a good thing. However, the nuances can be complicated to explain to patients. Listen in to learn how experts Richard Colgan, MD and Brenda L. Tesini, MD, discuss changing pneumococcal vaccine recommendations. Topics covered include:
- Epidemiologic changes: S. pneumoniae over time
- Burden on patients and the health system
- Adjustments to pneumococcal vaccine recommendations
- Considerations for vaccine selection
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Richard Colgan, MD
Professor Emeritus
Department of Family and Community Medicine
University of Maryland School of Medicine
Medical Alumni Association
Carolyn Frenkil Selvin Passen History of Medicine
Scholar in Residence
Baltimore, Maryland
Brenda L. Tesini, MD
Associate Professor of Medicine, Pediatrics, and Community Health
Division of Infectious Diseases
University of Rochester Medical Center
Rochester, New York
Link to program page:
https://bit.ly/3RNHkHr
Links mentioned in this episode:
PneumoRecs VaxAdvisor App for Vaccine Providers | Pneumococcal | CDC
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Viral hepatitis is an ongoing public health threat, despite the long-standing availability of effective vaccines for hepatitis A and B. Here, experts Paul Kwo, MD, Jewel Mullen, MD, MPH, MPA, FACP, and Su Wang, MD, MPH, FACP, discuss how to incorporate knowledge of hepatitis A and B risk factors and disease burden into patient counseling to enhance uptake of hepatitis A and B vaccines. Topics covered include:
- The burden of hepatitis A and B in the United States
- Risk factors for infection
- Current evidence-based recommendations for hepatitis A and B vaccination.
Follow along with the slides here, and get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Stanford, California
Jewel Mullen, MD, MPH, MPA, FACP
Associate Professor of Population Health and Internal Medicine
University of Texas at Austin Dell Medical School
Austin, Texas
Su Wang, MD, MPH, FACP
Medical Director, Center for Asian Health & Viral Hepatitis Programs
Cooperman Barnabas Medical Center/RWJBarnabas-Rutgers Medical Group
Assistant Clinical Professor, Rutgers New Jersey Medical Group
Florham Park, New Jersey
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in to learn the latest on ART switch strategies for people living with virologically suppressed HIV. Hear from experts Chloe Orkin, MBChB, FRCP, MD, and Peter J. Ruane, MD, as they review how the recent approvals fit in the treatment landscape of 2-drug, single-tablet regimens. Stream on the go or follow along with our expert-curated slides.
Topics covered include:
- Guideline recommendations on ART switch in the setting of virologic suppression
- Phase III clinical trial data supporting ART switch
- Individual considerations for ART switch
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Dean for Healthcare Transformation
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom of Great Britain and Northern Ireland
Honorary Consultant Physician
Barts Health NHS Trust
London, United Kingdom
Peter J. Ruane, MD
President
Ruane Clinical Research
Los Angeles, California
Link to program page:
https://bit.ly/3PkPoP4
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen now as experts, Chloe Orkin, MBChB, FRCP, MD, and Jihad Slim, MD, explore the potential clinical implications of new data on novel options for optimizing HIV therapy, especially for treatment-experienced people with challenges using currently available regimens, high pill burdens, and reduced adherence. Listen on the go or follow along with our expert-curated slides. Topics covered include:
- Current Options for Simplifying ART
- DHHS and EACS Recommendations for 2-Drug Regimens
- The Latest Results of the ARTISTRY-1 and -2 Trials
- Future Directions for HIV Therapy
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Dean for Healthcare Transformation
Faculty of Medicine and Dentistry
Queen Mary University of London
Honorary Consultant Physician
Barts Health NHS Trust
London, United Kingdom
Jihad Slim, MD
Assistant Professor of Medicine
New York Medical College
Valhalla, New York
Chief of Infectious Disease
Saint Michael’s Medical Center
Newark, New Jersey
Link to program page:
https://bit.ly/4u31NGv
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen as Bright Ansah, patient advocate, describes his experience with being diagnosed with chronic hepatitis B as a recent immigrant to the United States and the unique barriers to treatment faced by the African immigrant community. Through his story, learn how healthcare professionals can reduce these barriers for this key population.
Topics covered include:
- Key barriers to care for African immigrant patients
- Myths and misconceptions about HBV in the African immigrant community
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Link to program page:
https://bit.ly/4uz25Vc
Presenter:
Bright Ansah
HBV Patient Advocate
Frederick, Maryland
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen as experts Charlotte-Paige Rolle, MD, MPH, and Paul E. Sax, MD, discuss the most recent studies on emerging treatment options for treatment-experienced people living with HIV. Topics covered include:
- ARTISTRY-1 and -2 data on the investigational combination of BIC/LEN
- Data on investigational DOR/ISL, specifically in people with multidrug-resistant HIV
- bNAb combinations
- SUPLA trial of LA CAB plus RPV in people with viremia who have challenges with their oral regimens
To download the accompanying slides, please visit the program page:
https://bit.ly/4cHPI1Y
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Charlotte-Paige Rolle, MD, MPH
Director of Research Operations
Orlando Immunology Center
Adjunct Assistant Professor of Global Health
Emory University Rollins School of Public Health
Atlanta, Georgia
Paul E. Sax, MD
Clinical Director, Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
For US veterans, support for continued engagement in hepatitis B (HBV) care has been lacking. Listen in as Richelle M. Gaiter, DMSc, MPAS, Med, shares her experiences with HBV care as an Air Force veteran and what can be done to improve HBV care for veterans and civilians alike. Topics include:
- Key barriers to HBV care for US veterans
- What has improved in the last decade
- Strategies for improved engagement in care
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify.
Link to program page:
https://bit.ly/4vAqSJT
Presenter:
Richelle M. Gaiter, CMSGT Retired USAFR, DMSc, MPAS, Med
Family Medicine, Prevention, Patient Education
Crescent City, California
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Unwanted body habitus changes among people living with HIV receiving antiretroviral therapy (ART) can negatively affect physical and mental health and may even affect ART adherence. Listen to learn from experts Grace A. McComsey, MD, FIDSA, and Richard A. Elion, MD, how to identify people who may be candidates for pharmacologic weight interventions, and hear firsthand from patient advocates how unwanted weight gain impacts their daily life.
Topics covered include:
- The burden of unwanted weight gain among people living with HIV
- Potential causes for unwanted weight gain
- Available pharmacologic agents for weight loss
- Clinical trial data supporting pharmacologic agents for weight loss in people living with HIV
- Patient advocate perspectives
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify.
Link to full program:
https://bit.ly/4cpeJ1I
Presenters:
Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University School of Medicine
Washington, DC
Grace A. McComsey, MD, FIDSA
Vice Dean for Clinical and Translational Research
Director, Clinical and Translational Science Institute (CTSI)
Principal Investigator, Clinical and Translational Science Collaborative (CTSC) of Northern Ohio
Gertrude Chandler Tucker Professor of Pediatrics and Medicine
Case Western Reserve University
Research Integrity Officer
Senior Faculty, Pediatric and Adult Infectious Diseases
University Hospitals Health System
Cleveland, Ohio
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, featuring audio from a local live workshop, experts Richard Colgan, MD, and Christopher Smith, MD, explore the burden of complicated urinary tract infection (cUTI) on patients and the healthcare system, highlight advances in the treatment of complicated UTIs, and examine approaches to empiric and definitive antibiotic therapy. Topics covered include:
- The Burden of cUTI and Antimicrobial Resistance
- Changes in IDSA Guidelines for cUTI
- Diagnosing cUTI
- Selection of Empiric and Definitive Therapy
- Novel Treatments for cUTI
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Richard Colgan, MD
Professor Emeritus
Department of Family and Community Medicine
University of Maryland School of Medicine
Baltimore, Maryland
Christopher Smith, MD
Infectious Disease Physician
Chase Brexton Healthcare
Clinical Assistant Professor
Shock Trauma Center, University of Maryland Medical Center
Baltimore, Maryland
Link to program page:
https://bit.ly/3Q4TgDK
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
“Good enough” is no longer good enough when caring for treatment-experienced people with HIV. Tune in to find out what’s new in management of multidrug-resistant HIV and dig into the latest data from CROI 2026. Topics covered include:
Real-world experiences with LEN in the United States and Europe for management of multidrug-resistant HIV
- Pharmacokinetic profiles of combined LA CAB + LEN
- Ibalizumab for multidrug-resistant HIV
- Long-term 7-year outcomes for heavily treatment–experienced people living with HIV and 4-class drug resistance
To download the accompanying slides, please visit the program page:
https://bit.ly/4pEenZC
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Onyema Ogbuagu, MD, FACP, FIDSA
Professor of Medicine and Pharmacology
Director, Yale Antivirals and Vaccines Research Program
Yale School of Medicine
New Haven, Connecticut
Charlotte-Paige Rolle, MD, MPH
Director of Research Operations
Orlando Immunology Center
Adjunct Assistant Professor of Global Health
Emory University Rollins School of Public Health
Atlanta, Georgia
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune into this podcast, featuring audio from a live conference coverage webinar, to learn from global experts, Monica Gandhi, MD, MPH, and Jean-Michel Molina, MD, as they summarize and discuss the latest updates on HIV treatment and prevention from CROI 2026. Topics covered include:
- Emerging HIV treatments
- Advances in HIV prevention
- Investigational agents for HIV prevention
- Early-phase investigational HIV treatments
For more coverage of CROI 2026, and to follow along with the downloadable slides, visit the program page:
https://bit.ly/4bmS062
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Monica Gandhi, MD, MPH
Professor of Medicine and Associate Chief
Division of HIV, Infectious Diseases, and Global Medicine
Director, UCSF Center for AIDS Research (CFAR)
Director of HIV Special Program
"Ward 86" HIV Clinic
San Francisco General Hospital
San Francisco, California
Jean-Michel Molina, MD
Professor of Medicine
Saint-Louis and Lariboisire Hospitals
Université Paris Cité
Paris, France
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT), but there have been major advances in CMV management to date. In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV.
Topics include:
- Considerations for CMV management in HCT recipients
- New definitions of refractory and resistant CMV
- Risk factors for refractory and resistant CMV infections
- Identifying drug-resistant CMV
- Treatment options for refractory/resistant CMV
To view the full educational program and download the accompanying slides, visit our website:
https://bit.ly/4lfrDTT
Presenters:
Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID
Professor and Chair
G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases
President, The International Immunocompromised Host Society (ICHS)
Director, Clinical Virology Research
Department of ID/IC/EH
UT MD Anderson Cancer Center
Houston, Texas
Marcus Pereira, MD, MPH, FAST
Associate Professor of Medicine
Director of Clinical Services, Division of Infectious Diseases
Medical Director, Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Cytomegalovirus (CMV) infection is one of the most significant infectious complications after hematopoietic cell transplant (HCT). In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID and Marcus Pereira, MD, MPH, FAST, discuss the burden of CMV in HCT recipients and explore strategies effectively identify and monitor high-risk patients. Topics include:
- Epidemiology of CMV among HCT recipients
- Direct and indirect effects of CMV after HCT
- Dynamics of risk factors for CMV infection
- Strategies for prevention of CMV infection
To view the full educational program and download the accompanying slides, visit our website:
https://bit.ly/4lfrDTT
Presenters:
Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID
Professor and Chair
G.P. Bodey, Sr. Distinguished Professorship in Infectious Diseases
President, The International Immunocompromised Host Society (ICHS)
Director, Clinical Virology Research
Department of ID/IC/EH
UT MD Anderson Cancer Center
Houston, Texas
Marcus Pereira, MD, MPH, FAST
Associate Professor of Medicine
Director of Clinical Services, Division of Infectious Diseases
Medical Director, Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, experts Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH; Ruth Carrico, PhD, DNP, FNP-C, FAAN; and Dalilah Restrepo, MD, discuss improving shingles vaccine uptake. Topics covered include:
- The Burden of Shingles
- Care Coordination Between Primary and Specialty Care
- Promoting Shingles Vaccine Series Completion
- Addressing Disparities in Shingles Vaccine Access and Uptake
Presenters:
Jacinda (JAM) Abdul-Mutakabbir, PharmD, MPH
Associate Professor of Clinical Pharmacy
University of California, San Diego
Department of Pharmacy Practice and Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences
Division of the Black Diaspora and African American Studies
La Jolla, California
Ruth Carrico, PhD, DNP, FNP-C, FAAN
Senior Partner
Carrico & Ramirez PLLC
Professor, Adjunct
Division of Infectious Diseases
University of Louisville School of Medicine
Louisville, Kentucky
Dalilah Restrepo, MD
Infectious Diseases Specialist
University of California, Irvine
Los Alamitos Hospital
Orange County, California
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Historically, key symptoms of primary biliary cholangitis (PBC), such as pruritus and fatigue, have been understudied and undertreated. Listen now to learn how symptom management should be considered independently of PBC management, and how new therapeutic agents can help.
Topics covered include:
- Mechanisms of pruritus and fatigue in PBC
- Nonpharmacologic treatment options
- An overview of clinical trial data supporting second-line agents for symptom management:
- Bezafibrate
- Elafibranor
- Seladelpar
- Investigational agents:
- Volixibat
- Linerixibat
- Setanaxib
This episode is the third of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode:
https://bit.ly/44ZJ5os
Presenters:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Aliya F. Gulamhusein, MD,
MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada
Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
New therapeutic agents for second-line treatment are raising the bar for primary biliary cholangitis (PBC) management. Listen now to learn how to incorporate these new agents into clinical practice and how these agents will impact attainment of treatment goals.
Topics covered include:
- Available agents for second-line treatment of PBC
- An overview of clinical trial data supporting second-line agents:
- Obeticholic acid (OCA)
- Bezafibrate
- Elafibranor
- Seladelpar
This episode is the second of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/48MEc3r
Presenters:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Aliya F. Gulamhusein, MD, MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada
Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Advancements in our understanding of primary biliary cholangitis (PBC) and new therapeutic agents have reshaped the care landscape of PBC. Listen now to learn how these developments are helping to redefine and elevate treatment goals. Topics covered include:
- How and when to assess treatment response
- Risk factors in PBC
- Biochemical treatment response and fibrosis stage as predictors of transplant-free survival
- Dynamics of liver stiffness measurements and clinical outcomes in PBC
- The importance of bilirubin and alkaline phosphatase normalization
This episode is the first of 3 recap podcasts, featuring audio from our live satellite symposium, Raising the Bar: Innovations in PBC Care. For the full on-demand webcast of this satellite symposium, and to download the accompanying slides, visit the program page for this episode: https://bit.ly/44ZJ5os
Presenters:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Aparna Goel, MD
Clinical Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Aliya F. Gulamhusein, MD, MPH, FRCPC
Professorship in PSC Research
Clinician Investigator, Toronto General Hospital
Assistant Professor, University of Toronto
Division of Gastroenterology and Hepatology
University Health Network
Toronto, Canada
Get access to all of our new episodes by subscribing to the Decera Clinical Education Medical Specialties Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune in to listen as expert faculty, Dr Christopher L. Bowlus and Dr Sonal Kumar, discuss recent developments in treating primary biliary cholangitis (PBC) with new and emerging agents, as well as strategies to integrate these advances into clinical practice.
Topics covered include:
- Methods of Assessing PBC Disease Progression
- Newer Agents for Second-line Treatment of PBC
- Prioritizing Symptom Management and Quality of Life With PBC Treatment
Presenters:
Christopher L. Bowlus, MD
Lena Valenta Professor and Chief
Division of Gastroenterology and Hepatology
School of Medicine
University of California Davis
Sacramento, California
Sonal Kumar, MD, MPH
Assistant Professor of Medicine
Division of Gastroenterology and Hepatology
Weill Cornell Medical College
New York, New York
Link to full program:
https://bit.ly/43nHx6U
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Nancy Reau, MD, reviews key highlights of the most impactful primary biliary cholangitis (PBC) research and gain insights on how to apply these new advances to clinical practice.
Topics covered include:
- Treatment Goals
- Long-term Data With PPAR Agonists
- Investigational Therapies for Pruritus
Presenter:
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois
To download the accompanying slides, visit the program page for this episode:
https://bit.ly/4b2d6YD
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Recent advances in primary biliary cholangitis (PBC) care have resulted in a new focus on personalized care and symptom management. Tune in to learn from patient advocate, Maria G. Morais, RN, how you can integrate patient insights and priorities into treatment plans for PBC. Topics covered include:
- The Canadian PBC Society Survey: Comorbidities and Treatment Goals
- Defining and Achieving Goal-Driven Care for PBC
- Recent Advances in PBC Management
- Newer Agents for Second-line Treatment of PBC
Presenters:
Maria G. Morais, RN
PBC Transplant Patient
VP Patient Advocacy
Canadian PBC Society
Toronto, Canada
Link to full program:
https://bit.ly/44ySoL3
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen to this podcast featuring highlights from our expert roundtable discussion to learn about the most pressing issues in pediatric influenza vaccines, including current vaccine technologies, recent vaccine uptake and epidemiologic trends, and how to discuss the vast benefits of timely vaccination in pediatric patients with their parents and caregivers. Topics covered include:
- Groups at High Risk for Complications
- Guideline Recommendations for Influenza Vaccination
- Available Seasonal Flu Vaccine Formulations and Their Characteristics
- Practical Considerations for Selecting Pediatric Influenza Vaccines
- Uptake of Influenza Vaccines in Children: Reversing the Trends
Presenters:
Ravi Jhaveri, MD, FIDSA, FPIDS, FAAP
Division Head
Pediatric Infectious Diseases
Ann & Robert H. Lurie Children’s Hospital of Chicago
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Tina Q. Tan, MD, FAAP, FIDSA, FPIDS
Professor of Pediatrics
Feinberg School of Medicine of Northwestern University
Pediatric Infectious Diseases Attending
Medical Director, International Adoptee Clinic
President, Lurie Medical/Dental Staff
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
Jennifer M. Walsh, DNP, CPNP-PC, CNE
Certified Pediatric Nurse Practitioner, Primary Care
Assistant Professor
George Washington University
School of Nursing
Washington, DC
Link to full program:
https://bit.ly/45UVzy6
Get access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune in as Princy N. Kumar, MD, MACP, FRCP, and Charlotte-Paige Rolle, MD, MPH discuss the latest in immune recovery, chronic inflammation, and more in the management of treatment-experienced people living with HIV.
Topics covered include:
- Immunologic nonresponse
- Theories around soluble gp120 and antibody-dependent cellular cytotoxicity
- Latest data from BRIGHTE, RECOVER, and more
- Future Directions
Presenters:
Princy N. Kumar, MD, MACP, FRCP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine
Vice Dean for Student Affairs
Georgetown University School of Medicine
Washington, DC
Charlotte-Paige Rolle, MD, MPH
Director of Research Operations
Orlando Immunology Center
Adjunct Assistant Professor of Global Health
Emory University Rollins School of Public Health
Atlanta, Georgia
To download the accompanying slides, please visit the program page:
https://bit.ly/4pEenZC
Get access to all of our new podcasts by subscribing on Apple Podcasts, YouTube Music, or Spotify!
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune into this podcast to revisit discussions led by global experts, Karine Lacombe, MD, PhD, and Chloe Orkin, MBChB, FRCP, MD, featuring the latest updates on HIV treatment and prevention from the 2025 IDWeek and EACS conferences.
Topics covered include:
- Real-world safety and efficacy of long-acting ART
- ART switch: preferences, treatment satisfaction, changes in weight and metabolic parameters, and HBV reactivation risk
- Investigational therapies
- Updates on long-acting PrEP: persistence, use in people with substance use disorder, and coadministration with gender-affirming hormone therapy
- HIV and STI screening with PrEP
- STI prevention
To download the accompanying slides, visit the program page for this episode:
https://bit.ly/3MGvegM
Presenters:
Karine Lacombe, MD, PhD
Professor of Medicine
Sorbonne University
Head of Infectious Diseases Unit
St Antoine Hospital, AP-HP
Paris, France
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
Honorary Consultant Physician
Barts Health NHS Trust
London, United Kingdom
Get access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, featuring audio from an expert roundtable video module, listen as 3 multidisciplinary faculty, Tracey Q. Davidoff, MD, FCUCM; Carina Marquez, MD, MPH; and Jeffrey D. Whitman, MD, MS, discuss the benefits of diagnosing respiratory syncytial virus (RSV) and optimal testing strategies. Topics covered include:
- The annual burden of RSV and the benefits of diagnosis
- Whom to test and what diagnostic techniques to use
- Logistical considerations for implementation
- Potential benefits of RSV testing
For the full video module and to download the accompanying slides, visit the program page for this episode:
https://bit.ly/3MrXTpI
Presenters:
Tracey Q. Davidoff, MD, FCUCM
Attending Physician
Baycare Urgent Care
Assistant Professor, Family Medicine
Florida State University College of Medicine
Tallahassee, Florida
Carina Marquez, MD, MPH
Associate Professor of Medicine
Division of HIV, Infectious Diseases and Global Medicine
University of California, San Francisco
San Francisco, California
Jeffrey D. Whitman, MD, MS
Co-Director of Clinical Microbiology
Associate Professor
Department of Laboratory Medicine
University of California, San Francisco
San Francisco, California
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Every day, I hear patients share worries shaped by the growing wave of vaccine misinformation—questions that reveal just how overwhelming today’s “infodemic” has become. In this podcast, I explore what vaccine hesitancy really looks like and how pharmacists can use empathy, strong recommendations, and meaningful dialogue to help rebuild confidence in immunization.
Presenter:
Mary Barna Bridgeman, PharmD, BCPS, BCGP
Clinical Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Internal Medicine Clinical Pharmacy Specialist
Robert Wood Johnson University Hospital-New Brunswick
New Brunswick, New Jersey
Link to full program:
https://bit.ly/4oHDWZq
Get access to all of our new episodes by subscribing to the Decera Clinical Education Infectious Diseases Podcast on Apple Podcasts, YouTube Music, or Spotify
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This episode focuses on hearing the voices of transgender people living with HIV and their advocates as they share what matters most to them when it comes to healthcare services and where HIV fits among those priorities. We also consider how these insights can assist healthcare professionals in configuring HIV care to better meet the needs of this key population. Topics addressed include:
- Overarching health and well-being priorities within the broader context of everyday life challenges
- Personal experiences of suboptimal interactions with healthcare services, and their impact on health-seeking behaviors
- Key components of a transgender-welcoming healthcare environment
- Principles of people-centered care including integrating HIV care with gender-affirming care
- Concerns regarding HIV management that HIV healthcare professionals should anticipate and address
Faculty:
Torrey Burke
Patient Advocate
United States
Erika Castellanos
Executive Director
Global Action for Trans Equality
The Netherlands
Aryah Lester, IC/SME
Patient Advocate
United States
Tanya Laguing
President DIOSSA (Decent Image of South Signal Association)
Hub Manager (Lily By LoveYourself x DIOSSA)
Hub Manager (Orange By LoveYourself x DIOSSA)
Taguig City, Philippines
Paranaque City, Philippines
Las Pinas, Philippines
Link to full program:
https://bit.ly/4oLXa08
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Molecular point-of-care testing has the potential to substantially mitigate the impact of sexually transmitted infections (STIs) on personal and public health. Listen in to learn how it may even limit the development of antimicrobial resistance. Topics covered include:
- CDC and US Preventive Services Task Force STI screening recommendations
- Whether or not laboratory-based STI tests contribute to increasing antibiotic resistance
- Role of point-of-care testing and strategies for implementation
Presenter:
Jeffrey D. Klausner, MD, MPH
Clinical Professor of Medicine
Population and Public Health Sciences Lead
Infectious Diseases Epidemiology and Applies Studies (I.D.E.A.S.) Initiative
Keck School of Medicine of the University of Southern California
Los Angeles, California
Link to full program:
https://bit.ly/4nS7rYE
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
The crux of HIV care and prevention is quick and accurate diagnosis. Listen in to learn from Aniruddha (Anu) Hazra, MD, and Dr. Nancy S. Miller about the advantages and potential pitfalls of different HIV testing algorithms to find out which one is best suited for your practice.
Presenters:
Aniruddha (Anu) Hazra, MD
Associate Professor, Section of Infectious Diseases and Global Health
Medical Director, UCM Sexual Wellness Clinic
Director of STI Services, Chicago Center of HIV Elimination
Department of Medicine
University of Chicago
Chicago, Illinois
Nancy S. Miller, MD
Medical Director, Clinical Microbiology and Molecular Diagnostics
Clinical Professor, Department of Pathology and Laboratory Medicine
Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine
Boston, Massachusetts
Link to full program:
https://bit.ly/4nS7rYE
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as experts Thomas P. Lodise, PharmD, PhD, and George Sakoulas, MD, FIDSA, explore tailored antibiotic strategies for diverse patients with acute bacterial skin and skin structure infections (ABSSSIs). Their insightful discussion focuses on antibiotic developments that followed publication of the IDSA practice guidelines in 2014 and the challenges unique to ABSSSIs, including a lack of determined bacterial etiology for many cases.
Presenters
Thomas P. Lodise, PharmD, PhD
Professor
Albany College of Pharmacy and Health Sciences
Infectious Diseases Clinical Pharmacy Specialist
Stratton VA Medical Center
Albany, New York
George Sakoulas, MD, FIDSA
Chief, Infectious Diseases
Sharp Rees-Stealy Medical Group
Adjunct Professor of Pediatrics
University of California San Diego School of Medicine
San Diego, California
Link to full program:
https://bit.ly/4oIKwzs
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Look beyond viral suppression to learn how people living with virologically suppressed HIV may still be candidates for antiretroviral therapy (ART) switch to improve treatment satisfaction and quality of life. Topics covered include:
- Reasons to consider regimen optimization in setting of viral suppression
- Available switch regimens, including 2-drug regimens and long-acting ART
- Approaches to assess for resistance before starting long-acting cabotegravir plus rilpivirine
- DHHS recommendations on proviral DNA genotyping
- ART optimization strategies for patients living with viral suppression and history of underlying resistance
Presenters:
Brian R. Wood, MD
Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington
Seattle, Washington
Cristina Mussini, MD
Professor of Infectious Diseases
Chief of the Division of Infectious Diseases, Policlinico, Modena
University of Modena and Reggio Emilia
Modena, Italy
Link to full program and accompanying slides:
https://bit.ly/4pAI66g
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join Ryan K. Shields, PharmD, MS, in the third of 3 podcasts from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients” to learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:
- Mechanisms of resistance in S. maltophilia
- Current frontline therapies
- 2024 IDSA guidance for treatment
Presenter:
Ryan K. Shields, PharmD, MS
Associate Professor of Medicine
Co-Director, Center for Innovative Antimicrobial Therapy
University of Pittsburgh
Co-Director, Antibiotic Management Program
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania
Link to full program and downloadable slides:
https://bit.ly/3JWaqRv
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join Marin H. Kollef, MD in the first of 3 podcasts from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients” to learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include
- Antimicrobial resistance mechanisms
- Diagnostic strategies for identifying resistance
- Antibiotic selection strategies
- Preferred and alternative antibiotics according to guideline recommendations
Presenter:
Marin H. Kollef, MD
Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine
Professor of Medicine
Division of Pulmonary & Critical Care Medicine
Director, Critical Care Research
Director, Respiratory Care Services
Washington University School of Medicine
St Louis, Missouri
Link to full program and downloadable slides:
CCO:
https://bit.ly/4omLRLB
ProCE:
https://bit.ly/4pA1Xm4
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join Ryan K. Shields, PharmD, MS, in the second of three recap podcasts taken from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients.” Learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:
- The diverse mechanisms of β-lactam resistance
- The effect of resistance mechanisms on susceptibility to antimicrobials
- 2024 IDSA guidance for treatment
- Considerations for antibiotic selection
- The role of combination therapy
Presenter:
Ryan K. Shields, PharmD, MS
Associate Professor of Medicine
Co-Director, Center for Innovative Antimicrobial Therapy
University of Pittsburgh
Co-Director, Antibiotic Management Program
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania
Link to full program and downloadable slides:
CCO:
https://bit.ly/3LXzate
ProCE:
https://bit.ly/3Mjao6G
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:
- Efficacy of switching to 2-drug oral ART: real-world evidence
- Real-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirine
- Patient selection to reduce risk of virologic failure with switch
- Regimen-specific switch considerations
Presenters:
Dima Dandachi, MD, MPH, FIDSA, FACP
Associate Professor of Medicine
Division of Infectious Diseases
University of Missouri
Medical Director
HIV Treatment and Prevention Program, MUHC
Medical Director
Boone County Public Health and Human Services
Columbia, Missouri
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
Honorary Consultant Physician
Barts Health NHS Trust
London, United Kingdom
Link to full program and accompanying slides:
https://bit.ly/3KPN0xb
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Unnecessary broad-spectrum antibiotics can drive antimicrobial resistance and cause adverse events, whereas inadequate antibiotic coverage is linked to increased mortality and length of stay for patients with bloodstream infections (BSIs). Listen now to learn from Jose Alexander, MD, D(ABMM), CIC, FCCM, SM/MB(ASCP), how to use rapid genotypic and phenotypic antimicrobial susceptibility testing results to inform antibiotic selection for patients with gram-negative BSIs. Topics covered include:
- Typical patterns of intrinsic antibiotic susceptibility and resistance in Enterobacterales
- Mechanisms of resistance in gram-negative bacteria
- Genotypic rapid diagnostic tests for BSIs
- Resistance markers for earlier targeted therapy
- Rapid phenotypic antimicrobial susceptibility test platforms for blood cultures
Presenter:
Jose Alexander, MD, D(ABMM), CIC, FCCM, SM/MB(ASCP)
Medical and Public Health Microbiologist
Medical and Technical Director of Microbiology
AdventHealth
Orlando, Florida
Link to full program and downloadable slides:
https://bit.ly/4inoXCx
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Rapid phenotypic antimicrobial susceptibility testing (AST) significantly reduces time to actionable results and can improve antibiotic decision-making for patients with bloodstream infections. Listen in to learn from Michael P. Veve, PharmD, MPH, how to optimally integrate rapid phenotypic AST into clinical practice, including incorporation into your existing antimicrobial stewardship workflow. Topics covered include:
- Considerations for implementation
- Decision-making steps for implementation
- The role of antimicrobial stewardship programs in AST workflow
Presenter:
Michael P. Veve, PharmD, MPH
Clinical Associate Professor
Department of Pharmacy Practice
Eugene Applebaum College of Pharmacy and Health Sciences
Wayne State University
Clinical Pharmacy Specialist, Infectious Disease
Henry Ford Hospital
Detroit, Michigan
Link to full program and downloadable slides:
https://bit.ly/4inoXCx
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Sepsis and bloodstream infections (BSIs) are common and cause millions of deaths each year, with a disproportionate burden in low-income and middle-income countries. Tune in to learn from Jasmine R. Marcelin, MD, FACP, FIDSA, how inadequate antibiotic coverage can be linked to increased mortality and length of stay and how unnecessary broad-spectrum antibiotics can drive antimicrobial resistance. Topics covered include:
- The worldwide burden of sepsis and BSIs
- The ongoing threat of antimicrobial resistance
- US and global health disparities in sepsis, BSI, and antimicrobial resistance
- Barriers toward optimizing antibiotic use in BSIs
Presenter:
Jasmine R. Marcelin, MD, FACP, FIDSA
Associate Professor, Infectious Disease
Associate Medical Director, Antimicrobial Stewardship Program
Vice Chair for Belonging and Community Engagement, Department of Internal Medicine
Co-Director, Digital Innovation & Social Media Strategy, Division of Infectious Diseases
University of Nebraska Medical Center
Omaha, Nebraska
Link to full program and downloadable slides:
https://bit.ly/4inoXCx
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Stream this podcast to learn from experts Tessa Rife-Pennington, PharmD, BCGP, and Frank North, PharmD, MPA, DPLA, DASPL, how specialty pharmacists can apply practical strategies within different pharmacy settings to overcome barriers to PrEP use, especially among underserved patient subpopulations. Topics covered include:
- PrEP candidacy
- Selection of individualized regimens
- Key barriers to PrEP use
- Strategies for overcoming key barriers to PrEP access
- Evolving state-based legislation on PrEP provision by pharmacists
- Models of pharmacy-managed PrEP
- Strategies for addressing inequities in PrEP care
- Comprehensive HIV prevention services
Presenters:
Tessa Rife-Pennington, PharmD, BCGP
Dr. Dawn K. Smith HIV Prevention Clinical Fellow
American Academy of HIV Medicine
Volunteer Assistant Clinical Professor
University of California, San Francisco, School of Pharmacy
San Francisco, California
Frank North, PharmD, MPA, DPLA, DASPL
Instructional Assistant Professor, Irma Lerma Rangel College of Pharmacy
Director of Learning in Practice
Office of Interprofessional Practice, Education and Research
Texas A&M University Health Science Center
Past President, National Pharmaceutical Association
College Station, Texas
Link to full program:
https://bit.ly/49SLc0y
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, expert patient navigators Shellye Jones and Lauren Jackson discuss the key take-home points of our online educational program on facilitating engagement in HIV care and propose a framework for effectively retaining people in care. Topics covered include:
- How to approach a patient with complex barriers to engagement in healthcare
- Resources for staying in care, such as wraparound services
- Setting SMART goals and formulating action plans with patients
- Deconstructing stigma and implementing a trauma-informed approach to care
Presenters:
Shellye Jones, MSW, LCSW
Clinical Supervisor
Charles R. Drew University, Drew CARES
Los Angeles, California
Lauren Harris Jackson
Street Medicine Patient Navigator
Healthcare in Action
Los Angeles, California
Link to full program:
https://bit.ly/3Wh4Z1T
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Don’t settle! Listen in to learn how a proactive approach to ART switch can improve treatment satisfaction and quality of life for people living with virologically suppressed HIV. Topics covered include:
- International AIDS Society (IAS) USA and European AIDS Clinical Society (EACS) Guidance on Switching ART With Viral Suppression
- Considerations for switching to a 2-drug regimen or long-acting ART
- Methods for assessing patient satisfaction with their current ART regimen
Presenters:
Monica Gandhi, MD, MPH
Director, UCSF-Bay Area Center for AIDS Research (CFAR)
Professor of Medicine and Associate Chief, Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, “Ward 86” HIV Clinic, San Francisco General Hospital
University of California, San Francisco (UCSF)
San Francisco, California
Luis Buzon Martin, MD
Division of Infectious Diseases
Hospital Universitario de Burgos
Burgos, Espana
Link to full program and accompanying slides:
https://bit.ly/3KPN0xb
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Detectable HIV-1 RNA (viral load) can seem very worrisome for people living with HIV who are receiving antiretroviral therapy (ART) and for their healthcare professionals. Tune in to learn how Brian R. Wood, MD, differentiates HIV-1 RNA “blips” from persistent low-level viremia and from virologic failure, and how he handles each scenario.
Presenter:
Brian R. Wood, MD
Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington
Seattle, Washington
Link to full program:
https://bit.ly/4nS7rYE
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune into this podcast from Dr Clíona Ní Cheallaigh to learn how to provide person-centered care for treatment-experienced people with HIV. Gain strategies to address each individual’s specific history and needs while considering the potential impact of comorbidities and other health challenges. Topics covered include:
- Individualizing Antiretroviral Regimens for Treatment-Experienced People With HIV
- Strategies to Improve Adherence and Addressing Barriers to Engagement in Care
- Person-Centered, Trauma-Informed Care
- Resistance Testing in the Setting of Virologic Failure
- Selection of ARVs With a Failing Regimen
Presenters:
Clíona Ní Cheallaigh, MB, MRCP, PhD
Consultant Physician
Inclusion Health Services
St James’s Hospital Dublin
Associate Professor
Department of Medicine
Trinity College Dublin
Dublin, Ireland
Link to full program:
https://bit.ly/4oiYxEx
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, expert faculty Atul Humar, MD, FRCP (C), and Camille Kotton, MD, FIDSA, FAST, take a deep dive into complex clinical scenarios and explore designing antiviral regimens for refractory CMV infections to minimize antiviral toxicities and maximize efficacy. Topics covered include:
- Management for suspected drug-resistant CMV infection
- Illustrative patient cases
- Gene mutations in CMV
Presenters:
Atul Humar, MD, FRCPC, FAST
Professor
Department of Medicine
University of Toronto
Eaton Family Chair in Transplant Infectious Diseases
Ajmera Transplant Centre
University Health Network
Toronto, Canada
Camille Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Mass General Brigham Endowed Cancer Chair IV
Massachusetts General Hospital
Associate Professor, Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/4lOa2kA
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Learn to appropriately modify antiviral therapy in solid organ transplant recipients with treatment-refractory cytomegalovirus (CMV) infections with expert faculty, Atul Humar, MD, FRCP (C). Topics covered include:
- Comparisons of available CMV antiviral therapies:
- Ganciclovir, valganciclovir, foscarnet, cidofovir, maribavir
- Considerations for renal function monitoring with ganciclovir and valganciclovir
- A treatment algorithm for relapsed/refractory CMV
- The latest clinical trial data and guideline recommendations
Presenter:
Atul Humar, MD, FRCP (C)
Professor
Department of Medicine
University of Toronto
Eaton Family Chair in Transplant Infectious Diseases
Ajmera Transplant Centre
University Health Network
Toronto, Canada
Link to full program:
https://bit.ly/4lOa2kA
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune in to learn the fundamentals for timely identification of refractory cytomegalovirus (CMV) infections following solid organ transplantation from expert faculty, Camille Kotton, MD, FIDSA, FAST. Topics covered include:
- Direct and indirect effects of CMV infection
- Risk factors for resistant/refractory CMV
- Defining resistant/refractory CMV
Presenter:
Camille Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Mass General Brigham Endowed Cancer Chair IV
Massachusetts General Hospital
Associate Professor, Harvard Medical School
Boston, Massachusetts
Link to full program:
http://bit.ly/4lOa2kA
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Dr Marcus Pereira and Dr Raymund R. Razonable explore strategies for individualization of CMV management in high-risk kidney transplant recipients. Topics include:
- Risk factors and prevention of late-onset CMV disease
- Early detection of late CMV infection
- CMV cell-mediated immunity monitoring
- Primary and secondary prophylaxis
Presenters:
Marcus Pereira, MD, MPH, FAST
Associate Professor of Medicine
Director of Clinical Services, Division of Infectious Diseases
Medical Director, Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York
Raymund R. Razonable, MD, FIDSA, FAST
Professor of Medicine
Division of Infectious Diseases
Mayo Clinic College of Medicine and Science
Rochester, Minnesota
Link to full program:
https://bit.ly/41ejruC
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Dr Marcus Pereira and Dr Raymund R. Razonable discuss the fundamentals of cytomegalovirus (CMV) in kidney transplant recipients. Topics include:
- CMV pathogenesis
- Direct and indirect effects of CMV infection
- Overview of patient risk factors
- CMV risk based on serologic status
Presenters:
Marcus Pereira, MD, MPH, FAST
Associate Professor of Medicine
Director of Clinical Services, Division of Infectious Diseases
Medical Director, Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York
Raymund R. Razonable, MD, FIDSA, FAST
Professor of Medicine
Division of Infectious Diseases
Mayo Clinic College of Medicine and Science
Rochester, Minnesota
Link to full program:
https://bit.ly/41ejruC
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Dr Trevor Van Schooneveld explores rapid syndromic testing for gastrointestinal and joint infections and discusses how to apply best practices for diagnostic and antimicrobial stewardship in syndromic testing.
Topics covered include:
- Who should be tested for infectious diarrhea
- Types of gastrointestinal syndromic panels
- Types of syndromic panels for joint infections
- Real-world applications for joint syndromic panels
Presenters:
Trevor Van Schooneveld, MD
Professor, Division of Infectious Diseases
Medical Director, Antimicrobial Stewardship Program
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska
Link to full program:
https://bit.ly/4mHOTtW
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Dr Marcus Pereira discusses how to design cytomegalovirus (CMV) antiviral regimens for high-risk kidney transplant recipients to mitigate the impact of infection while minimizing drug toxicities. Topics include:
- Strategies for CMV prevention: prophylaxis, preemptive therapy, and hybrid methods
- Characteristics of available antiviral drugs
- Monitoring considerations for antivirals
Presenters:
Marcus Pereira, MD, MPH, FAST
Associate Professor of Medicine
Director of Clinical Services, Division of Infectious Diseases
Medical Director, Transplant Infectious Disease Program
Columbia University Irving Medical Center
New York, New York
Link to full program:
http://bit.ly/41ejruC
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join Alicia Stillman of the American Society for Meningitis Prevention, as she shares a very personal story of loss that might change how you view meningitis vaccination.
Presenter:
Alicia Stillman, MBA, MPH
Patient Advocate
Co-Executive Director, American Society for Meningitis Prevention
Executive Director, Emily Stillman Foundation
Detroit, Michigan
Link to full program:
https://bit.ly/4mYvTXQ
Register for the practical symposium:
https://bit.ly/4mUOsvV
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Michael Satlin, MD, MS, FIDSA,explores rapid syndromic testing for bloodstream infections and discusses how to apply best practices for diagnostic and antimicrobial stewardship in syndromic testing.
Topics covered include:
- Types of upper and lower respiratory infection panels
- Considerations for when to use respiratory syndromic testing
- How to use syndromic testing to guide both therapy escalation and de-escalation
- How syndromic testing fits in with traditional testing methods, such as culture, antimicrobial susceptibility testing, Gram stain, and BAL cell count
Presenter:
Michael Satlin, MD, MS, FIDSA
Associate Professor of Medicine and Pathology and Laboratory Medicine
Weill Cornell Medicine
New York, New York
Link to full program:
https://bit.ly/3UAB1oU
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Stream this podcast to learn from experts Alexis E. Horace, PharmD, BCACP,andNimish Patel, PharmD, PhD, AAHIVP, how specialist pharmacists can overcome key barriers to care and apply best practices for optimization of antiretroviral therapy for HIV. Topics covered include:
- Leveraging pharmacists’ expertise to advance HIV treatment
- Pharmacist roles in HIV care and management
- The current ART landscape
- Regimen simplification
- Consideration of patient preferences, health factors, and comorbidities for ART optimization
- ART management for treatment-experienced patients, including those with multidrug-resistant HIV
Presenters:
Alexis E. Horace, PharmD, BCACP
Professor of Pharmacy Practice
University of Louisiana at Monroe College of Pharmacy
New Orleans Campus
CrescentCare Ambulatory Care Clinical Pharmacist, HIV Specialty
New Orleans, Louisiana
Nimish Patel, PharmD, PhD, AAHIVP
Professor of Clinical Pharmacy
Division of Clinical Pharmacy
Skaggs School of Pharmacy & Pharmaceutical Sciences
University of California, San Diego
La Jolla, California
Link to full program:
https://bit.ly/41agtqQ
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune in to learn how the recent FDA approval of lenacapavir (LEN) for PreP integrates into the current field of HIV prevention. Listen on the go or follow along with our expert-curated slides. Topics covered include:
- The current landscape of PrEP
- FDA approval of lenacapavir
- Phase III efficacy and safety data for lenacapavir
- Recommendations and perspectives on the future of PrEP
Presenters:
Colleen F. Kelley, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Co-Director, Emory Center for
AIDS Research
Associated Dean for Research,
Emory at Grady
Emory University School of Medicine
Atlanta, Georgia
Raphael J. Landovitz, MD, MSc
Professor of Medicine
Chief, Division of Infectious Diseases
Associate Vice Chair for
Clinical Research
Department of Medicine
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Research & Education (CARE)
Director, Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Los Angeles, California
Link to full program:
https://bit.ly/4m8RaOg
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Hear from experts in HIV care Beatriz Grinsztejn, MD, PhD, and Rosie Mnggibisa, MBChB, MPH, as they discuss their insights on some of the most clinically relevant new data presented at IAS 2025, including studies on:
- Gaps in care for adolescents and young adults living with HIV
- Global impact of funding cuts
- Antiretroviral therapy for treating HIV
- Patient management strategies for people living with HIV and obesity
Presenters:
Beatriz Grinsztejn, MD, PhD
Director
STI/HIV Clinical Research Laboratory
Evandro Chagas National Institute of Infectious Diseases – FIOCRUZ
Rio de Janeiro, Brazil
Rosie Mngqibisa, MBChB, MPH
Clinical Director
Principal Investigator
Enhancing Care Foundation
Durban, South Africa
Link to full program:
https://bit.ly/4otF8AR
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Dr Emily Heil explores rapid syndromic testing for bloodstream infections and discusses how to apply best practices for diagnostic and antimicrobial stewardship in syndromic testing.
Topics covered include:
- The importance of good blood culture practices and finding the balance between overuse and underuse
- Blood culture improvement programs
- The utility of rapid diagnostic tests
- Resistance markers for earlier targeted therapy
Presenters:
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Professor
Department of Practice, Sciences, and Health Outcomes Research
University of Maryland School of Pharmacy
Baltimore, Maryland
Link to full program:
https://bit.ly/45Ajz92
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune in as Dr George Behrenspresents the fundamentals on specialized agents for treatment-experienced people living with HIV.
Topics covered include:
- Key targets and mechanisms of action for specialized HIV drugs
- Clinical trial data supporting safety and efficacy of these agents
- Considerations for potential drug–drug interactions
- Strategies for leveraging these agents to construct new ART regimens for treatment-experienced individuals
Presenters:
Georg Behrens, MD
Professor of Immunology
Senior Consultant
Department of Rheumatology and Immunology
Hannover Medical School, Germany
Hannover, Germany
Link to full program:
https://bit.ly/4oiYxEx
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Dr Josep M. Llibrereviews the essentials on ART selection for treatment-experienced people with HIV and comorbidities.
Topics covered include:
- Underlying reasons for development of multidrug-resistant HIV
- Inflammation and immune activation associated with frequency of age-related conditions
- General principles for designing ART regimens for persons with multidrug-resistant HIV
- Treatment options for highly treatment‒experienced people
- Considerations for comorbidities and drug–drug interactions
Presenters:
Josep M. Llibre, MD, PhD
Senior Consultant
Infectious Diseases Division
Fight Infections Foundation
University Hospital Germans Trias
Badalona, Barcelona, Spain
Link to full program:
https://bit.ly/4oiYxEx
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Tune in as Dr Daniel R. Kuritzkes presents a quick and easy primer on managing multidrug resistant HIV.
Topics covered include:
- How to recognize key populations who may present with multidrug-resistant HIV
- Identifying underlying reasons for regimen failure
- Evaluating resistance profiles
- Constructing new ART regimens for treatment-experienced individuals.
Presenters:
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/4oiYxEx
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
| In this episode, Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGH, discusses the most recent developments in primary biliary cholangitis (PBC) treatment, including cutting-edge data on new and emerging agents and how these updates may be integrated into your practice. Topics include:* Steatotic liver disease and PBC * Vibration-controlled transient elastography (VCTE) and discordant biochemical responses in PBC * PPAR agonists and IBATs for PBC treatment
Presenter:Palak J. Trivedi, BSc, MBBS, PhD, MRCP, ESEGHAssociate ProfessorNIHR Birmingham BRCUniversity of BirminghamConsultant Hepatologist, Liver UnitUniversity Hospitals BirminghamBirmingham, United KingdomLink to full program: https://bit.ly/4lKaO2HFollow along with the slides: https://bit.ly/44PPBysGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. |
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen as expert faculty answer your most pressing questions on optimizing immunization in clinical practice.
Topics covered include:
- Practical methods for improving confidence in vaccines
- How to educate patients on vaccine development and safety monitoring
- Effective strategies to tailor recommendations, such as motivational interviewing
- Ways to navigate clinical encounters and address vaccine hesitancy
Presenters:
Robert H. Hopkins, Jr., MD, MACP
Professor of Internal Medicine and Pediatrics
University of Arkansas for Medical Sciences
College of Medicine
Little Rock, Arkansas
Litjen (L.J.) Tan, MS, PhD
Chief Policy and Partnership Office, Immunize.org
Chair, National Adult Influenza Immunization Summit
Co-Chair, Global Influenza Initiative
St Paul, Minnesota
Link to full program:
https://bit.ly/3I5jBh0
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Dr Gideon Hirschfield meets with patient advocate Jess Schnur to discuss challenges related to the diagnosis and management of primary biliary cholangitis (PBC) to provide actionable strategies for healthcare professionals to incorporate into patient care, including:
- Disease concerns and frequently asked questions from a patient perspective
- Managing symptoms
- Treatment options and supportive care
- Importance of awareness and education
Presenters:
Gideon Hirschfield, MA, MB BChir, FRCP, PhD
Lily and Terry Horner Chair in Autoimmune Liver Disease Research
Professor, Division of Gastroenterology and Hepatology
University of Toronto
Director, The Autoimmune and Rare Liver Disease Programme
Director, Francis Family Liver Clinic
Toronto General Hospital, University Health Network
Ontario, Canada
Jess N. Schnur, BSN-RN
National PBC Patient Advocate
American Liver Foundation
Donation Support Services Coordinator
Lifeline of Ohio
Columbus, Ohio
To learn more, see the program
Hear Me: Patient Perspectives on PBC
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, Sonal Kumar, MD, MPH, meets with patient advocate Maria Morais to discuss actionable steps that healthcare providers can incorporate into the care of people with primary biliary cholangitis (PBC). Listen as they discuss:
- The chronic nature of PBC
- Going beyond biochemical markers to assess and address symptoms such as fatigue and pruritus
- The importance of referral to patient support groups
Presenters:
Sonal Kumar, MD, MPH
Assistant Professor of Medicine
Director, General Gastroenterology and Hepatology
Weill Cornell Medical College
New York, New York
Maria G. Morais, RN
VP Patient Advocacy
Canadian PBC Society
Toronto, Canada
To learn more, see the program
Hear Me: Patient Perspectives on PBC
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau, use an illustrative patient case to explore the roles of ALP and other biochemical markers in PBC management, and explain what to expect from treatment. Topics covered include:
- How baseline ALP can affect ALP normalization after second-line treatment with elafibranor and seladelpar
- Potential outcomes if ALP normalization cannot be achieved
- The importance of managing fatigue, pruritus, and sleep disturbances independently of the biochemical response
Presenters:
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois
To learn more about PBC management, check out our program,
Curbside Consults: Expert Insights on Challenges in PBC Management.
Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, expert faculty, Dr Stuart Gordon and Dr Nancy Reau discuss an illustrative patient case to demonstrate how they individualize primary biliary cholangitis (PBC) therapy for patients with cirrhosis. Topics covered include:
- AASLD guideline recommendations for second-line therapy for PBC
- Considerations when using newer agents for second-line treatment of PBC in patients with cirrhosis: elafibranor and seladelpar
Presenters:
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois
To learn more about PBC management, check out our program,
Curbside Consults: Expert Insights on Challenges in PBC Management.
Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, Brett M. Elicker, MD, and David E. Griffith, MD, ATSF, FACCP, FRSM, discuss the pathophysiology of non–cystic fibrosis bronchiectasis (NCFBE), the patient burden, and best practices with diagnosing NCFBE, including:
- The vicious vortex of NCFBE (ie, airway dysfunction, inflammation, infection)
- Cough as the most significant symptom and burden
- Imaging bronchiectasis with classic and inflammatory findings
- Differentiating the causes of NCFBE to inform patient care
Presenters
Brett M. Elicker, MD
Professor of Clinical Radiology
Chief, Cardiothoracic Imaging Division
Department of Radiology & Biomedical Imaging
University of California, San Francisco
San Francisco, California
David E. Griffith, MD, ATSF, FACCP, FRSM
Professor of Medicine
Division of Mycobacterial and Respiratory Diseases
Department of Medicine
National Jewish Health
Denver, Colorado
Program page:
https://bit.ly/4mZbYsm
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss how they assess the symptoms of primary biliary cholangitis (PBC) and explore how new therapeutic agents may help alleviate symptom burden. Topics include:
- Strategies and tools for assessing pruritus
- Nonpharmacologic and pharmacologic management of pruritus
- Second-line agents and their impact on pruritus
- Investigational treatments for pruritus
Presenters:
Alan Bonder, MD, AGAF
Associate Professor of Medicine
Medical Director of Liver Transplant
Department of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Aparna Goel, MD
Associate Clinical Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.
To learn more about PBC management, check out our program, Curbside Consults: Expert Insights on Challenges in PBC Management.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
How do you decide when to move from first-line to second-line treatment for primary biliary cholangitis (PBC)? In this podcast, listen as experts Alan Bonder, MD, AGAF, and Aparna Goel, MD, discuss this question and more, including:
- How and when to measure treatment response
- Evidence-based goals of therapy
- Considerations for second-line treatment
- New agents for second-line treatment: PPAR agonists
Presenters:
Alan Bonder, MD, AGAF
Associate Professor of Medicine
Medical Director of Liver Transplant
Department of Gastroenterology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Aparna Goel, MD
Associate Clinical Professor of Medicine
Division of Gastroenterology and Hepatology
Stanford University
Palo Alto, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences, Inc., and Ipsen Biopharmaceuticals, Inc.
To learn more about PBC management, check out our program,
Curbside Consults: Expert Insights on Challenges in PBC Management.
Supported by educational grants from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Respiratory Syncytial Virus (RSV) significantly impacts adults, especially those over age 60 and those with chronic conditions.
In this podcast, nurse practitioners Drs. Carrico and Stevenson discuss the underestimated burden of RSV. The podcast also explores practical strategies for increasing vaccine uptake that you can apply to your practice starting today so that you can protect your patients against RSV.
Listen as they discuss:
- The Burden of Adult RSV
- RSV Vaccines for Adults: Data and Recommendations
- RSV Vaccine Uptake
- Practical Strategies to Increase RSV Vaccine Uptake
Faculty:
Dr. Ruth Carrico is a family nurse practitioner and senior consultant with Carrico & Ramirez, PLLC focused on infectious diseases, infection prevention and control, and vaccinology. She is based in Louisville, Kentucky and is a Professor, adjunct faculty, with the University of Louisville School Medicine, Division of Infectious Diseases. Dr. Carrico has received training specific for healthcare epidemiology at the Centers for Disease Control and Prevention (CDC) in conjunction with the Rollins School of Public Health at Emory University in Atlanta and the Society for Healthcare Epidemiology of America (SHEA).
Dr. Carrico has worked in the field of infectious diseases and infection control for more than thirty years. Dr. Carrico also maintains a clinical practice focused on vaccines, vaccination, and immunization processes.
Dr. Audrey M. Stevenson is a family nurse practitioner with over 40 years of clinical, public health, and leadership experience.
Dr. Stevenson, who holds a master of public health and master of nursing degrees, received her doctorate in public health from the University of Utah. She formerly worked in public health for over 34 years and was the former Division Director of Family Health and Clinical Services of the Salt Lake County Health Department in Salt Lake City, Utah. She currently works as a consultant and teaches graduate FNP and MPH students at two universities.
Dr. Stevenson is also a member of the statewide vaccine advisory board, where she collaborates on vaccine policies and recommendations for the state. Previously, Dr. Stevenson served as Vaccination Branch Director for the COVID-19 Incident Command for Salt Lake County, where she directed the vaccination strategies for 1.2 million residents of Salt Lake County. She has been a vaccine champion for over 30 years.
Learn more:
Download this practical infographic to help you integrate RSV vaccination into your clinical practice.
https://bit.ly/43mzacq
For more information for nurses, subscribe to the PCE podcast channel on your favorite player!
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Carolyn Bridges, MD, FACP, and Laura P. Hurley, MD, MPH, discuss barriers to respiratory syncytial virus (RSV) vaccination for adults, including insurance coverage and vaccine hesitancy, and explore effective, practical strategies for overcoming these barriers. Topics covered include:
- Helping patients understand why they need an RSV vaccine
- Ways to discuss real-world vaccine efficacy
- Approaches to build vaccine confidence and discuss vaccine safety
- Methods to overcome financial barriers and time constraints
- Vaccine delivery infrastructure
Presenters:
Carolyn Bridges, MD, FACP
Consulting Physician and Director of Adult Immunizations
Immunize.org
St Paul, Minnesota
Laura P. Hurley, MD, MPH
Associate Professor of Medicine
Division of General Internal Medicine
University of Colorado Anschutz Medical Campus
Aurora, Colorado
General Internist and Health Services Researcher
Denver Health
Denver, Colorado
Link to full program:
https://bit.ly/4mHHKu2
Downloadable slides:
https://bit.ly/3FzWREP
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Carolyn Bridges, MD, FACP, reviews the estimated burden of respiratory syncytial virus (RSV) disease in older adults and discusses the latest updates on RSV vaccination recommendations and safety data. Topics covered include:
- Rates of RSV hospitalizations and emergency department visits
- RSV vaccine development
- FDA-approved RSV vaccines
- Vaccine safety data: rates of atrial fibrillation and Guillain-Barré syndrome
- ACIP RSV vaccine recommendations
- Risk factors for severe RSV disease
- RSV vaccine uptake
Presenter:
Carolyn Bridges, MD, FACP
Consulting Physician and Director of Adult Immunizations
Immunize.org
St Paul, Minnesota
Link to full program:
https://bit.ly/4mHHKu2
Downloadable slides:
https://bit.ly/3FzWREP
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
| In this episode, Jewel Mullen, MD, MPH, MPA, and Dallas Nelson, MD, CMD, FACP discuss overcoming barriers to RSV vaccine uptake in post-acute and long-term care facilities, including:* How to incorporate the latest RSV vaccination recommendations into clinical practice * Practical strategies for navigating insurance * Effective and empathetic methods of addressing vaccine hesitancy.
Presenters:Jewel Mullen, MD, MPH, MPAAssociate Dean for Health EquityAssociate Professor of Population Health and Internal MedicineUniversity of Texas at Austin Dell Medical SchoolAustin, TexasDallas Nelson, MD, CMD, FACPProfessor of MedicineDivision of Geriatrics and AgingUniversity of RochesterMedical DirectorUR Medicine Geriatrics GroupRochester, New YorkLink to full program: https://bit.ly/4lrwa5uFollow along with the slides: https://bit.ly/3RdWAKeGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. |
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Chloe Orkin, MBChB, FRCP, MD, and Jean-Michel Molina, MD, PhD, discuss highlights from CCO’s independent conference coverage of CROI 2025, including:
- Advances in HIV treatment based on results from CARES
- Potential HIV therapies in the pipeline, such as doravirine/islatravir
- Effects of broadly neutralizing antibodies on HIV treatment and cure
- Key clinical data on HIV and STI prevention obtained from PILLAR, HPTN 083, PURPOSE 1, and STOMP
Presenters:
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Dean for Healthcare Transformation
Honorary Consultant Physician, Barts Health NHS Trust
Faculty of Medicine and Dentistry
Queen Mary University of London
London, United Kingdom
Jean-Michel Molina, MD, PhD
Professor of Medicine
University of Paris Cite
Department of Infectious Diseases
Saint-Louis and Lariboisiere Hospitals, APHP
Paris, France
Link to full program:
bit.ly/3E1bAYQ
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Cristina Mussini, MD; Martin Witzenrath, MD, FERS; and Michele Bartoletti, MD, PhD, discuss treatment strategies for people who are immunocompromised with COVID-19 in the hospital setting, including:
- Antiviral therapy with remdesivir
- Dexamethasone for patients with hematologic malignancies
- Considerations regarding other immunomodulators such as JAK inhibitors or IL-6 inhibitors
- A detailed patient case to illustrate key takeaways
Presenters:
Michele Bartoletti, MD, PhD
Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy
Cristina Mussini, MD
Full Professor of Infectious Diseases
Chief of the Department of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy
Martin Witzenrath, MD, FERS
Medical Director
Charite Centrum 12
Internal Medicine & Dermatology
Professor and Chair for Respiratory Medicine and Critical Care
Department of Infectious Disease, Respiratory Medicine and Critical Care
Charite Campus Mitte/Campus Virchow Klinikum/Campus Benamin Franklin
Charite – University of Berlin
Berlin, Germany
Link to full program:
https://bit.ly/4fs7Hcb
Downloadable slides:
https://bit.ly/3XP1fpJ
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss treatment strategies for people who have severe COVID-19, including:
- Antiviral therapy with remdesivir
- Dexamethasone and other systemic corticosteroids
- Immunomodulators, such as JAK inhibitors or IL-6 inhibitors
- Overviews of clinical trial data demonstrating how and when to use these therapies
Presenters:
Stephen Cantrill, MD, FACEP
Associate Director and Medical Director (Retired)
Department of Emergency Medicine
Denver Health Medical Center
Associate Professor
Department of Emergency Medicine
University of Colorado Health Sciences Center
Denver, Colorado
Rajesh T. Gandhi, MD
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Payal K. Patel, MD, MPH, FIDSA
Systemwide Director of Antimicrobial Stewardship
Associate Professor, Division of Infectious Diseases
Intermountain Health
Salt Lake City, Utah
Link to full program:
https://bit.ly/4gu2gcU
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Patricia D. Jones, MD, MSCR; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and patient advocate, Jennifer Wild, MS, RN, OCN, discuss practical strategies to overcome barriers to hepatitis B virus (HBV) care, including:
- Overcoming health insurance navigation
- Improving access to HBV care in immigrant communities
- Dispelling HBV myths and stigma
- Solutions to language barriers
- Community-based interventions
Presenters:
Patricia D. Jones, MD, MSCR
Associate Professor of Clinical Medicine
Director of Clinical Operations-Hepatology
Division of Digestive Health and Liver Diseases
Department of Medicine
University of Miami Miller School of Medicine
Sylvester Comprehensive Cancer Center
Miami, Florida
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (GI & Hepatology,
Liver Transplant)
Professor of Epidemiology & Population Health
(by Courtesy)
Director of Hepatology Clerkship
Faculty Search LENS Advocates,
Stanford Department of Medicine
Faculty Fellow, Stanford Center for Innovation
in Global Health
Member, Stanford Cancer Institute, Maternal &
Child Health Research Institute, & Stanford Bio-C
Stanford, California
Past Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)
28th President: The International Association for the Study of the Liver (IASL)
Jennifer Wild, MS, RN, OCN
Clinical Nurse – GI Medical Oncology
UCSF Cancer Center
San Francsico, California
Link to full program:
https://bit.ly/4j973TN
Downloadable slides:
https://bit.ly/3WQkIWl
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss:
- Workup of COVID-19 in the emergency department
- Methods of COVID-19 risk stratification
- Treatment recommendations for people with severe COVID-19, including how to effectively use antiviral therapy, dexamethasone, and other immunomodulators[CC1] in this population
- A detailed patient case to illustrate key takeaways
Presenters:
Stephen Cantrill, MD, FACEP
Associate Director and Medical Director (Retired)
Department of Emergency Medicine
Denver Health Medical Center
Associate Professor
Department of Emergency Medicine
University of Colorado Health Sciences Center
Denver, Colorado
Rajesh T. Gandhi, MD
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Payal K. Patel, MD, MPH, FIDSA
Systemwide Director of Antimicrobial Stewardship
Associate Professor, Division of Infectious Diseases
Intermountain Health
Salt Lake City, Utah
Link to full program:
https://bit.ly/4gu2gcU
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Martin Witzenrath, MD, FERS, and Michele Bartoletti, MD, PhD, discuss the management of mild to moderate COVID-19 in patients who are immunocompromised, including:
- Initial workup, which may include laboratory tests and/or imaging
- Latest data on the use of remdesivir or nirmatrelvir plus ritonavir for mild to moderate COVID-19, including considerations for drug–drug interactions
Presenters:
Martin Witzenrath, MD, FERS
Medical Director
Charite Centrum 12
Internal Medicine & Dermatology
Professor and Chair for Respiratory Medicine and Critical Care
Department of Infectious Disease, Respiratory Medicine and Critical Care
Charite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin Franklin
Charite – University of Berlin
Berlin, Germany
Michele Bartoletti, MD, PhD
Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy
Link to full program:
https://bit.ly/4gu2gcU
Downloadable slides:
https://bit.ly/3CGlDBS
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Patricia D. Jones, MD, MSCR; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and patient advocate, Jennifer Wild, MS, RN, OCN, discuss best practices in hepatitis B virus (HBV) care, including:
- 2023 CDC HBV screening recommendations
- Summary of guideline recommendations for hepatitis delta virus (HDV) screening
- Use of HDV reflex testing to avoid loss to follow-up
- 2024 WHO HBV treatment recommendations, including recommendations for pregnant persons
Presenters:
Patricia D. Jones, MD, MSCR
Associate Professor of Clinical Medicine
Director of Clinical Operations-Hepatology
Division of Digestive Health and Liver Diseases
Department of Medicine
University of Miami Miller School of Medicine
Sylvester Comprehensive Cancer Center
Miami, Florida
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (GI & Hepatology,
Liver Transplant)
Professor of Epidemiology & Population Health
(by Courtesy)
Director of Hepatology Clerkship
Faculty Search LENS Advocates,
Stanford Department of Medicine
Faculty Fellow, Stanford Center for Innovation
in Global Health
Member, Stanford Cancer Institute, Maternal &
Child Health Research Institute, & Stanford Bio-C
Stanford, California
Past Chair: HBV SIG, The American Association for the Study of Liver Diseases (AASLD)
28th President: The International Association for the Study of the Liver (IASL)
Jennifer Wild, MS, RN, OCN
Clinical Nurse – GI Medical Oncology
UCSF Cancer Center
San Francsico, California
Link to full program:
https://bit.ly/4j973TN
Downloadable slides:
https://bit.ly/3WQkIWl
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Cristina Mussini, MD, Martin Witzenrath, MD, FERS, and Michele Bartoletti, MD, PhD, discuss:
- Current SARS-CoV-2 trends in the EU
- Risk factors for severe COVID-19 outcomes, including the spectrum of risk based on immune system status
- Factors that may affect vaccine efficacy in chronic lymphocytic leukemia and other lymphoid malignancies
- Considerations for determining people at high risk for COVID-19 progression
Presenters:
Cristina Mussini, MD
Full Professor of Infectious Diseases
Division of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy
Martin Witzenrath, MD, FERS
Medical Director
Charite Centrum 12
Internal Medicine & Dermatology
Professor and Chair for Respiratory Medicine and Critical Care
Department of Infectious Disease, Respiratory Medicine and Critical Care
Charite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin Franklin
Charite – University of Berlin
Berlin, Germany
Michele Bartoletti, MD, PhD
Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy
Link to full program:
https://bit.ly/4gu2gcU
Downloadable slides:
https://bit.ly/42IlpEL
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Tzu-Hao (Howard) Lee, MD; Tatyana Kushner, MD, MSCE; and patient advocate Andrew Reynolds discuss hepatitis C virus (HCV) care in men who have sex with men and pregnant people, including:
- HCV disease burden in the United States
- Screening recommendations
- Strategies to overcome barriers to HCV screening
- Treatment recommendations, including simplified treatment guidance and considerations for pregnant people
- Strategies to improve treatment uptake
Presenters:
Tzu-Hao (Howard) Lee, MD
Assistant Professor
Section of Gastroenterology and Hepatology, Department of Medicine
Division of Abdominal Transplant, Department of Surgery
Baylor College of Medicine
Houston, Texas
Tatyana Kushner, MD, MSCE
Associate Professor
Division of Gastroenterology/Hepatology
Department of Obstetrics & Gynecology
Weill Cornell Medicine
New York, New York
Andrew Reynolds
Director, Health of People Who Use Drugs
San Francisco AIDS Foundation
San Francisco, California
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Link to full program:
https://bit.ly/4j973TN
Downloadable slides:
https://bit.ly/4gXuBcu
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:
- ELATIVE, a phase III trial of elafibranor for PBC
- RESPONSE, a phase III trial of seladelpar for PBC
- ASSURE, another phase III trial of seladelpar for PBC
Presenter:
Sonal Kumar, MD, MPH
Director, Clinical Gastroenterology and Hepatology
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York
Link to full program:
https://bit.ly/41tvSDu
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss current trends in and risk factors for progression to severe COVID-19, including for those for whom COVID-19 is not their primary concern when presenting to the emergency department (ED). Key topics of discussion include:
- How to complete a comprehensive patient workup in the ED
- Considerations regarding pulse oximetry
- Risk stratification—what places patients at higher risk of severe disease?
- A detailed patient case to illustrate key takeaways
Presenters:
Stephen Cantrill, MD, FACEP
Associate Director and Medical Director (Retired)
Department of Emergency Medicine
Denver Health Medical Center
Associate Professor
Department of Emergency Medicine
University of Colorado Health Sciences Center
Denver, Colorado
Rajesh T. Gandhi, MD
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Payal K. Patel, MD, MPH, FIDSA
Systemwide Director of Antimicrobial Stewardship
Associate Professor, Division of Infectious Diseases
Intermountain Health
Salt Lake City, Utah
Link to full program:
https://bit.ly/4fs7Hcb
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Stacey B. Trooskin, MD, PhD, MPH, Mark S. Sulkowski, MD, FIDSA, FAASLD, and Ronni Marks discuss hepatitis C virus (HCV) screening and treatment, focusing on people who use drugs, and highlight the following topics:
- Screening recommendations
- Strategies to improve HCV screening
- HCV testing
- Treatment goals
- Strategies to improve HCV treatment uptake
Presenters:
Stacey B. Trooskin, MD, PhD, MPH
Executive Medical Officer
Mazzoni Center
Faculty, University of Pennsylvania
Perelman School of Medicine
Philadelphia, Pennsylvania
Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Ronni Marks
Founder/Director, The Hepatitis C Mentor and Support Group (HCMSG)
Patient Advocate
New York, New York
Link to full program:
https://bit.ly/4grbwPT
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen in as Stephen Cantrill, MD, FACEP; Rajesh T. Gandhi, MD; and Payal K. Patel, MD, MPH, FIDSA, discuss best practices in treating patients hospitalized with mild to moderate COVID-19, including:
- Current guidelines from the Infectious Diseases Society of America and National Institutes of Health
- How to optimize therapy selection based on patient risk factors, including key data supporting best practices
- A detailed patient case to illustrate key takeaways
Presenters:
Stephen Cantrill, MD, FACEP
Associate Director and Medical Director (Retired)
Department of Emergency Medicine
Denver Health Medical Center
Associate Professor
Department of Emergency Medicine
University of Colorado Health Sciences Center
Denver, Colorado
Rajesh T. Gandhi, MD
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Payal K. Patel, MD, MPH, FIDSA
Systemwide Director of Antimicrobial Stewardship
Associate Professor, Division of Infectious Diseases
Intermountain Health
Salt Lake City, Utah
Link to full program:
https://bit.ly/4fs7Hcb
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Clinical gaps in the treatment of pruritus in primary biliary cholangitis (PBC) remain. In this episode, taken from a recent symposium, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss emerging therapies currently in clinical trials for the management of this disease that can dramatically affect patients’ quality of life.
Listen as they discuss:
- Gaps in current management
- Patient perspectives: why we should not dismiss itching as an underlying psychologic problem
- PPAR agonists and how they affect pruritus
- BEZURSO and FITCH
- ELATIVE
- ENHANCE and RESPONSE
- IBATs (inhibitors of bile acid transport)
- GLIMMER
- Common questions
Presenters:
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Pam Rivard, RN
Person living with PBC
Link to full program:
https://bit.ly/3Dnfb2E
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss the clinical management of pruritus in PBC, including:
- Pruritus assessment tools
- Optimal use of tools, including frequency of assessment
- Current management of pruritus
- Nonpharmacologic interventions
- Pharmacologic agents
- Strategies to optimize assessment and management of pruritus
- Collaborative care
- Development of a treatment plan
- Ongoing assessment and adjustment of therapy
- Resources and support for patients
Presenters:
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Pam Rivard, RN
Person living with PBC
Link to full program:
https://bit.ly/3Dnfb2E
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with primary biliary cholangitis (PBC), discuss the burden of pruritus in PBC and the impact it has on quality of life, including both physical and mental health, from a patient’s perspective.
Presenters:
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas
Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Pam Rivard, RN
Person living with PBC
Link to full program:
https://bit.ly/4gDGDaB
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Jean-Michel Molina, MD, PhD, and Joseph J. Eron, Jr., MD, discuss results from key clinical trials on HIV prevention and treatment as well as sexually transmitted infection (STI) prevention presented at IDWeek and Glasgow 2024, including:
- PURPOSE 1 and 2 comparing lenacapavir injection vs oral TDF/FTC
- TRIO Health Cohort and OPERA examining long-acting cabotegravir as PrEP
- DOLCE comparing DTG/3TC as first-line therapy in treatment-naive patients with HIV
- PRIDOX evaluating the use of DoxyPEP on STI incidence in men who have sex with men on PrEP
Presenters:
Jean-Michel Molina, MD, PhD
Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and lariboisière
Paris, France
Joseph J. Eron, Jr., MD
Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology, Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Link to full program:
https://bit.ly/3BBaZvJ
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Christopher L. Bowlus, MD, discusses recent advances in the management of primary biliary cholangitis (PBC), including:
- Treatment goals
- Use of PPAR agonists for the treatment of PBC
- Clinical trial results for elafibranor (ELATIVE), seladelpar (RESPONSE), and bezafibrate (BEZURSO)
Presenter:
Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
University of California Davis School of Medicine
Sacramento, California
Link to full program:
https://bit.ly/41tvSDu
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, a transfemme nonbinary individual living with HIV shares her experience navigating the healthcare system, alongside her infectious disease physician, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS. Hear them discuss key considerations when caring for gender-diverse individuals, including:
- Understanding how people are more than just a diagnosis
- Prioritizing individuals’ needs and providing whole-person care using shared decision-making
- Strategies to make an environment more affirming and welcoming
- How to be an ally to transgender individuals
- Listen to the individual in front of you
- Hear what they’re telling you
- Make sure they are being affirmed and seen
Link to the full program:
https://bit.ly/3AAOGpv
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Listen in as Rebekah Fenton, MD, MPH, and Sharon G. Humiston, MD, MPH, discuss strategies to achieve health equity in HPV vaccination, including:
- Trends among males vs females
- Messaging considerations for those from diverse populations (eg, LGTBQ+ and rural communities)
- How healthcare professionals can address barriers to care
Then, hear answers from the experts to frequently asked questions regarding HPV vaccination recommendations, timing, and example case studies.
Presenters:
Rebekah Fenton, MD, MPH
Adolescent Medicine Physician
Alivio Medical Center
Chicago, Illinois
Sharon G. Humiston, MD, MPH
Director for Research
Associate Editor of IZ-Express
Immunize.org
Rochester, New York
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Follow along with the slides:
https://bit.ly/4flDxYb
Link to full program:
https://bit.ly/4f06tW4
In this rapid webinar, Meredith E. Clement, MD, and Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD, provide an overview of important topics and studies presented at HIVR4P 2024, including:
- Expanding PrEP options based on results from PURPOSE 2, IMPOWER-22, IMPOWER-24, IPM 054, MTN-025/HOPE OLE, CATALYST, and the HPTN 084 substudy
- Implementing injectable PrEP based on results from PEPFAR, the USAID DISCOVER-Health LA CAB Demonstration Project in Zambia, and the LA CAB PrEP Rapid Start Model in Public Health Clinics
- Improving PrEP uptake based on results from SPrEP and HPTN 091
Presenters:
Meredith E. Clement, MD
Associate Professor
Infectious Diseases
Louisiana State University Health Sciences Center
New Orleans, Louisiana
Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD
Director and Professor, The Desmond Tutu HIV Centre, UCT
CEO, The Desmond Tutu Health Foundation
Cape Town, South Africa
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Link to full program:
https://bit.ly/3NJIDSA
Listen in as Rebekah Fenton, MD, MPH, and Sharon G. Humiston, MD, MPH, discuss strategies to improve your messaging techniques with the HPV vaccine, including:
- Persisting in vaccine recommendation after initial refusal
- Educating patients and their families together
- Ensuring staff are trained to correctly answer questions
- Knowing when interested patients in your state can consent to vaccination without needing parental consent
Presenters:
Rebekah Fenton, MD, MPH
Adolescent Medicine Physician
Alivio Medical Center
Chicago, Illinois
Sharon G. Humiston, MD, MPH
Director for Research
Associate Editor of IZ-Express
Immunize.org
Rochester, New York
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Follow along with the slides:
https://bit.ly/4flDxYb
Link to full program:
https://bit.ly/4f06tW4
Listen in as Sharon G. Humiston, MD, MPH, discusses current trends in HPV, including:
- Incidence and prevalence trends in the US
- Sex-related features of HPV-attributable cancers
- How HPV vaccination uptake can prevent certain types of cancer
- Current guidelines and recommendations for HPV vaccination
Presenter:
Sharon G. Humiston, MD, MPH
Director for Research
Associate Editor of IZ-Express
Immunize.org
Rochester, New York
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Follow along with the slides:
https://bit.ly/4flDxYb
Link to full program:
https://bit.ly/4f06tW4
In this episode, Kathleen Page, MD, and Glenn J. Treisman, MD, PhD, discuss the interplay between addiction and HIV. Learn as they share their approaches to reframing the conversation about addiction and overcoming barriers to effective addiction care for people living with HIV.
Presenters:
Kathleen Page, MD
Professor
Infectious Diseases
Johns Hopkins School of Medicine
Baltimore, Maryland
Glenn J. Treisman, MD, PhD
Eugene Meyer III Professor of Psychiatry and Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
Downloadable slides:
https://bit.ly/3TR3OVV
Program:
https://bit.ly/3WB2VCO
In this episode, Alexander Wong, MD, FRCPC, discusses how to optimize treatment and engagement in care for individuals with HIV and substance use disorder, including:
- Barriers to care for persons with substance use disorder
- Colocating HIV and other services (eg, addiction care medicine, social services)
- Leveraging a multidisciplinary approach to care
- Integrating a low-barrier model to foster an environment of open discussion
- Best practices for opioid agonist therapy implementation
- Considerations for cultural dynamics to provide personalized treatment plans
- Importance of supporting his team members
Presenter
Alexander Wong, MD, FRCPC
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Saskatchewan
Regina, Saskatchewan, Canada
Link to full program:
https://bit.ly/3xicSeF
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:
- The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender women
- An open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy
- 48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIV
- A substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV
Presenters:
Jennifer Cocohoba, PharmD, AAHIVP
Professor of Clinical Pharmacy
Department of Clinical Pharmacy
University of California San Francisco School of Pharmacy
San Francisco, California
David Koren, PharmD, MPH, AAHIVP, FIDSA
Adjunct Clinical Professor
Temple University School of Pharmacy
Clinical Pharmacist Specialist
Temple University Health System
Philadelphia, Pennsylvania
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
See the full program here.
In this episode, Tristan J. Barber, MA, MD, FRCP, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating PTSD in people with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, sharing their own experiences and approaches to thinking about PTSD, structuring appointments, and integrating care.
Presenters:
Tristan J. Barber, MA, MD, FRCP
Consultant in HIV Medicine
Royal Free London NHS Foundation Trust
Honorary Associate Professor
Institute for Global Health
University College London
London, United Kingdom
Glenn J. Treisman, MD, PhD
Eugene Meyer III Professor of Psychiatry and Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
Downloadable slides:
https://bit.ly/4dBu929
Program:
https://bit.ly/3WB2VCO
In this episode, Colleen F. Kelley, MD, MPH, and Jemma Samitpol discuss key considerations to improve the patient experience among transgender persons with HIV, including:
- Unique circumstances faced by transgender people trying to access HIV care (eg, stigma, discrimination)
- Best practices to improve access and linkage to HIV care
- Ways to integrate gender-affirming care into HIV care
- Creating a welcoming and inclusive environment
- Offering same-day HIV treatment
- Addressing potential drug–drug interactions with gender-affirming hormone therapy (GAHT), including ART and natural remedies
- Understanding and communicating expectations of GAHT (eg, treatment response, timing of effects)
- Providing information on the safety of gender-affirming surgeries
- Importance of providing person-centered care (eg, mental health, substance abuse, housing, harm reduction)
- Strategies on how to promote a gender-affirming environment (eg, wearing pronoun buttons, staff training)
- Consequences to the lack of gender recognition laws
- How to “be an ally” for transgender people with HIV
Presenters
Colleen F. Kelley, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Co-Director, Emory Center for AIDS Research
Associated Dean for Research, Emory at Grady
Emory University School of Medicine
Atlanta, Georgia
Kritima Jemma Samitpol
Tangerine Clinic Supervisor
Institute of HIV Research and Innovation
Bangkok, Thailand
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast channel on Apple Podcasts, Google Podcasts, or Spotify.
In this episode featuring faculty from the United States and Europe, Aadia I. Rana, MD, and Laurence Slama, MD, PhD, discuss the subtleties of deciding among HIV treatment options in people with adherence challenges.
Listen as they debate the potential risks and benefits of long-acting ART in this population, considerations for people with viremia or resistance, recommendations concerning proviral DNA genotyping, and how to interpret guidelines and provide truly patient-centered care.
Presenters
Aadia I. Rana, MD
Professor of Medicine
Division of Infectious Diseases
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, Alabama
Laurence Slama, MD, PhD
Doctor
Department of Infectious Diseases
Hôtel Dieu University Hospital
University Paris Cité
Paris, France
Follow along with the slides here.
See the full program here.
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast channel on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.
Listen as he discusses:
- The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
- Options in people with multiclass resistance
- Studies of agents with novel mechanisms of action:
- BRIGHTE (fostemsavir)
- TMB-301/-311 (ibalizumab)
- CAPELLA (lenacapavir)
Faculty
Gregory Huhn, MD, MPHTM,
Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois
Follow along with the slides.
https://bit.ly/4fHmxg5
Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Yvonne Gilleece, MB BCh, BAO, FRCP, uses a case study to illustrate why giving people space and time to engage in HIV care on their terms is key to overcoming potential shame and stigma.
She discusses how people can be very vulnerable when engaging in HIV care, and trauma-informed care can help address these vulnerabilities in a safe, respectful way. Listen as she gives her perspectives on:
- Trauma-informed care
- Overcoming stigma and shame
- Staying in care
Presenter:
Yvonne Gilleece, MB BCh, BAO, FRCP
Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health
Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust
Chair of the British HIV Association
Lead for HIV & Women
Lead for HIV & Hepatitis
Brighton, United Kingdom
Content based on an online CME program supported by an educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3xicSeF
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, George Lau, MD, FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD, MBBS (HKU), and a patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including:
- Consequences to poor adherence to antiviral therapy
- Strategies to promote medication adherence (eg, patient education, setting up routines)
- The role of routine monitoring to prevent complications related to HBV such as hepatocellular carcinoma
Presenter:
George Lau, MD, FRCP (Edin, Lond), FHKAM (Med), FHKCP, FAASLD, MBBS (HKU)
Specialist in Gastroenterology & Hepatology
Chairman and Senior Consultant in Gastroenterology and Hepatology
Humanity and Health Medical Group
Hong Kong, China
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/49TuZ8U
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Gregory Huhn, MD, presents a case study exploring how to optimize oral ART for a person with a long history of different ART regimens.
Listen as he discusses:
- Reasons to consider regimen optimization in the setting of viral suppression
- Evidence for INSTIs in the setting of resistance
- Data on when 2-drug regimens and long-acting regimens may or may not be good options
Faculty
Gregory Huhn, MD
Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, IL
Follow along with the slides.
https://bit.ly/4fHmxg5
Get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Lucas Hill, PharmD, AAHIVP, BCACP, and Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP,discuss what pharmacists need to know to provide high-quality HIV care beyond viral suppression, including treatment strategies and tips for addressing and improving patients’ quality of life.
Listen as they discuss:
- Reasons to consider regimen optimization in the setting of viral suppression
- Evidence that LA ART may reduce internalized stigma
- DHHS recommendations on proviral DNA genotyping
Faculty
Lucas Hill, PharmD, AAHIVP, BCACP
HIV Pharmacist Specialist
UC San Diego Owen Clinic
Assistant Clinical Professor
UC San Diego Skaggs School of Pharmacy
San Diego, California
Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP|
Associate Clinical Professor
Department of Pharmacy Practice and Administrative Sciences
University of New Mexico College of Pharmacy
Albuquerque, New Mexico
In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss strategies for optimizing PBC pruritus care in the clinic setting.
Listen to their conversation on how important it is to ask patients about their pruritus, validate their symptoms and feelings, and offer treatment options framed with realistic expectations.
Presenters:
Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
University of Texas Southwestern
Dallas, Texas
Brenda Remo
Person living with PBC
Downloadable slides:
https://bit.ly/3LHHiuf
Program:
https://bit.ly/4fBLQ3l
To get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD; Marlyn J. Mayo, MD; and Brenda Remo discuss the patient experience with cholestatic pruritus in PBC.
Listen to their conversation on how people describe the experience of cholestatic pruritus, the extent to which pruritus negatively affects quality of life, and the importance of educating healthcare professionals on this important symptom of PBC.
Presenters:
Stuart C. Gordon, MD, FACP, FACG, AGAF, FAASLD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
University of Texas Southwestern
Dallas, Texas
Brenda Remo
Person living with PBC
Downloadable slides:
https://bit.ly/3LHHiuf
Program:
https://bit.ly/4fBLQ3l
To get access to all of our new podcast episodes, subscribe to the CCO podcast channels on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Bradley N. Gaynes, MD, MPH, and Glenn J. Treisman, MD, PhD, discuss the importance of screening, diagnosing, and treating depression in people living with HIV. They illustrate their discussion through a patient case and provide strategies for accomplishing this, including creation of a virtual network and employment of measurement-based care.
Presenters:
Bradley N. Gaynes, MD, MPH
Ray M. Hayworth, MD and Family Distinguished Professor
Professor of Psychiatry and Epidemiology
Director, Division of Global Mental Health
Co-Director, Physician Scientist Training Program
Department of Psychiatry
University of North Carolina School of Medicine
Chapel Hill, North Carolina
Glenn J. Treisman, MD, PhD
Eugene Meyer III Professor of Psychiatry and Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
Downloadable slides:
https://bit.ly/3YgqqSO
Program:
https://bit.ly/3WB2VCO
To get access to all of our new infectious disease podcast episodes, subscribe to the CCO infectious disease podcast channel on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Cristina Mussini, MD,and William R. Short, MD, MPH, FIDSA,discuss the potential role of ART in weight change among people living with HIV.
Listen to their conversation on whether ART switch can lead to weight loss after weight gain and how to counsel people living with HIV on weight loss options, including lifestyle modifications and nonpharmacologic methods.
Presenters
Cristina Mussini, MD
Director of Infectious Diseases Clinics
Professor of Infectious Diseases
University of Modena School of Medicine
Modena, Italy
William R. Short, MD, MPH, FIDSA
Associate Director of the
HIV Clinical Trials Unit
Associate Professor of Medicine
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Follow along with the slides here.
https://bit.ly/3RLdrET
See the full program here.
https://bit.ly/450Ql2x
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast channel on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, uses a case study to illustrate why patients living with HIV may disengage with their care and how best to reengage them once they present at the clinic, including discussion of:
- The valid reasons patients have for disengaging with their HIV care
- Why the return to care should be celebrated
- How to support people living with HIV as they reengage in care
- How to prevent future loss to follow-up
Presenter:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
CEO, Desmond Tutu Health Foundation
Director, Desmond Tutu HIV Centre
Professor of Medicine
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Content based on an online CME program supported by an educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3xicSeF
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
In this second podcast of our series, hear expert faculty explore the CDC recommendations for mpox protection and discuss how vaccination can lead to immunologic equity. Topics include:
- Should we consider mpox an STI?
- What strategies can be used to improve mpox vaccination and overcome the challenges of vaccine implementation?
- Can mpox vaccine be coadministered with other vaccines?
- What is the intersection between mpox and HIV?
Presenters
Carlos del Rio, MD
Distinguished Professor of Medicine (Infectious Diseases)
Emory University School of Medicine
Professor of Global Health and Epidemiology
Rollins School of Public Health
Atlanta, Georgia
Aniruddha (Anu) Hazra, MD
Assistant Professor of Medicine, Section of Infectious Disease and Global Health
Director, Infectious Diseases Fellowship Program
Medical Director, UCM Sexual
Wellness Clinic
University of Chicago
Chicago, Illinois
Learn more about the key aspects of mpox infections and prevention through vaccination in our full program,“Protection Beyond Outbreaks: Routine Mpox Vaccination for Vulnerable Populations.”
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hear expert faculty answer common questions about the risk, impact, and recommendations for protection against mpox, including:
- Why is mpox relevant to clinical practice?
- Who is at highest risk for mpox?
- How is mpox transmitted, and what are the clinical manifestations and complications of mpox infections?
- What are current ACIP recommendations for mpox vaccination?
- What about pre- and postexposure vaccination?
Presenters
Carlos del Rio, MD
Distinguished Professor of Medicine (Infectious Diseases)
Emory University School of Medicine
Professor of Global Health and Epidemiology
Rollins School of Public Health
Atlanta, Georgia
Aniruddha (Anu) Hazra, MD
Assistant Professor of Medicine, Section of Infectious Disease and Global Health
Director, Infectious Diseases Fellowship Program
Medical Director, UCM Sexual
Wellness Clinic
University of Chicago
Chicago, Illinois
Learn more about thekey aspects of mpox infections and prevention through vaccination in our full program,“Protection Beyond Outbreaks: Routine Mpox Vaccination for Vulnerable Populations.”
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Roger Bedimo, MD, MS, FACP, examines patient and regimen-based PrEP barriers and discusses practical interventions to support PrEP adherence in key populations. Topics covered include:
- Individual and community perspectives on PrEP barriers
- Key barriers by principal populations
- Strategies to support PrEP delivery
- PrEP options for key populations
- PrEP efficacy based on adherence in cisgender men and women
- Comparing FTC/TDF vs FTC/TAF or CAB for PrEP
- PrEP in pregnancy and breastfeeding
- Drug–drug interactions with gender-affirming hormone therapy
Presenter:
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Interim Director, Office of Global Health
UT Southwestern Medical Center
Chief, Infectious Diseases Section
VA North Texas Health Care System
Dallas, Texas
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/49x0W6D
Follow along with the slides:
https://bit.ly/3KmW4pN
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Roger Bedimo, MD, MS, FACP, discusses strategies to overcome health disparities to improve PrEP uptake, including:
- Targeting key populations that would benefit from PrEP but have low rates of uptake, such as transgender women and people who inject drugs
- Addressing intersectionality
- Overcoming implicit bias
- Addressing PrEP inequity by geographic region
- Expanding PrEP uptake by expanding HCPs who prescribe it
- Improving PrEP education for both patients and HCPs
Presenter:
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Interim Director, Office of Global Health
UT Southwestern Medical Center
Chief, Infectious Diseases Section
VA North Texas Health Care System
Dallas, Texas
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/49x0W6D
Follow along with the slides:
https://bit.ly/3KmW4pN
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Roger Bedimo, MD, MS, FACP, examines provider-based and structural PrEP barriers and discusses practical methods for healthcare professionals to overcome these challenges. Topics covered include:
- Potential provider barriers to prescribing PrEP
- Strategies to facilitate conversations about PrEP
- Addressing the gap in PrEP provider training
- Structural barriers for PrEP coverage, such as lack of insurance and complexity of billing
- Informed consent for minors
- CDC guidelines on HIV testing and renal or lipid monitoring while on PrEP
- The role of PrEP champions or PrEP navigators, such as in the SNAPS PrEP Navigation Program
- Solutions to common problems with PrEP persistence, such as use of telehealth and same-day PrEP initiation
- Expanding PrEP options
Presenter:
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Interim Director, Office of Global Health
UT Southwestern Medical Center
Chief, Infectious Diseases Section
VA North Texas Health Care System
Dallas, Texas
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/49x0W6D
Follow along with the slides:
https://bit.ly/3KmW4pN
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Tristan J. Barber, MA, MD, FRCP, and Roger Bedimo, MD, MS, FACP, help you decide whether and how to modify ART in virologically suppressed individuals by critically appraising whether using newer agents may improve their treatment satisfaction.
Listen to their conversation about their own approaches to evaluating whether each person living with HIV is taking the best ART regimen for them, as well as ways to proactively assess challenges people may be facing with their HIV ART.
Presenters
Tristan J. Barber, MA, MD, FRCP
Consultant in HIV Medicine
Royal Free London NHS Foundation Trust
Honorary Associate Professor
Institute for Global Health
University College London
London, United Kingdom
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Interim Director, Office of Global Health, UT Southwestern Medical Center
Chief, Infectious Diseases Section,
VA North Texas Health Care System
Dallas, Texas
Follow along with the slides here.
https://bit.ly/44N2w2Q
See the full program here.
https://bit.ly/450Ql2x
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the updated CDC guidance on how to monitor for HIV in people receiving PrEP, including:
- Rationale for why HIV monitoring differs for people receiving LA vs daily PrEP
- Description of LEVI syndrome
- How to transition a person from LA PrEP to HIV ART if they test positive for HIV
Presenter:
Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier, Jr., MD Education Director and Professor of Internal Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Medical Director
Care Point Health and Wellness
Tallahassee, Florida
Link to the full program:
https://bit.ly/49x0W6D
Link to the slideset:
https://bit.ly/4bzZoth
To get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Jonathan Appelbaum, MD, FACP, AAHIVS, discusses the newest data supporting LA ART use in people with adherence challenges or viremia, including:
- The LATITUDE study, an open-label phase III study of LA CAB + RPV in people with a suboptimal response or nonadherence to oral ART
- Updates to the Ward 86 cohort, which showed 81% of patients with viral suppression on LA CAB + RPV at Week 48
- The CARES study, an open-label, noninferiority phase IIIb study of LA CAB + RPV in people with baseline resistance mutations
Presenter:
Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier, Jr., MD Education Director and Professor of Internal Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Medical Director
Care Point Health and Wellness
Tallahassee, Florida
Link to the full program:
https://bit.ly/49x0W6D
Link to the slideset:
https://bit.ly/4bzZoth
To get access to all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
In this episode, Angela Branche, MD, FIDSA, and Jewel Mullen, MD, MPH, MPA, FACP, address commonly asked questions about the RSV vaccine, including:
- Considerations for vaccine eligibility
- Recommendations for pregnant persons
- Vaccine administration based on RSV seasonality
- Use of the vaccine in persons receiving immunosuppressive medications
- Safety data (eg, risk of serious adverse events)
- Natural immunity of RSV
- Vaccine cost and insurance coverage
Faculty:
Angela Branche, MD, FIDSA
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York
Jewel Mullen, MD, MPH, MPA, FACP
Associate Dean for Health Equity
Associate Professor of Population Health and Internal Medicine
University of Texas at Austin Dell Medical School
Austin, Texas
Content based on a CME program supported by an educational grant from GlaxoSmithKline.
Follow along with a downloadable slideset at:
https://bit.ly/44vCnFu
Link to full program:
https://bit.ly/3WvSY9Z
To get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Jewel Mullen, MD, MPH, MPA, FACP, discusses strategies for implementing RSV vaccines into practice, with an emphasis on:
- Understanding the reasoning for Advisory Committee on Immunization Practices RSV vaccine recommendations
- Factors that influence vaccine uptake and patient decision-making
- Considerations for patient and healthcare professional vaccine hesitancy
- Building vaccine confidence in both patients and healthcare professionals
- Using shared decision-making models (eg, SHARE approach)
Faculty:
Jewel Mullen, MD, MPH, MPA, FACP
Associate Dean for Health Equity
Associate Professor of Population Health and Internal Medicine
University of Texas at Austin Dell Medical School
Austin, Texas
Content based on a CME program supported by an educational grant from GlaxoSmithKline.
Follow along with a downloadable slideset at:
https://bit.ly/44vCnFu
Link to full program:
https://bit.ly/3WvSY9Z
To get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Angela Branche, MD, FIDSA, explores the burden of RSV disease in older adults, including:
- RSV seasonality and disease burden
- Symptoms and complications of RSV infection
- Older age as a key risk factor for severe RSV disease and complications (eg, pneumonia, hospitalization)
- Comorbidities associated with increased risk of RSV hospitalization
- RSV hospitalization rates among different racial and ethnic minority groups and socioeconomic statuses
Faculty:
Angela Branche, MD, FIDSA
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York
Content based on a CME program supported by an educational grant from GlaxoSmithKline.
Follow along with a downloadable slideset at:
https://bit.ly/44vCnFu
Link to full program:
https://bit.ly/3WvSY9Z
To get access to all of our new podcasts, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify
Using common case scenarios, Robert H. Hopkins, Jr., MD, MACP, and Laura P. Hurley, MD, MPH, discuss strategies for optimizing shingles vaccine uptake, including:
- The pathophysiology of shingles to better understand risk and burden
- CDC guidelines and ACIP shingles vaccine recommendations, including considerations for those who are immunocompromised
- Strategies for optimizing shingles vaccine uptake no matter the clinical setting
- How to address shingles vaccine‒related adverse events
- Addressing insurance-related concerns
Presenters:
Robert H. Hopkins, Jr., MD, MACP
Professor of Internal Medicine and Pediatrics
Chief, Division of General Internal Medicine
University of Arkansas for Medical Sciences
School of Medicine
Little Rock, Arkansas
Laura P. Hurley, MD, MPH
General Internist and Health Services Researcher
Associate Professor of Medicine
Department of General Internal Medicine
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Link to downloadable slides:
https://bit.ly/4aWn6jh
Link to full program:
https://bit.ly/4aWBiJ0
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, and Nimish Patel, PharmD, PhD, AAHIVP, cover the most impactful clinical studies presented at CROI 2024, including:
- New data on long-acting ART, including:
- The CARES study of LA CAB + RPV in a sub-Saharan African population using a public health approach
- The IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIV
- The ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ART
- Updated data from San Francisco’s Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baseline
- Case series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV alone
- Data on HIV and STI prevention, including:
- The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San Francisco
- BIC/FTC/TAF for PEP
- Offering PrEP following PEP
Presenters:
Samantha Strong, PharmD, BCACP, AAHIVP, CDCES
Clinical Director of Pharmacy
Nevada Health Centers
Las Vegas, Nevada
Nimish Patel, PharmD, PhD, AAHIVP
Professor of Clinical Pharmacy
Skaggs School of Pharmacy & Pharmaceutical Sciences
University of California, San Diego
La Jolla, California
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
See the full program here:
https://bit.ly/49x0W6D
In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:
- Engage key stakeholders in the provision of HBV care
- Provide HBV management resources to support PCPs who are doing screening
- Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBV
Presenters:
Su Wang, MD, MPH, FACP
Medical Director
Center for Asian Health and Viral Hepatitis Programs
Cooperman Barnabas Medical Center
RWJBarnabas-Rutgers Medical Group
Associate Member
Health Care Policy and Aging Research
The Rutgers Institute for Health
Senior Advisor
Global Health, Hepatitis B Foundation
Florham Park, New Jersey
Richard R. Andrews, MD, MPH
President, Houston Viral Hepatitis Task Force
Former Co-Chair, National Task Force on Hepatitis B
Board-Certified Family Medicine
Addiction Medicine Physician
Houston, Texas
Ruth Brogden, MPH
Patient Advocate
Amy S. Tang, MD
Former Co-Chair, National Task Force on Hepatitis B
Director of Immigrant Health
North East Medical Services
San Francisco, California
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/44hXpHu
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Gregory Huhn, MD, MPHTM, uses a case study to explore the reasons healthcare professionals and people living with HIV may want to further optimize ART in the setting of viral suppression.
To determine the best outcome for this case study, Dr Huhn discusses the reasons individuals may not be satisfied with daily oral ART and examines data to suggest that, for some individuals with virologic suppression, switching to long-acting ART may address internalized HIV stigma.
Finally, Dr Huhn takes a look at the optimal candidates for switching to a long-acting ART regimen and settings where proviral DNA genotyping may be considered prior to switching.
Presenter:
Gregory Huhn, MD, MPHTM
Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois
To access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
See the full program here.
In this episode, Maria Buti, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including:
- Barriers to HBV screening, including patient- and provider-specific barriers (eg, lack of education, failure to disclose or discuss risk factors, perceived low risk, stigma)
- Applying CDC recommendations for universal HBV screening in adults
- Strategies to improve HBV transitions of care (eg, improved education, simplify criteria for screening and monitoring, alternative testing sites)
- Importance of testing close contacts for HBV after initial diagnosis and promoting HBV vaccination
Presenter:
Maria Buti, MD
Professor of Medicine
Senior Consultant
Liver Unit
Hospital Universitario Valle Hebron
Barcelona, Spain
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/49TuZ8U
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Joseph J. Eron, Jr., MD, and Monica Gandhi, MD, MPH, discuss the key HIV studies from CROI 2024 that are influencing their clinical practice, including:
- New data surrounding long-acting ART, including:
- The CARES study of LA CAB + RPV in a Sub-Saharan African population using a public health approach
- The IMPAACT 2017 MOCHA study evaluating switching to LA CAB + RPV in adolescents living with HIV
- The ACTG A5359 LATITUDE study of LA CAB + RPV in people with adherence challenges to oral ART
- Updated data from San Francisco’s Ward 86 Clinic using LA CAB + RPV in people without viral suppression at baseline
- Case series of LA CAB (± RPV) + LEN for select people living with HIV unable to take oral ART and unable to use LA CAB + RPV alone
- Data on comorbidities and coinfections, including:
- A REPRIEVE proteomic analysis to elucidate mechanistic pathways of statin effects on plaque
- The ACTG A5371 SLIM LIVER study of semaglutide for MASLD in people living with HIV
- The impact of Doxy-PEP guideline implementation on STIs in men who have sex with men and transgender women in San Francisco
- Potential novel treatment options on the horizon for people living with HIV, including:
- Phase II data on LEN + ISL dosed orally once weekly
- Early data on other oral weekly options
- Data on bNAbs in combination or with other ART agents
Presenters:
Joseph J. Eron, Jr., MD
Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology
Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco
San Francisco, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.
Link to full program:
https://bit.ly/4awdWJM
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:
- Patient subgroups to consider for treatment outside guideline criteria
- Adverse event and cost-effectiveness considerations
- Integration of patient perspectives in wider treatment
Presenters:
Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Jacki Chen, PhD
Patient Advocate
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/4a60GM4
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Robert Wong, MD, MS, and a patient discuss opportunities to optimize care for people living with hepatitis B virus (HBV), including:
- Opportunities to improve patient education, including education for expectant mothers with HBV
- Potential cultural considerations that may result in delayed HBV diagnosis and care
- Stigma reduction with universal HBV screening and vaccination
- Strategies to improve patient education (eg, online resources, advocacy groups, use of layman’s terms and diagrams, repetition)
Presenter:
Robert Wong, MD, MS
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/49TuZ8U
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Listen to Roger Bedimo, MD, MS, FACP, discuss considerations for older people living with HIV, including:
- Polypharmacy and deprescribing
- The risk of cardiovascular events with various ART regimens
- Approaches for managing weight gain
Presenter:
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Interim Director, Office of Global Health
UT Southwestern Medical Center
Chief, Infectious Diseases Section
VA North Texas Health Care System
Dallas, Texas
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
To download the slides:
https://bit.ly/49zrnZs
To view the full online program:
https://bit.ly/49x0W6D
In this episode, Dr. Bedimo discusses best practices for individualized care in transgender women living with HIV, including:
- Providing services in a gender-affirmative care model
- Proactive counseling on drug-drug interactions with gender-affirming hormone therapy
- Strategies to reduce adverse events
Presenter:
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Interim Director, Office of Global Health
UT Southwestern Medical Center
Chief, Infectious Diseases Section
VA North Texas Health Care System
Dallas, Texas
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
To download the slides:
https://bit.ly/49zrnZs
To view the full online program:
https://bit.ly/49x0W6D
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss how to optimize the use of COVID-19 antivirals and how to navigate drug-drug interactions between COVID-19 treatments and a patient’s home medications. Their discussion includes:
- Current COVID-19 landscape
- COVID-19 testing and vaccination recommendations
- Treatment guidelines and antiviral options for nonhospitalized adults with COVID-19
- Resources for assessing and managing COVID-19 antiviral-related drug-drug interactions
- Answers to learners’ most pressing questions
Presenters:
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
Trinh P. Vu, PharmD, BCIDP
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmacy
Emory University Hospital Midtown
Atlanta, Georgia
Slideset: https://bit.ly/4c6kwbJ
Downloadable resource:
https://bit.ly/49rofP6
Full program:
https://bit.ly/3P16TR8
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.
In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:
- Current therapies
- Studies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDF
- Kaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis B
- Early vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV Transmission
- Investigational functional cure strategies
- B-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV Infection
- MARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV Infection
- REEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBeAg-Positive CHB
- HBV003: VTP-300 + Nivolumab Added to NA Therapy for Chronic HBV Infection
- CVP-NASVAC: Nasally Administered Therapeutic Vaccine for Chronic HBV Infection
Presenter:
Nancy Reau, MD
Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center
Chicago, Illinois
Link to full program:
https://bit.ly/47XJlU4
In this episode, LaRon E. Nelson, PhD, RN, FNP, FNAP, FNYAM, FAAN, discusses the role that healthcare professionals (HCPs) may be playing in their patients’ pre-exposure prophylaxis (PrEP) persistence and strategies to modify their approach to encourage persistence, from Clinical Care Options (CCO), including:
- Racial disparities in the PrEP care continuum
- Consideration that PrEP persistence may be less about relationship to the drug than the environment
- Examples of HCP implicit bias regarding PrEP responsibility based on racism and sexual prejudice
- Impact of HCP implicit bias on PrEP persistence
- Impact of racism on clinical cognition
- The demonstrated effects of stereotype threat and the potential healthcare implications
- Ways to improve clinical conversations about PrEP
- Providing person-centered care to encourage PrEP persistence using the Client‑Centered Care Coordination (C4™) Model
Faculty
LaRon E. Nelson, PhD, RN, FNP, FNAP, FNYAM, FAAN
Independence Foundation Professor
School of Nursing
Yale University
New Haven, Connecticut
Follow along with the slides:
https://bit.ly/497cahK
Link to full program:
https://bit.ly/3ZlICsL
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Nancy Reau, MD, and her patient discuss opportunities to optimize care for people living with hepatitis B virus and hepatitis delta virus, including:
- The importance of patient education along the care continuum
- Ensuring smooth transitions of care and communication between medical teams
- Screening hepatitis delta in persons with chronic hepatitis B
- Managing hepatitis delta, including considerations for clinical trials
- Promoting patient advocacy
Presenter:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program: bit.ly/3SrMuGO
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, David Saunders discusses the value of nonstigmatizing discussions between people using HIV pre-exposure prophylaxis (PrEP) and healthcare professionals, including:
- Encouraging accountability to individualize adherence strategies and improve persistence to PrEP
- Reducing stigma, discrimination, and prejudice in healthcare settings to foster PrEP persistence
Faculty:
David Saunders
PrEP User and Advocate
Link to full program:
https://bit.ly/3ZlICsL
To automatically get new episodes as soon as they launch, subscribe to the CCO Infectious Disease podcast.
In this episode, Sarah M. Wood, MD, MS, discusses data and recommendations for long-acting pre-exposure prophylaxis (PrEP) as a strategy to support PrEP persistence and engagement for adolescents, including:
- The PrEP care continuum for adolescents
- System barriers to PrEP coverage and privacy concerns for adolescents
- The benefits and challenges of same-day PrEP initiation and real-world data to support it
- Interventions to support PrEP persistence
- PrEP options for different populations and the data to support the efficacy of long-acting cabotegravir (CAB) PrEP from HPTN 083 and HPTN 084
- Data and recommendations for a CAB PrEP oral lead-in
- Data from HPTN 083 showing no interaction between feminizing hormone therapy and long-acting CAB PrEP
- Project LifeSkills: a culturally specific, empowerment-based, group-delivered behavioral HIV prevention intervention for young transgender women
Faculty
Sarah M. Wood, MD, MS
Assistant Professor of Pediatrics
Division of Adolescent Medicine
Perelman School of Medicine
University of Pennsylvania
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania
Follow along with the slides:
https://bit.ly/3Ha9Kmt
Link to full program:
https://bit.ly/3ZlICsL
To automatically get new episodes as soon as they launch, subscribe to the CCO Infectious Disease podcast show.
In this episode, Angela Branche, MD, discusses RSV vaccines in older adults, including:
- Current Advisory Committee on Immunization Practices recommendations
- Risk factors associated with severe RSV disease, including RSV-related hospitalizations
- Approach to stratifying risk factors (eg, age, comorbidities) in determining which adults may benefit from the RSV vaccine
- Ongoing research on RSV vaccines in younger adults (eg, aged 40s and 50s years) with chronic comorbidities
- Health disparities related to RSV vaccines
- Considerations for a risk-based approach, rather than age alone, to determine vaccine candidacy
Faculty:
Angela Branche, MD
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York
Link to full program:
https://bit.ly/3nb25xe
Link to downloadable slides:
https://bit.ly/3TsXym5
In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:
- Updated CDC recommendations for one-time universal screening for HBV
- Addressing patient-, provider-, and system-level barriers to universal HBV screening
- Best practices for implementation of HDV screening
Presenters:
Douglas Dieterich, MD
Director, Institute for Liver Medicine
Professor of Medicine
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Robert Wong, MD, MS
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/4atS42z
In this episode, Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP, and Anne Teitelman, PhD, FNP-BC, FANNP, FAAN, discuss key PrEP considerations for advanced practice providers in primary care settings, including:
- The importance of having PrEP navigators to help with logistics and be a point of contact for patients
- Where to find education and resources to familiarize yourself with PrEP and its prescribing
- Safety considerations and adverse events associated with PrEP options
- PrEP coverage and cost
- How to discontinue PrEP and the risk of resistance if someone acquires HIV while taking PrEP
Faculty
Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP
Director, HIV Prevention and Treatment
St. Thomas Community Health Center
New Orleans, Louisiana
Anne Teitelman, PhD, FNP-BC, FANNP, FAAN
Associate Professor Emeritus of Nursing and Global Women’s Health
Department of Family and Community Health
School of Nursing
University of Pennsylvania
Professor
Thomas Jefferson University
College of Nursing
Philadelphia, Pennsylvania
Link to full program:
https://bit.ly/3PZGYdR
In this podcast episode, Mark Brennan-Ing, PhD, and Nina I. Martinez discuss mental health challenges in people living with HIV and much-needed strategies to overcome these challenges to optimize engagement in HIV care, including:
- The increased rates of mental health disorders and substance use among people living with HIV
- How mental health disorders contribute to challenges with adherence to HIV treatment and engagement in care
- How social isolation and stigma can affect outcomes despite access to HIV care and ART
- The importance of mental health screenings as part of HIV care
- Integrating mental health services into HIV care as a strategy to overcome mental health challenges being a barrier to care
Presenter:
Mark Brennan-Ing, PhD
Director of Research and Evaluation
Brookdale Center for Healthy Aging
Hunter College
The City University of New York
New York, New York
Nina I. Martinez
Public Health Consultant
Link to full program:
https://bit.ly/3TqVnl1
In this podcast episode, Isolde Butler, MD, MPH, a healthcare professional caring for people living with HIV, and Marissa Gonzalez, an individual living with HIV, discuss strategies to improve healthcare professionals’ competencies in delivering optimal HIV care from the start to better support patients in overcoming barriers to sustained care engagement.
The topics they discuss include:
- An introduction to the guidelines on ART initiation—start quickly and choose the therapy that is effective and tolerable
- The patient experience, from initial diagnosis to treatment selection, noting that where people get diagnosed matters in determining the level of support they will receive
- The complete HIV care team: healthcare professionals, navigators, case managers, behavioral health providers, mental health providers, and so on. Smaller clinics may not be able to provide adequate support to meet all patient needs
- How to navigate the first visit after an HIV diagnosis, including patient–provider treatment discussions on the available therapies that can help with stigma
- HIV stigma education; navigating the miseducation and misinformation
Presenters:
Isolde F. Butler, MD, MPH
Chief Medical Officer
Cresentcare
New Orleans, Louisiana
Marissa Gonzalez
Chair
Community Advisory Board
The Well Project
Link to full program:
https://bit.ly/3TqVnl1
In this podcast episode, Babafemi Taiwo, MBBS, and Vincent Crisostomo discuss the evolving treatment landscape for aging people living with HIV, encompassing the clinical and external resources necessary to support physical and psychosocial health. The topics discussed include:
• Mindful prescribing and understanding the impact an HIV diagnosis can have on one’s mental health, including social isolation
• How to address patients’ needs and establish a trusting relationship within the confines of a 15-minute clinic visit
• How research is helping healthcare professionals better understand this clinical situation and discover opportunities to equalize metrics
• The critical role of social workers and community organizations in patients’ overall care
• Accessing federal HIV disability resources
• Informed patient–provider discussion and counseling on medical decision-making regarding ART
• How healthcare professionals can move toward clinical practice that leaves no one behind
Presenter:
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Vincent Crisostomo
Director
Aging Services
San Francisco AIDS Foundation
San Francisco, California
Link to full program:
https://bit.ly/3TqVnl1
In this episode, Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discusses data and recommendations for providing HIV prevention options as a strategy to support PrEP persistence and engagement, including:
- Postexposure prophylaxis (PEP) recommendations and the data for PEP-in-Pocket
- Offering PrEP to everyone who receives PEP
- Currently recommended PrEP options and the safety and adverse event considerations with each option
- Monitoring recommendations for the different PrEP options
- The importance of proactively addressing PrEP safety concerns that could lead to PrEP discontinuation
Faculty
Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES
Assistant Professor
Pharmacotherapeutics and Clinical Research
University of South Florida Taneja College of Medicine
Tampa, Florida
Follow along with the slides:
bit.ly/48cULUN
Link to full program:
bit.ly/3ZlICsL
During the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.
In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including:
- A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the treatment regimen of people with PBC with an incomplete response to ursodeoxycholic acid
- Lessons learned from a long-term outcomes study of people with PBC
- Results from 2 phase II studies of obeticholic acid plus bezafibrate in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid
Presenter:
Kris V. Kowdley MD, FAASLD, FACP, FACG
Professor, Elson S. Floyd College of Medicine
Washington State University
Director, Liver Institute Northwest
Seattle, Washington
Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI
In this episode, Dr Tavell Kindall and Jona Tanguay discuss actionable strategies for advanced practice providers to increase the frequency at which PrEP is offered and initiated in primary care settings. Topics covered include:
- Available training resources on how to offer PrEP in primary care
- Affordable, accessible PrEP options, including patient assistance programs
- Using electronic health records to identify candidates for PrEP
- Opportunities to offer PrEP during appointments regarding birth control, STIs, or any other sexual health concerns
- How to offer 3-site STI testing at your facility
- Wrapping PrEP into primary care
- Incorporating navigators or care coordinators to reduce logistical barriers and reach underserved populations
- Rapid testing, mobile testing, and Tele-PrEP as ways to facilitate PrEP initiation and simplify routine PrEP visits
- Healthcare professionals’ personal biases as a potential barrier to PrEP
- Using ICD-10 codes for HIV PrEP as a way to further destigmatize PrEP and simplify billing
Faculty:
Tavell L. Kindall, PhD, DNP, ARNP, FNP-BC, AACRN, AAHIVS, FAANP
Director, HIV Prevention and Treatment
St. Thomas Community Health Center
New Orleans, Louisiana
Jona Tanguay, MMSc, PA-C, AAHIVS
Medical Program Lead - Substance Use Disorders at Whitman-Walker Health
Associate Medical Director - Transgender Health at Amida Care
President-Elect at GLMA: Health Professionals Advancing LGBTQ+ Equality
Clinical Instructor at Yale School of Medicine
Founder at ChemsexHarmReduction.org
Washington, DC
Content is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.
Link to full program:
https://bit.ly/3PZGYdR
In this third of 3 episodes, global HIV experts and advocates discuss the current status of HIV cure research, including key concepts to understand and communicate when counselling patients, colleagues, and the broader community on HIV cure:
- Latest understanding of the viral reservoir
- New insights and questions on the best timing for cure interventions
- Current investigational strategies showing promise
- Ethical considerations related to participant education, representation in clinical trials, and planning for broad global access
Faculty:
Katharine J. Bar, MD
Associate Professor of Medicine
Director, Penn CFAR Virus and Reservoirs Core
University of Pennsylvania
Philadelphia, Pennsylvania
Jennifer Blanchette, PhD
Independent Contractor
Clinical Care Options
Colorado, United States
Krista L. Dong, MD
Clinical Director, FRESH Cohort
Assistant Professor of Medicine
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts
Karine Dubé, DrPH, MPhil
Associate Professor
UCSD School of Medicine
Division of Infectious Diseases and Global Public Health
San Diego, California
Richard Jefferys
Basic Science, Vaccines & Cure Project Director
Treatment Action Group
New York, New York
Sharon R. Lewin, AO, FRACP, PhD, FAA, FAHMS
Director
Doherty Institute
Melbourne Laureate Professor and Head
Department of Infectious Diseases
The University of Melbourne
Consultant Physician
Victorian Infectious Diseases Service
Royal Melbourne Hospital
Consultant Physician and Adjunct Professor Department of Infectious Diseases
Alfred Hospital and Monash University
Melbourne, Australia
Angelina Namiba
Founder Member
4M Network of Mentor Mothers
London, United Kingdom
Link to full program:
https://bit.ly/3QFwv7n
In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:
- Burden of CRE infections in the United States
- Mechanisms of resistance
- Changing epidemiology
- Use of rapid diagnostic tests
- IDSA guidance recommendations, including supporting data
- Approach to designing treatment regimens, including weighing patient- and infection-related factors
Faculty:
Julie Ann Justo, PharmD, MS, FIDSA, BCPS
Clinical Pharmacist Lead – Infectious Diseases
Inpatient Pharmacy
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Link to full program:
https://bit.ly/41a8Mj0
Link to accompanying ClinicalThought commentary:
https://bit.ly/4865T57
Link to downloadable infographic:
https://bit.ly/3t7NpT2
In this episode, Errol L. Fields, MD, PhD, MPH, and Armonté Butler, MPH, a pre-exposure prophylaxis (PrEP) advocate, discuss strategies for overcoming barriers to uptake of PrEP for HIV in adolescents and young adults, based on the unique needs of this patient population. Topics covered include:
- Methods for building trust between patients and providers
- Ways to practice shared decision-making and how this process hinges on respecting patients’ autonomy and personhood
- How to empower young people to ask for the assistance they need
- How to navigate consent and confidentiality issues
- Information about payment options
- Strategies to improve adherence for youth
- The best ways to provide support and flexibility throughout this process to promote persistence on PrEP
Faculty:
Errol L. Fields, MD, PhD, MPH
Associate Professor of Pediatrics
Division of Adolescent/Young Adult Medicine
Department of Pediatrics
Johns Hopkins School of Medicine
Baltimore, Maryland
Armonté Butler, MPH
Associate Director, LGBTQ Health & Rights
Advocates for Youth
Washington, DC
Content is supported by independent educational grants from Gilead Sciences, Inc. and ViiV Healthcare.
Link to full program:
https://bit.ly/3PZGYdR
During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.
In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including:
- A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acid
- A study that explored racial differences as they relate to the presentation and diagnosis of PBC
Presenter:
Stuart C. Gordon, MD, FAASLD
Director of Hepatology
Henry Ford Health System
Professor of Medicine
Wayne State University School of Medicine
Detroit, Michigan
Link to commentary:
https://bit.ly/3GzRMt2
Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI
During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.
In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including:
- A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)
- A study that evaluated the effectiveness and safety of second-line therapy in PBC where obeticholic acid with or without a fibrate was added to the treatment regimen of people with PBC with an incomplete response to UDCA
- A retrospective review of the rates of hyperlipidemia, atherosclerosis, and/or hepatic steatosis in patients with PBC
Presenter:
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas
Link to commentary:
https://bit.ly/47PmGdc
Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI
In this episode, Martin Rios discusses how pre-exposure prophylaxis (PrEP) persistence depends on healthcare professional knowledge, including:
- Their own experiences with the various PrEP providers they have seen
- The relief that has come with seeing PrEP providers who are supportive and knowledgeable about the different PrEP options
- The challenges that have come with seeing PrEP providers who are unwilling to prescribe PrEP altogether or who will prescribe PrEP when asked but are not knowledgeable about the options
Faculty:
Martin Rios
PrEP User and Advocate
Philadelphia, Pennsylvania
Link to full program:
https://bit.ly/3ZlICsL
In this episode, Meredith Clement, MD, and Whitney C. Irie, MSW, PhD, discuss key considerations for pre-exposure prophylaxis (PrEP) uptake in cisgender women, including:
- How to incorporate conversations on PrEP during a short clinic visit
- Helpful resources about PrEP to share with patients
- Leveraging clinic staff to improve PrEP uptake and persistence
- Available data on on-demand PrEP
- Approach to discussing PrEP contraindications and adverse events with patients
- Considerations for PrEP in pregnant persons or those wanting to conceive
- The importance of inclusiveness in PrEP marketing
- Key barriers limiting PrEP uptake in cisgender women (eg, stigma, risk perception)
- Interventions to improve PrEP uptake
Faculty
Meredith Clement, MD
Associate Professor
Infectious Diseases
Louisiana State University
Health Sciences Center
New Orleans, Louisiana
Whitney C. Irie, MSW, PhD
Assistant Professor
Department of Social Work
Boston College
Brighton, Massachusetts
Link to full program:
https://bit.ly/3PZGYdR
In this episode, Helen Y. Chu, MD, MPH, shares updates on RSV seasonality, including:
- Surveillance limitations due to the testing availability in adults
- Current 2023/2024 season trends, including predictions for other respiratory viruses (eg, influenza, SARS-CoV-2)
- Considerations for RSV administration
- RSV vaccine coadministration with influenza and COVID-19 vaccines
Faculty:
Helen Y. Chu, MD, MPH
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
School of Medicine
Seattle, Washington
Link to full program: https://bit.ly/3nb25xe
Link to downloadable slides: https://bit.ly/3TsXym5
In this episode, Rick Zimmerman, MD, MPH, FAAFP, discusses RSV vaccines in older adults, including:
- Breakthroughs in RSV vaccine development
- RSV vaccine snapshot in older adults
- FDA-approved RSV vaccines for older adults
- CDC evidence to recommendations framework for vaccines
- RSV burden in older populations
- Benefits and harms of RSV vaccination
- RSV vaccine efficacy and safety in older adults
- CDC Advisory Committee Immunization Practices recommendations for RSV vaccines in older adults
- Populations at high risk for severe RSV disease
- Vaccination considerations based on the upcoming RSV season
Faculty:
Richard Zimmerman, MD, MPH, FAAFP
Professor
Department of Family Medicine and Clinical Epidemiology
University of Pittsburgh
Pittsburgh, Pennsylvania
Content based on an online CME program supported by an independent educational grant from GlaxoSmithKline.
Link to full program: https://bit.ly/49YBZ4r
Link to downloadable slides: https://bit.ly/3GocjRe
In this episode, Angela Branche, MD; Pamela Rockwell, DO, FAAFP; and Richard Zimmerman, MD, MPH, FAAFP, discuss the clinical presentation of RSV in older adults and available diagnostic tests for RSV, including:
- Comparison of RSV clinical symptoms to influenza and COVID-19, including differentiating symptoms at infection onset
- RSV disease progression
- RSV diagnostic approaches
- How RSV diagnosis of adults may differ from diagnosis of children
- Clinical considerations for RSV testing
- How to improve RSV awareness among patients
Program Director:
Pamela Rockwell, DO, FAAFP
Professor
Family Medicine
University of Michigan Medical School
Ann Arbor, Michigan
Faculty:
Angela Branche, MD
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York
Richard Zimmerman, MD, MPH, FAAFP
Professor
Department of Family Medicine and Clinical Epidemiology
University of Pittsburgh
Pittsburgh, Pennsylvania
Content based on an online CME program supported by an independent educational grant from GlaxoSmithKline.
Link to full program:
https://bit.ly/49YBZ4r
Link to downloadable slides:
https://bit.ly/3GocjRe
In this episode, Samantha V. Hill, MD, MPH, and Eunice E. Radcliff, MD, discuss key considerations for PrEP uptake in adolescents, including:
- Advice on talking with parents about the importance of adolescents having alone time with their healthcare professionals
- Maintaining confidentiality when someone is on their parents’ insurance
- Strategies to increase awareness, uptake, engagement, and persistence on PrEP among adolescents
- Having discussions about HIV prevention and PrEP along with the HPV vaccine, STI testing, or contraception
Faculty
Samantha V. Hill, MD, MPH
Assistant Professor
Division of General Pediatrics
Section on Adolescent Health
Department of Pediatrics
Emory University
Atlanta, Georgia
Eunice E. Radcliff, MD
Assistant Professor General Pediatrics
Emory University School of Medicine
Atlanta, Georgia
Link to full program: https://bit.ly/3PZGYdR
In this episode, Jean-Michel Molina, MD, PhD, discusses the data and recommendations for considering on-demand PrEP as a strategy to support PrEP persistence and engagement for men who have sex with men, including:
- Nondaily PrEP options recommended for cisgender men
- Data from the ANRS IPERGAY study evaluating on-demand FTC/TDF vs placebo in men who have sex with men
- Real-world data on the effectiveness of on-demand PrEP
- Considerations for on-demand FTC/TDF in people with renal dysfunction
- Data on hypertension and statin initiation risk with FTC/TAF PrEP
- Data on weight gain with the different PrEP options
Faculty
Jean-Michel Molina, MD, PhD
Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and Lariboisière
Paris, France
Follow along with the slides
https://bit.ly/47VGZVL
Link to full program:
https://bit.ly/3ZlICsL
Should quantitative HBsAg testing be used routinely in clinical practice for patients living with chronic hepatitis B?
In this episode, Tatyana Kushner, MD, MSCE, discusses the role of quantitative hepatitis B surface antigen testing in people living with chronic hepatitis B, including:
- Determination of inactive carrier status
- Prediction of liver fibrosis/cirrhosis
- Prediction of hepatocellular carcinoma development
- Monitoring response to treatment, including future HBV treatments in the development pipeline
- Prediction of HBsAg loss
Joining her for the panel discussion are Ira M. Jacobson, MD, and Paul Y. Kwo, MD.
Presenters:
Ira M. Jacobson, MD
Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York
Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at
Mount Sinai
New York, New York
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Link to the full program:
https://bit.ly/3R1PMi4
Link to the slides:
https://bit.ly/3N5Fpsm
Are we treating HBV early enough? Is it time to move the goalposts regarding the timing of treatment initiation? What are the potential benefits of earlier treatment?
To answer these questions, Ira M. Jacobson, MD, leads a panel discussion with Tatyana Kushner, MD, MSCE, and Paul Y. Kwo, MD, exploring which patients with HBV we should be treating, including a focus on:
- Guideline-based treatment recommendations and their limitations
- Data describing the relationship between viral suppression and HBV DNA integration
- More expansive indications for HBV treatment based on virologic considerations
Presenters:
Ira M. Jacobson, MD
Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York
Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at
Mount Sinai
New York, New York
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Link to the full program: https://bit.ly/3R1PMi4
Link to the slides: https://bit.ly/3N5Fpsm
In this episode, Angela Branche, MD; Pamela Rockwell, DO, FAAFP; and Rick Zimmerman, MD, MPH, FAAFP, discuss the burden of RSV in older adults, including:
- RSV burden throughout life
- RSV seasonality in the United States
- Comparative burden and incidence of RSV and influenza in adults aged 65 years or older
- Cardiopulmonary hospitalizations of long-term care facility residents with influenza and/or RSV
- Risk factors for severe RSV (eg, hospitalization, mortality) in older adults
- RSV incidence by presence of underlying medical conditions
- RSV awareness among healthcare professionals and patients
Program Director:
Pamela Rockwell, DO, FAAFP
Professor
Family Medicine
University of Michigan Medical School
Ann Arbor, Michigan
Faculty:
Angela Branche, MD
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York
Richard Zimmerman, MD, MPH, FAAFP
Professor
Department of Family Medicine and Clinical Epidemiology
University of Pittsburgh
Pittsburgh, Pennsylvania
Content based on an online CME program supported by an independent educational grant from GlaxoSmithKline.
Link to full program: https://bit.ly/49YBZ4r
Link to downloadable slides: https://bit.ly/3GocjRe
In this episode, Beatriz Grinsztejn, MD, PhD, discusses the data and recommendations for addressing social determinants as a strategy to support PrEP persistence and engagement for transgender women, including:
- HIV prevalence among transgender women
- Data on the PrEP cascade from the PrEParadas study of daily FTC/TDF among transgender women
- Data from the ImPrEP Study on early loss to follow-up, adherence, long-term engagement, and HIV incidence among transgender women
- Barriers to PrEP uptake and adherence for transgender women
- Drug–drug interactions between PrEP and feminizing hormone therapy
- Increasing PrEP uptake and retention with peer health navigation for transgender women
Faculty
Beatriz Grinsztejn, MD, PhD
Director
HIV/STI Clinical Research Laboratory
Instituto Nacional de Infectologia Evandro Chagas-Fiocruz
Rio de Janeiro, Brazil
IAS President-Elect
Link to full program:
https://bit.ly/3ZlICsL
In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman provide practical strategies for implementing RSV vaccination into practice, including:
- Educating older adults on RSV vaccines
- Providing effective, evidence-based recommendations
- Shared decision-making
- Identifying and addressing vaccine hesitancy
- Proactive strategies in vaccinating for RSV
- Predicting and overcoming barriers to RSV vaccination
Presenters:
Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP
Clinical Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Internal Medicine Pharmacist
Robert Wood Johnson University Hospital
New Brunswick, New Jersey
Christina M. Madison, PharmD, FCCP, AAHIVP
Clinical Pharmacist
Founder and CEO, The Public Health Pharmacist, PLLC
Adjunct Associate Professor of Pharmacy Practice
Roseman University of Health Sciences
College of Pharmacy
Henderson, Nevada
Other program activities:
- Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role
https://bit.ly/49GUv1g
Link to CME: Claim Credit –
https://bit.ly/3uoY7VH
[After selecting the “Continue to Post Test” button:]
To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.
In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman discuss the latest practical strategies for preventing RSV infection in older adults, including:
- Role of basic public health precautions
- Available and emerging vaccines
- Mechanisms of action, therapeutic targets, and pharmacology
- Efficacy and safety data
- FDA approval status and ACIP recommendations
Presenters:
Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP
Clinical Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Internal Medicine Pharmacist
Robert Wood Johnson University Hospital
New Brunswick, New Jersey
Christina M. Madison, PharmD, FCCP, AAHIVP
Clinical Pharmacist
Founder and CEO, The Public Health Pharmacist, PLLC
Adjunct Associate Professor of Pharmacy Practice
Roseman University of Health Sciences
College of Pharmacy
Henderson, Nevada
Other program activities:
• Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role
In this accredited podcast episode, Dr Mary Bridgeman discusses the most important things for pharmacists across all settings to know about RSV infections in patients 60 years of age or older, including:
- Incidence and prevalence of RSV in older adults, including hospitalization, mortality, epidemiology
- Seasonality
- Clinical manifestations
- Risk factors for severe outcomes
- Vulnerable groups and comorbidities
Presenter:
Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAP
Clinical Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
Piscataway, New Jersey
Internal Medicine Pharmacist
Robert Wood Johnson University Hospital
New Brunswick, New Jersey
Other program activities:
- Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role
https://bit.ly/49GUv1g
Link to CME: Claim Credit – https://bit.ly/47GtNnK
[After selecting the “Continue to Post Test” button:]
To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom.
In this episode, Aniruddha (Anu) Hazra, MD, and Ofole Mgbako, MD, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including:
- Data on drug–drug interactions between PrEP options and gender-affirming hormone therapy
- Contributing factors to inequities in PrEP uptake for Black and Latino individuals
- Data on FTC/TAF PrEP for transgender individuals
- How to decide whether to do an oral lead-in before starting injectable cabotegravir PrEP
- Time to effectiveness after starting PrEP
- PrEP resources available for transgender communities, especially regarding stigma
- Integration of PrEP with gender-affirming hormone therapy
- Strategies to increase PrEP uptake, specifically in the south
- Counseling patients on drug–drug interactions, adverse events, and transmission risk when starting PrEP
- Involving PrEP navigators in the care of people receiving PrEP
- Supporting PrEP adherence and retention in care
- The use of DoxyPEP in transgender individuals receiving PrEP
Faculty
Aniruddha (Anu) Hazra, MD
Assistant Professor, Section of Infectious Disease and Global Health
Director, Infectious Diseases Fellowship Program
Medical Director, UCM Sexual Wellness Clinic
Director of STI Services, Chicago Center of HIV Elimination
Department of Medicine
University of Chicago
Chicago, Illinois
Ofole Mgbako, MD
Assistant Professor of Medicine and Population Health
Section Chief of Infectious Disease
Bellevue Hospital
Clinical Pillar Lead, NYU Institute for Excellence in Health Equity
NYU Grossman School of Medicine
NYU Langone Health
New York, New York
Link to full program: https://bit.ly/3PZGYdR
In this episode,Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections caused by NDM-producing Enterobacterales, including:
- Ambler classification of β-lactamases
- Mechanisms of resistance
- 2023 IDSA guidance recommendations
- The latest clinical data by antimicrobial regimen:
- Ceftazidime/avibactam and aztreonam
- Cefiderocol
- Investigational aztreonam/avibactam
- Clinical case of NDM-producing E. coli with pan-β-lactam resistance
Program Director:
Trevor Van Schooneveld, MD, FSHEA, FACP
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska
Faculty:
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland
Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine
Atlanta, Georgia
Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Follow along with a downloadable slideset at:
https://bit.ly/476v2wI
Link to full program:
https://bit.ly/40HyvPy
In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including:
- Mechanisms of β-lactam resistance
- Effect of resistance mechanism on susceptibility to antipseudomonal agent
- 2023 IDSA guidance recommendations
- Activity against newer antipseudomonal β-lactams in the United States
-
The latest clinical data by antimicrobial regimen:
-
Ceftolozane/tazobactam
- Ceftazidime/avibactam
- Imipenem/cilastatin/relebactam
-
Cefiderocol
-
Applying antimicrobial stewardship principles
Program Director:
Trevor Van Schooneveld, MD, FSHEA, FACP
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska
Faculty:
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center|
Baltimore, Maryland
Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine
Atlanta, Georgia
Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Follow along with a downloadable slideset at: https://clinicaloptions.com/CE-CME/infectious-disease/cmv-prevention-in-sot-recipients/26139
Link to full program: https://bit.ly/40HyvPy
In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including:
- Mechanisms for β-lactam resistance
- Additional resistance mechanisms and virulence factors
- 2023 IDSA guidance recommendations for moderate to severe CRAB infections
- The latest clinical data by antimicrobial therapy/regimen:
- Sulbactam
- Meropenem and colistin
- Carbapenem, sulbactam, and polymyxin B
- Tetracyclines
- Cefiderocol
- Sulbactam/durlobactam and carbapenems
Program Director:
Trevor Van Schooneveld, MD, FSHEA, FACP
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska
Faculty:
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland
Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine
Atlanta, Georgia
Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Follow along with a downloadable slideset at:
https://bit.ly/476v2wI
Link to full program:
https://bit.ly/40Mmicz
In this second of 3 episodes, global HIV experts and advocates discuss how HIV care can better meet the diverse needs of people living with HIV as new treatment strategies emerge and continue to evolve, including:
- How the emergence of long-acting injectable HIV treatment has been a game-changer for many people living with HIV
- Emerging strategies that are expanding the application of long-acting ART to address unmet treatment needs
- Potential for future innovations in ART that are hoped will further address unmet needs and preferences of people living with HIV
Faculty:
Ann Avery, MD
Professor of Medicine
Case Western Reserve University
Division of Infectious Diseases
MetroHealth Medical Center
Cleveland, Ohio
Jennifer Blanchette, PhD
Independent Contractor
Clinical Care Options
Colorado, United States
Isolde Butler, MD, MPH
Chief Medical Officer
CrescentCare
New Orleans, Louisiana
Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Director, Center for AIDS Research (CFAR)
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco (UCSF)
San Francisco, California
Marissa Gonzalez
Chair
Community Advisory Board
The Well Project
Angelina Namiba
Founder Member
4M Network of Mentor Mothers
London, United Kingdom
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
Blizard Institute
Barts Health NHS Trust
London, United Kingdom
Link to full program:
https://bit.ly/3QFwv7n
Links to programs discussed in the episode:
www.4mmm.org
In this episode, global PrEP experts and advocates discuss how current PrEP regimens represent a revolutionary step forward in enabling many individuals to avoid HIV acquisition, including:
- How PrEP has empowered people to take control of their sexual lives, revolutionized people’s sexual experiences, and, for some, improved their experiences with healthcare in general
- The extraordinary progress that has been made in New South Wales and specifically in inner Sydney toward HIV transmission elimination and the role of PrEP in the prevention of new HIV infections
- The importance of having PrEP options, including on-demand options and long-acting formulations, available to different populations who could benefit to see progress toward HIV transmission elimination globally
Faculty:
Jessica L. Adams, PharmD, AAHIVE
Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States
Linda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhD
Professor and Director
The Desmond Tutu HIV Centre
University of Cape Town
South Africa
Chief Executive Officer
The Desmond Tutu Health Foundation
Cape Town, South Africa
Kenyon R. Farrow
PrEP Advocate
Vice President of Policy
Point Source Youth
Contributing Editor
TheBody.com
Ohio, United States
Beatriz Grinsztejn, MD, PhD
Director
STI/AIDS Clinical Research Laboratory
Instituto Nacional de Infectologia Evandro Chagas-Fiocruz
Rio de Janeiro, Brazil
Andrew Grulich, MBBS, PhD
Scientia Professor
Head, HIV Epidemiology and Prevention Program
The Kirby Institute
University of New South Wales, Sydney
New South Wales, Australia
Jean-Michel Molina, MD, PhD
Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and Lariboisière
Paris, France
Brittany Williams, PhD
PrEP Advocate
Assistant Professor of Higher Education and Student Affairs Administration
Department of Education
University of Vermont
Vermont, United States
Link to full program:
https://bit.ly/3FbPBey
In this episode, global PrEP experts and advocates discuss barriers that have prevented the full potential of today’s PrEP regimens from being delivered, how those barriers might be overcome, and how the next generation of PrEP modalities may address unmet needs, including:
- How access and implementation of PrEP have limited its benefit and led to disparities in uptake among racial and ethnic groups in the United States and among key populations globally
- The challenges of adherence to PrEP for healthy individuals who are required to consistently take medication and engage with the healthcare system when they aren’t sick
- The potential for longer-acting PrEP modalities and a greater number of PrEP options for individuals in the future to expand PrEP uptake and adherence with equitable global access
Faculty:
Jessica L. Adams, PharmD, AAHIVE
Scientific Director, Infectious Diseases
Clinical Care Options
New York, United States
Linda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhD
Professor and Director
The Desmond Tutu HIV Centre
University of Cape Town
South Africa
Chief Executive Officer
The Desmond Tutu Health Foundation
Cape Town, South Africa
Kenyon R. Farrow
PrEP Advocate
Vice President of Policy
Point Source Youth
Contributing Editor
TheBody.com
Ohio, United States
Beatriz Grinsztejn, MD, PhD
Director
STI/AIDS Clinical Research Laboratory
Instituto Nacional de Infectologia Evandro Chagas-Fiocruz
Rio de Janeiro, Brazil
Brittany Williams, PhD
PrEP Advocate
Assistant Professor of Higher Education and Student Affairs Administration
Department of Education
University of Vermont
Vermont, United States
Link to full program:
https://bit.ly/3FbPBey
In this episode, Lilly C. Lee, MD, SM, FACEP, FAAEM, discusses the best practices in management of uUTI in the emergency department, including:
- Patient triage
- Diagnostic stewardship
- Interdisciplinary care
- Strategies to overcome treatment barriers
Presenter:
Lilly C. Lee, MD, SM, FACEP, FAAEM
Chief of Emergency Medicine
Jackson Memorial Hospital
Florida Poison Information Center
Roxcy Bolton Rape Treatment Center
Affiliated Assistant Professor of Surgery
DeWitt Daughtry Family Department of Surgery
Leonard M. Miller School of Medicine
University of Miami
Miami, Florida
Find other program activities here:
- “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIs
- Slides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIs
- Podcast 1: Burden on Uncomplicated Urinary Tract Infections
- Podcast 2: Updates in Antimicrobial Selection for uUTIs
- ClinicalThought: When Care Gets Complicated: Uncomplicated UTI Management in Acute Care Settings
In this episode, Richard Colgan, MD, discusses the burden of uncomplicated UTIs (uUTIs) and best practices in their management, including:
- Accurate diagnosis and classification
- Risk factors for uUTIs and treatment failure
- Burdens of uUTIs on patients
- Innovations in care, including self-diagnosis and virtual management
- The importance of avoiding screening and management of asymptomatic bacteriuria in most patients
We will also hear from a patient who details the impact of uUTI on her quality of life.
Presenter:
Richard Colgan, MD
Executive Vice Chair
Professor of Family and Community Medicine
University of Maryland School of Medicine
Baltimore, Maryland
Find other program activities here:
- “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIs
- Slides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIs
- Podcast 2: Updates in Antimicrobial Selection for uUTIs
- Podcast 3: When Things Get Complicated: Managing uUTIs in Acute Care
- ClinicalThought: Uncomplicated but Not Insignificant: The Burden of Uncomplicated UTIs
In this episode, Lillian Abbo, MD, MBA, FIDSA, discusses appropriate antimicrobial selection for managing uncomplicated UTIs, including:
- Balancing discrepancies in available guidelines
- Individualizing antimicrobial selection based on patient characteristics and local resistance patterns
- Incorporating tools, like antibiograms, into daily practice
- Being a good steward of currently available antimicrobial agents
- Planning ahead for emerging therapies for uncomplicated UTIs
Presenter:
Lillian Abbo, MD, MBA, FIDSA
Associate Chief Medical Officer
Infectious Diseases
Jackson Health System
Professor of Clinical Infectious Diseases
University of Miami Miller School of Medicine
Miami Transplant Institute
Miami, Florida
Find other program activities here:
- “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIs
- Slides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIs
- Podcast 1: Burden on Uncomplicated Urinary Tract Infections
- Podcast 3: When Things Get Complicated: Managing uUTIs in Acute Care
- ClinicalThought: Not Always an Easy Task: Antimicrobial Stewardship for Uncomplicated UTIs
In this episode, Atul Humar, MD, FRCP(C); Hannah Imlay, MD, MS; and Raymund Razonable, MD, discuss cytomegalovirus (CMV) management strategies in solid organ transplantation recipients, including:
- Evaluation of current data on CMV prevention in liver transplant recipients
- Practical considerations for switching an institution’s antiviral therapy of choice for primary prophylaxis
- Barrier of resistance to antiviral therapies
- Factors to consider when deciding CMV treatment duration
- Use of lymphocyte count to assess CMV cell–mediated immunity
Program Director:
Atul Humar, MD, FRCP(C)
Professor of Medicine
University of Toronto
Director, Ajmera Transplant Centre
University Health Network
R. Fraser Elliott Chair in Transplantation
Director University of Toronto Transplant Institute
Toronto, Ontario, Canada
Faculty:
Hannah Imlay, MD, MS
Assistant Professor of Medicine
Department of Internal Medicine, Division of Infectious Diseases
University of Utah
Salt Lake City, Utah
Raymund Razonable, MD
Professor of Medicine
Program Director, Infectious Diseases Fellowship
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota
Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Follow along with a downloadable slideset at:
https://bit.ly/476v2wI
Link to full program:
https://bit.ly/47lNK2K
In this episode, Hannah Imlay, MD, MS, discusses cytomegalovirus (CMV) prevention strategies in solid organ transplantation (SOT) recipients including:
- Strategies for preventing CMV in SOT
- International guideline recommendations for CMV prevention strategies by organ type
- Antivirals used for CMV prevention
- Comparison of preemptive therapy vs prophylaxis for CMV prevention in liver transplant recipients
- Comparison of letermovir vs valganciclovir for CMV prophylaxis in kidney transplant recipients
- Use of CMV cell–mediated immunity monitoring for primary prophylaxis
- Monitoring CMV viral loads, including limitations to quantitative nucleic acid testing
- Future prevention approaches
Faculty:
Hannah Imlay, MD, MS
Assistant Professor of Medicine
Department of Internal Medicine, Division of Infectious Diseases
University of Utah
Salt Lake City, Utah
Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Follow along with a downloadable slideset at:
https://bit.ly/476v2wI
Link to full program:
https://bit.ly/47lNK2K
In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:
- CMV treatment goals
- CMV treatment and monitoring recommendations
- Role of secondary prophylaxis
- Use of CMV cell–mediated immunity (CMI) monitoring for CMV relapse risk
- Use of CMV CMI for secondary prophylaxis
- Proposed use of CMV CMI monitoring for secondary prophylaxis
- Incidence and outcomes with antiviral resistance
- Risk factors for CMV resistance
- When to suspect antiviral resistance
- Testing for antiviral resistance using genotypic assays
- Outcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virus
- Treatment recommendations for resistant/refractory CMV
- Efficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE study
- Treatment algorithm for resistant/refractory CMV
- Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV
Faculty:
Raymund Razonable, MD
Professor of Medicine
Program Director, Infectious Diseases Fellowship
Vice Chair, Division of Infectious Diseases
Mayo Clinic
Rochester, Minnesota
Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.
Follow along with a downloadable slideset at:
https://bit.ly/476v2wI
Link to full program:
https://bit.ly/47lNK2K
Arthur Kim, MD, and Renslow Sherer, MD, discuss how new data on COVID-19 vaccines and treatments may affect practice, including:
- Real-world data on COVID-19 outcomes
- COVID-19 prevention: current and emerging concepts
- COVID-19 therapeutics: new clinical trial and real-world data
Presenters:
Arthur Kim, MD
Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Follow along with the slides at:
https://bit.ly/40DFjhv
Link to full program:
https://bit.ly/3FI8HJx
In this first of 3 episodes, global HIV experts and advocates discuss how innovative models of care are minimizing barriers to HIV care engagement to improve uptake by key underserved populations, including:
- How peer support programs empower people to combat stigma, become more educated about treatment, and be engaged participants in their HIV care
- Strategies for addressing potential unmet mental healthcare needs among people living with HIV
- Approaches to reengage people with HIV who transit through county jail systems
- How integrated care strategies and wrap-around services can overcome some of the barriers to care that are associated with social determinants of health
- Key considerations when providing HIV care for migrant and refugee populations
Faculty:
Ann Avery, MD
Professor of Medicine
Case Western Reserve University
Division of Infectious Diseases
MetroHealth Medical Center
Cleveland, Ohio
Jennifer Blanchette, PhD
Independent Contractor
Clinical Care Options
Colorado, United States
Isolde Butler, MD, MPH
Chief Medical Officer
CrescentCare
New Orleans, Louisiana
Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Director, Center for AIDS Research (CFAR)
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco (UCSF)
San Francisco, California
Marissa Gonzalez
Chair
Community Advisory Board
The Well Project
Angelina Namiba
Founder Member
4M Network of Mentor Mothers
London, United Kingdom
Chloe Orkin, MBChB, FRCP, MD
Professor of Infection and Inequities
Faculty of Medicine and Dentistry
Queen Mary University of London
Blizard Institute
Barts Health NHS Trust
London, United Kingdom
Miłosz Parczewski, MD, PhD
Professor of Medicine
Department Head
Consultant in Infectious Diseases
Department of Infectious, Tropical Diseases and Acquired Immunodeficiency
Pomeranian Medical University
Szczecin, Poland
Link to full program:
https://bit.ly/3QFwv7n
Links to programs discussed in the episode:
https://4mmm.org/
https://positivepeers.org/
In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:
- Macrolide resistance
- Predictors for disease progression
- 2020 NTM guideline recommended treatment options
- Emerging therapies
We will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.
Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.
Presenters:
Charles L. Daley, MD
Professor of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado
Shannon Kasperbauer, MD
Associate Professor of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado
Pamela J. McShane, MD
Professor of Medicine
Division of Pulmonary and
Critical Care Medicine
The University of Texas Health Science Center at Tyler
Tyler, Texas
Link to program page: https://bit.ly/3QzJo2B
Link to downloadable slides: https://bit.ly/3Qh8T7G
In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:
- Mycobacterium avium complex
- M. kansasii
- M. xenopi
We will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.
Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.
Presenters:
Charles L. Daley, MD
Professor of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado
Shannon Kasperbauer, MD
Associate Professor of Medicine
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado
Pamela J. McShane, MD
Professor of Medicine
Division of Pulmonary and
Critical Care Medicine
The University of Texas Health Science Center at Tyler
Tyler, Texas
Link to program page: https://bit.ly/3QzJo2B
Link to downloadable slides:https://bit.ly/3Qh8T7G
In this episode, Pamela J. McShane, MD, describes the 3 pillars for nontuberculous mycobacterial (NTM) lung disease diagnosis:
- Clinical symptoms
- Radiographic evidence
- Microbiologic data
We will also hear from a patient who details his diagnostic journey and will hear Dr. McShane discuss an illustrative clinical case.
Presenter:
Pamela J. McShane, MD
Professor of Medicine
Division of Pulmonary and
Critical Care Medicine
The University of Texas Health Science Center at Tyler
Tyler, Texas
Link to program page: https://bit.ly/3QzJo2B
Link to downloadable slides: https://bit.ly/3Qh8T7G
In this episode, David Alain Wohl, MD, discusses key considerations to PrEP barriers in cisgender women, including:
- Prevalence of PrEP use in the US
- Barriers to PrEP uptake
- PrEP efficacy based on adherence
- Interventions to support PrEP adherence
- Recommended PrEP regimens, including considerations for use in pregnancy and breastfeeding
Presenter:
David Alain Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases Clinical Trials Unit
University of North Carolina at
Chapel Hill
Chapel Hill, North Carolina
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program: https://bit.ly/3ZpM6uu
Follow along with the slides: https://bit.ly/3LyGgBj
In this podcast, experts Sarah M. Wood, MD, MS, and Errol L. Fields, MD, PhD, MPH, discuss some of the challenges and concerns clinicians face when prescribing PrEP to adolescents.
The faculty addresses the potential for adverse effects from PrEP, including the potential for renal impairment, decreased bone density, and whether PrEP can interfere with hormone therapy for gender-affirming care. They review the data behind these concerns and emphasize that the vast majority of adverse effects caused by PrEP are mild and reversible.
The experts also examine common barriers that adolescents face when attempting to initiate and adhere to PrEP, such as insurance coverage and confidentiality. Dr Fields and Dr Woods discuss strategies for overcoming these barriers and retaining adolescents on PrEP, including how to navigate tricky conversations with both patients and parents or within communities that may stigmatize PrEP and HIV.
Sarah M. Woods, MD, MS
Assistant Professor of Pediatrics
Division of Adolescent Medicine
University of Pennsylvania Perelman School of Medicine
Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania
Errol L. Fields, MD, PhD, MPH
Associate Professor of Pediatrics
Division of Adolescent/Young Adult Medicine
Department of Pediatrics
Johns Hopkins School of Medicine
Baltimore, Maryland
Content based on an online CME program supported by independent educational grants from Gilead Sciences Inc. and ViiV Healthcare.
Link to full program:
https://bit.ly/3PZGYdR
In this episode, we hear from 2 people living with HIV: Melanie Reese from the United States and Marc Thompson from the United Kingdom. Both Melanie and Marc have done important work in the HIV field as patient advocates. Today, they will be discussing their experiences in accessing and navigating their own HIV care, with a focus on some of the barriers that can complicate and even block a person's journey across the HIV care continuum. In reviewing these challenges, Marc and Melanie share their insights on key strategies that can help to facilitate HIV care for patients, making the experience more straightforward and minimizing the impact that HIV has on their daily lives.
Presenters:
Melanie Reese
Subject Matter Expert, Older Women Living and Aging with HIV, HIV North America Health Resources and Services Administration HIV/AIDS Bureau
Executive Director, Older Women Embracing Life
Board Secretary, International Community of Women Living with HIV
Baltimore, Maryland
Marc Thompson
Director, The Love Tank
Co-founder, Prepster
London, England
Content based on an online CME/CPE/CE program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3Pas4zn
In this podcast, expert Rasika Karnik, MD, MS, discusses how to manage the health risks posed by COVID-19 infection and long COVID in individuals with metabolic syndrome or obesity.
Dr Karnik discusses the interplay between COVID-19 outcomes, obesity/metabolic syndrome, and social determinants of health and delves into detail on how to address and mitigate these social determinants of health in a high-risk population.
Presenters:
Rasika Karnik, MD, MS
Assistant Professor
Division of Primary Care,
Department of Internal Medicine
University of Chicago
Chicago, Illinois
Content based on an online CME program supported by independent educational grants from Pfizer.
Link to full program:
https://bit.ly/46yuChS
In this podcast, experts Donna Ryan, MD, and Renslow Sherer, MD, discuss how to manage the health risks posed by COVID-19 infection and long COVID in individuals with metabolic syndrome or obesity.
First, Dr Ryan presents an overview of the relationship between COVID-19 and weight, including the mechanisms of how obesity may drive COVID-19 disease and how COVID-19 may in turn worsen obesity, through both immunologic and social or societal drivers.Dr Ryan also discusses the relationship between obesity and the risk for long COVID.
In his segment, Dr Sherer discusses COVID-19 vaccination and antiviral therapy within the context of obesity and metabolic syndrome. Dr Sherer also delves into detail on how obesity-related risk factors or comorbidities may affect treatment decisions and presents strategies on individualizing treatment, including in patients with long COVID.
This episode includes results from several reviews and meta-analyses examining the relationship between vaccination, as well as an observational study investigating the impact of nirmatrelvir/ritonavir therapy on long COVID in vaccinated patients.
Presenters:
Donna Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
New Orleans, Louisiana
Renslow Sherer, MD
Director of the International HIV Training Center
Professor of Medicine
Infectious Diseases and Global Health
Department of Medicine University of Chicago Department of Medicine
Chicago, Illinois
Content based on an online CME program supported by independent educational grants from Pfizer.
Link to full program:
https://bit.ly/46yuChS
In this episode, Oni Blackstock, MD, MHS, and Whitney Irie, MSW, PhD, discuss key considerations for PrEP uptake in cisgender women, including:
- Ways to perform a nonintimidating sexual history
- How to incorporate conversations on PrEP during a short clinic visit
- Discussing adverse events associated with PrEP options with patients
- Considerations for PrEP in women wanting to conceive
- How patients can navigate obtaining PrEP in areas with limited healthcare resources
- Guideline recommendation updates on PrEP eligibility
- Use of wrap-around services
- Interventions to improve PrEP access (eg, telehealth, nurse-led PrEP)
Faculty
Oni Blackstock, MD, MHS
Founder & Executive Director
Health Justice
New York, New York
Whitney Irie, MSW, PhD
Assistant Professor
Department of Social Work
Boston College
Brighton, Massachusetts
Link to full program: https://bit.ly/3PZGYdR
In this episode, Roger Bedimo, MD, MS, FACP, discusses key considerations to PrEP barriers in adolescents, including:
- New HIV diagnoses in the United States
- Adherence barriers
- Healthcare professional barriers
- Consent laws for minors to receive sexually transmitted infection diagnosis and treatment services
- Interventions to support PrEP adherence
Presenter:
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Division of Infectious Diseases
University of Texas UT Southwestern Medical Center
Section Chief
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ZpM6uu
Follow along with the slides:
https://bit.ly/3LyGgBj
In this episode, Brooke Bates, PharmD, BCPS, AAHIVP, and Neha Sheth Pandit, PharmD, AAHIVP, BCPS, discuss the most clinically relevant studies on HIV adverse events presented at IAS 2023, including:
- REPRIEVE study of pitavastatin for cardiovascular prevention in people living with HIV at low to moderate cardiovascular risk
- Data on weight change with switch from integrase inhibitor–based ART to doravirine/islatravir in the P017 and P018 studies
- DEFINE study evaluating weight change after a switch to DRV/COBI/FTC/TAF in people living with HIV who experienced weight gain with integrase inhibitor–based ART
Faculty:
Brooke Bates, PharmD, BCPS, AAHIVP
Specialty Pharmacy Clinical Manager
Pediatric HIV Clinical Pharmacist
Indiana University Health
Indianapolis, Indiana
Neha Sheth Pandit, PharmD, AAHIVP, BCPS
Professor
Vice Chair for Research and Scholarship
Department of Practice, Sciences, and Health Outcomes Research
School of Pharmacy
University of Maryland
Clinical Pharmacist
THRIVE Program
Baltimore, Maryland
Link to full program:
https://bit.ly/3ZjSFhg
In this episode, Tony Brown, MPH, discusses the importance of effective patient‒provider communication in supporting PrEP persistence including:
- His own experience with PrEP and reasons for fluctuations in adherence over the years
- The importance of open, honest, and judgement-free conversations about sexual health
- Engaging patients in conversations about PrEP effectiveness, adverse effects, and changing life circumstances
- Working together to find the most effective PrEP option for each individual patient that will help them to persist on PrEP long term
Faculty:
Tony Brown, MPH
PrEP User and Advocate
Doctoral Candidate
Health Services Policy and Management
University of South Carolina
Columbia, South Carolina
Link to full program: https://bit.ly/3ZlICsL
In this episode, Nikos Dedes, Jeff Taylor, and Bernadette Sharp—people living with HIV—discuss how switching to long-acting ART has affected their quality of life. They are joined by 2 healthcare professionals—Iskandar Azwa,MBChB, MRCP, and Beng Eu, MBBS—who provide insights on how they assess and document health-related quality of life for their patients. The discussion focuses on personal experiences with how LA ART has improved health-related quality of life, including:
- Avoidance of drug–drug interactions
- Improved confidentiality
- Decreased stigma
Presenters:
Iskandar Azwa, MBChB, MRCP
Associate Professor
Infectious Diseases
Faculty of Medicine
University of Malaya
Kuala Lumpur, Malaysia
Nikos Dedes
Positive Voice
Athens, Greece
Beng Eu, MBBS
Doctor
Prahran Market Clinic
Melbourne, Victoria, Australia
Bernadette Sharp
Advocate
Jeff Taylor
Executive Director
HIV+Aging Research Project
Palm Springs, California
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Link to downloadable slides:
https://bit.ly/488WwT7
Link to full program:
bit.ly/3EwEnRJ
In this episode, Jill Blumenthal, MD, MAS, and Kenric B. Ware, PharmD, MBA, AAHIVP, answer questions about HIV PrEP including:
- Considerations for selecting between oral and injectable PrEP in college students
- Strategies to promote PrEP persistence in adolescents
- Best approaches to address readiness to start PrEP in adolescents (eg, creating nonjudgmental environments, addressing misconceptions)
- Considerations for local consent laws
- Available data on PrEP young adolescents (eg, age and weight limits)
- Initiatives in place to address racial and ethnic disparities associated with PrEP uptake and persistence
- The role of on-demand PrEP in transgender individuals receiving gender-affirming hormone therapy
- Offering patient-centered care
- Educating healthcare professionals on how to prescribe PrEP
Faculty:
Jill Blumenthal, MD, MAS
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California
Kenric B. Ware, PharmD, MBA, AAHIVP
Clinical Associate Professor
Department of Pharmacy Practice
Mercer University College of Pharmacy
Atlanta, Georgia
Link to full program:
https://bit.ly/3Fqdgs9
In this episode, Iskandar Azwa, MBChB, MRCP; Nikos Dedes; Beng Eu, MBBS; Bernadette Sharp; and Jeff Taylor discuss challenges and opportunities with long-acting ART implementation, including:
- Personal experiences with receiving LA ART
- Views on long-acting ART in the development pipeline
- Perspectives on self-administration of LA ART
Presenters:
Iskandar Azwa, MBChB, MRCP
Associate Professor
Infectious Diseases
Faculty of Medicine
University of Malaya
Kuala Lumpur, Malaysia
Nikos Dedes
Positive Voice
Athens, Greece
Beng Eu, MBBS
Doctor
Prahran Market Clinic
Melbourne, Victoria, Australia
Bernadette Sharp
Advocate
Jeff Taylor
Executive Director
HIV+Aging Research Project
Palm Springs, California
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
Link to downloadable slides: https://clinicaloptions.com/CE-CME/infectious-disease/slides-fourth-90-and-la-art/17553-25368
Link to full program: https://bit.ly/3EwEnRJ
In this episode, Raphael J. Landovitz, MD, MSc, and Hyman Scott, MD, MPH, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including:
- Misconceptions about PrEP eligibility
- Strategies to improve lab monitoring on PrEP
- Leveraging patient navigators and clinic staff to expand PrEP access
- Data on PrEP efficacy in key populations (eg, transgender men, people who inject drugs)
- Considerations for prescribing on-demand and same-day PrEP
- Addressing healthcare professional hesitancy to prescribe PrEP
- US Preventive Services Task Force PrEP guideline updates
- Bundling sexually transmitted infection services with PrEP
Faculty
Raphael J. Landovitz, MD, MSc
Professor of Medicine
Division of Infectious Diseases
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services
Los Angeles, California
Hyman Scott, MD
Assistant Clinical Professor
Department of Medicine
University of California, San Francisco
Clinical Research Medical Director
Bridge HIV
San Francisco Department of
Public Health
San Francisco, California
Link to full program:
https://bit.ly/3PZGYdR
In this episode, Angela Branche, MD, discusses the Advisory Committee on Immunization Practices recommendations for RSV vaccines in older adults, including:
- Use of shared clinical decision-making
- How to approach the conversation about the RSV vaccine with patients
- Key populations who may benefit the most, such as those at risk for severe RSV disease (eg, increasing age and persons who are frail or have cardiopulmonary comorbidities)
Faculty:
Angela Branche, MD
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York
Link to full program: https://bit.ly/3nb25xe
Link to downloadable slides: https://bit.ly/3nb25xe
In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:
- Guideline recommendations for selecting a new ART regimen
- Options for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistance
- Data from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIV
Presenter:
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
To download the slides:
https://bit.ly/3OcqxIE
To view the full online program:
https://bit.ly/3ZjSFhg
In this episode, Oni Blackstock, MD, MHS, and Brittany Williams, PhD,discuss key considerations to pre-exposure prophylaxis (PrEP) uptake in cisgender women, including:
- The misconception by patients and healthcare professionals (HCP) that cisgender women are at low risk for HIV
- Reframing HIV prevention from “risks” to “reasons” such as promoting self-care and taking control of one’s own sexual health
- CDC PrEP guidance recommendations
- Increasing PrEP awareness by sharing PrEP experiences with others in the community
- The importance of community representation in PrEP marketing and campaigns
- Challenges with finding HCPs who prescribe PrEP for cisgender women
- Promoting self-advocacy when seeking care, including HIV prevention
- Strategies for patients to engage with their HCPs to learn about and obtain PrEP
- Available resources for PrEP coverage
Faculty:
Oni Blackstock, MD, MHS
Founder & Executive Director
Health Justice
New York, New York
Brittany Williams, PhD
Assistant Professor of Higher Education and Student Affairs Administration
Department of Education
University of Vermont
Burlington, Vermont
Link to full program: https://bit.ly/3PZGYdR
In this episode, Kyle Molina, PharmD, BCIDP, discusses key considerations for successful implementation of long-acting lipoglycopeptides into clinical practice. Listen as he gives perspectives on:
- Reasons to consider use of long-acting lipoglycopeptides (eg, poor adherence to oral antibiotics, PICC-related costs and complications)
- Data supporting and challenging cost effectiveness of long-acting lipoglycopeptides
- Identifying the target patient population
- Selecting the right location to provide long-acting lipoglycopeptides
- Strategies to maximize institutional impact with key stakeholders (eg, hospital avoidance, reduced ED and hospital length of stay)
- Key characteristics of available long-acting lipoglycopeptides
- Addressing logistical challenges, including navigating the reimbursement process
Faculty:
Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California
Link to full program:
- CCO: https://bit.ly/3J4mg8h
- ProCE: https://bit.ly/3P0vB4E
In this episode, Joseph Ahn, MD, MS, MBA; Christina Delacruz Leyson, MD; and Alice Chan, a person who experienced pregnancy as a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in people of childbearing potential and their infants, including:
- HBV screening and vaccination in pregnancy
- Management of pregnant people who are HBsAg positive
- Infant care
- Breastfeeding
Presenters:
Joseph Ahn, MD, MS, MBA
Professor of Medicine, Section Chief
Division of Gastroenterology and Hepatology
Oregon Health & Science University
Portland, Oregon
Christina Delacruz Leyson, MD
Associate Professor
Medical Director, Liver Transplant Program
Program Director, Hepatology Fellowship
University of Kentucky
Lexington, Kentucky
Alice Chan, person living with chronic hepatitis B
Link to downloadable slides:
https://bit.ly/3rXLTC7
Link to program:
https://bit.ly/3L3Kz6l
In this episode, Daniel R. Kuritzkes, MD, and Cristina Mussini, MD, discuss managing ART failure, including:
- The definitions of virologic blips, low-level viremia, and virologic failure on ART
- The infrequency of failure with resistance on first-line INSTI-based ART and the instances where this has occurred with BIC- and DTG-based ART in clinical trials and in the real world
- The potential reasons for ART failure, including patient/adherence-related factors, HIV-related factors, and regimen-related factors
- The impact of adherence on viral suppression with BIC- and DTG-based ART
- Drug-drug interactions as a reason for failure of first-line INSTI-based ART
- What to do if someone is experiencing virologic failure requiring an ART change
- The use of proviral DNA testing in patients with viral suppression or low-level viremia with ART treatment experience
- The impact of high HIV-1 RNA on ART effectiveness
- The impact of NRTI resistance, including the M184V and K65R mutations, on the effectiveness of BIC- and DTG-based ART
- Strategies to encourage and measure patient adherence to ART
Presenters
Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts
Cristina Mussini, MD
Professor
Department of Infectious Diseases
University of Modena and
Reggio Emilia
Modena, Italy
Link to full program: https://bit.ly/3HPu4Lk
In this episode, Renslow Sherer, MD, discusses managing a first ART failure in the setting of COVID-19, including:
- Guideline recommendations for resistance testing
- Guideline recommendations for selecting a new ART regimen
- Data on retained efficacy of NRTIs in second-line regimens in the EARNEST and NADIA studies
- Consideration of drug‒drug interactions between ART and COVID-19 treatment
Presenter:
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
To download the slides: https://bit.ly/3OcqxIE
To view the full online program: https://bit.ly/3ZjSFhg
In this episode, Kenyon R. Farrow and Raphael J. Landovitz, MD, MSc, discuss key considerations to PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including:
- Rates of HIV diagnoses in Black and Brown communities
- Issues stalling success in HIV prevention (eg, stigma, healthcare coverage, and administration and operational barriers)
- Considerations for healthcare professionals when discussing PrEP with patients
- Importance of representation (eg, racial and ethnic minority people, transgender people) at clinic offices
- Promoting cultural humility to build strong patient-provider relationships
Faculty:
Kenyon R. Farrow
Vice President of Policy
Point Source Youth
Contributing Editor
TheBody.com
Cleveland, Ohio
Raphael J. Landovitz, MD, MSc
Professor of Medicine
Division of Infectious Diseases
David Geffen School of Medicine
University of California, Los Angeles
Director, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services
Los Angeles, California
Link to full program:
https://bit.ly/3PZGYdR
In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, and Meredith Clement, MD, discuss PrEP initiation, including:
- The importance of taking a sexual history and getting to know your patient
- Recommendations for who should be considered for PrEP
- Practicalities of PrEP initiation including laboratory assessments, interview and physical exam, evaluating concomitant medications, counseling, and prescribing
- Summary of PrEP eligibility by regimen
- Review of the clinical trial and real-world data for each PrEP modality
- The likelihood of cross-resistance between PrEP options and ART options if someone were to become infected with HIV while receiving PrEP
- Time to effective concentrations of PrEP after initiation
- Whether there are data for on-demand dosing of FTC/TAF
- Recommendations for FTC/TDF on demand for heterosexual cisgender men
- Individualizing PrEP for each person to increase the likelihood of adherence, persistence, and efficacy
- Recommendations for the use of LA CAB for PrEP during pregnancy and in people of childbearing potential
- STI and point-of-care testing for people receiving PrEP
- The possibility of implantable PrEP in the future
Presenters:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Professor and Director
The Desmond Tutu HIV Centre University of Cape Town
Cape Town, South Africa
Meredith Clement, MD
Assistant Professor
Section of Infectious Diseases
Louisiana State University Health Sciences Center
University Medical Center
New Orleans, Louisiana
Link to full program:
https://bit.ly/3HPu4Lk
In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:
- Hepatitis B virus
- Durability of response with bepirovirsen
- HBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfa
- Hepatitis delta virus
- 96-week follow-up of immediate vs delayed bulevirtide
- Off-treatment response for lonafarnib + ritonavir ± pegIFN-alfa
- Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogue
- Hepatitis C virus
- Collaborative service at opiate substitution treatment clinic to improve linkage to care in Ireland
- Nurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United Kingdom
- FIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of health
Presenter:
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany
Link to full program:
https://bit.ly/3JQQj3J
In this episode, Kyle Molina, PharmD, BCIDP, provides an overview of treatment of skin and soft tissue infections (SSTIs) and challenges in practice. Listen as he gives perspectives on:
- Guideline recommendations for treatment of purulent and nonpurulent SSTIs
- Logistical challenges with IV and oral antibiotics
- Pros and cons of various locations of care
- Data supporting the safety and efficacy of long-acting lipoglycopeptides for treatment of SSTIs
- Use of long-acting lipoglycopeptides in special populations of interest, including patients with obesity, diabetes, and injection drug use
- Overall place in therapy of long-acting lipoglycopeptides for SSTIs
Faculty:
Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California
Link to full program:
- CCO: https://bit.ly/3J4mg8h
- ProCE: https://bit.ly/3P0vB4E
In this episode, Latesha Elopre, MD, MSPH, and Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, answer questions about HIV PrEP including:
- How long someone can receive PrEP and the monitoring that is needed over time
- Recommendations for monitoring bone health while receiving oral PrEP
- Treatment as prevention and PrEP efficacy data and options for people who inject drugs
- The role of circumcision in HIV prevention
- The use of PrEP in pregnancy
- Concern for ART resistance if someone seroconverts while receiving PrEP, especially when using nondaily PrEP options
- The possibility of using FTC/TAF on demand
- Inequities in adherence and persistence
- Cost considerations with different PrEP modalities
- Recommendations for hospitalized patients receiving PrEP
- PrEP considerations for patients with renal dysfunction and higher BMIs
- PrEP efficacy based on site of exposure
Presenters:
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama
Jason Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN
Professor
School of Nursing
Johns Hopkins University
Nurse Practitioner
Department of Infectious Diseases
John G. Bartlett Specialty Practice
Baltimore, Maryland
Link to full program:
https://bit.ly/3Fqdgs9
In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP, and Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES, discuss key considerations to barriers to PrEP uptake, including:
- Limited data on “on-demand” PrEP in cisgender women
- Strategies on improving communication with non‒English-speaking populations
- Role of pharmacists with injectable PrEP
- CDC PrEP guideline recommendations on routine HIV-1 RNA testing
- Engaging with pregnant persons who might want access to PrEP in the pharmacy setting
- Oral PrEP efficacy based on adherence in cisgender women, including recent data presented at CROI 2023 by Marrazzo and colleagues
Presenters:
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois
Kevin Astle, PharmD, BCPS, BCACP, AAHIVP, CDCES
Assistant Professor
Department of Pharmacotherapy and Clinical Research
University of South Florida
Clinical Pharmacist
Tampa General Medical Group
Tampa, Florida
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ZjSFhg
Downloadable slides:
https://bit.ly/3PsFNDt
In this episode, Robert S. Brown, Jr., MD, MPH; Nancy Reau, MD; and Eric, a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in older adults, including:
- Awareness of HBV and CHB in older adults
- Updated HBV screening and vaccination recommendations
- Monitoring of renal and bone disease
- Adjustment of monitoring and treatment as a person with HBV ages
Presenters:
Robert S. Brown, Jr., MD, MPH
Vincent Astor Distinguished
Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Eric, person living with chronic hepatitis B
Link to downloadable slides: please link to VM404 downloadable slides when ready
Link to program:
bit.ly/3L3Kz6l
In this episode, Tarik Asselah, MD, PhD, and Ira Jacobson, MD, provide expert insight on HDV screening, diagnosis, and management, including:
- Approach to screening
- Barriers to screening (eg, test availability)
- Disease progression and complications
- Differentiating between coinfection and superinfection
- Approach to treatment (eg, whom to treat and when, treatment options, considerations for combination therapy)
- Management of patients with decompensated cirrhosis
- Surrogate markers to measure treatment success
- Role of correcting thrombocytopenia before initiating therapy
Faculty:
Tarik Asselah, MD, PhD
Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France
Ira Jacobson, MD
Professor of Medicine
NYU School of Medicine
Director of Hepatology
Division of Gastroenterology and Hepatology
NYU Langone Health
New York, New York
Link to full program: https://bit.ly/3yp1Lxf
In this episode, Helen Y. Chu, MD, MPH, shares updates on RSV vaccines, including:
- An overview of vaccine candidates under investigation
- Recently FDA-approved RSV vaccines for older adults
- Considerations for the next respiratory viral season
- Coadministration of RSV vaccines with other respiratory viral vaccines (eg, influenza, SARS-CoV-2)
- Target populations for RSV vaccination
- RSV prevention in infants with the maternal vaccine and monoclonal
Faculty:
Helen Y. Chu, MD, MPH
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
School of Medicine
Seattle, Washington
Link to full program: https://bit.ly/3nb25xehttps://bit.ly/3nb25xe
Link to downloadable slides: https://bit.ly/3TsXym5
In this episode, Nancy Reau, MD, and Heiner Wedemeyer, MD, provide expert insight on HDV management, including:
- Use of noninvasive imaging or biopsy for staging liver disease
- Screening for hepatocellular carcinoma
- HBV treatment
- Role of comedications (eg, erythropoietin, eltrombopag)
- Approach to complex cases, such as patients with:
- Significant fibrosis and low HDV RNA levels
- Hepatitis delta antibody positivity, but HDV RNA negativity
- HIV coinfection
- Decompensated or recently decompensated cirrhosis
Faculty:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany
Link to full program:
http://bit.ly/3yp1Lxf
In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:
- Hyperlipidemia and cardiovascular disease risk among people living with HIV
- Recommendations for lipid screening for people living with HIV
- Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
- How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
- Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
- Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
- How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
- How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database
Maunank Shah, MD, PhD
Associate Professor
Infectious Diseases
Johns Hopkins University
Baltimore, Maryland
Link to full program: bit.ly/3pwaH2Y
In this episode, Martin Krsak, MD, MSc, FASAM, provides background and context on skin and soft tissue infections. Listen as he gives perspectives on:
- Epidemiology and clinical outcomes
- Economic impact
- Bacterial etiology
- Importance of appropriate antimicrobial prescribing
- Clinical presentation
- Severity classification and distinction between purulent and nonpurulent infections
- Role of incision and debridement vs antimicrobial management
- Complications to be ruled out prior to treatment
Faculty:
Martin Krsak, MD, MSc, FASAM
Associate Professor of Medicine
Division of Infectious Diseases
University of Colorado School of Medicine
Denver, Colorado
Link to full program:
- CCO: https://bit.ly/3J4mg8h
- ProCE: https://bit.ly/3P0vB4E
In this episode, Marta Boffito, MD, PhD, FRCP, and Michelle Cespedes, MD, MS, discuss initial ART options, including:
- Recommended first-line ART options for most PWH according to DHHS, IAS-USA, EACS, BHIVA, and WHO guidelines
- Data for weight gain after ART initiation with different ARV classes and drugs
- Weight gain disparities by race and gender after ART initiation
- Data from the RESPOND study including risk factors for weight gain and CV event risk with INSTI vs non-INSTI–based ART
- The impact of INSTIs on CV events in the Swiss HIV Cohort study
- Recommendations for ART and contraception for PWH of childbearing potential
- Drug–drug interactions between first-line ART and contraceptive options
- Guideline-recommended first-line ART options in pregnancy with a discussion of how these regimens differ from those recommended for most PWH
Marta Boffito, MD, PhD, FRCP
Consultant Physician
Clinical Director, HIV, Sexual and Gender Health, Dermatology
Chelsea and Westminster Hospital NHS Foundation Trust
Imperial College London
London, United Kingdom
Michelle Cespedes, MD, MS
Professor of Medicine
Division of Infectious Disease
Department of Medicine
Icahn School of Medicine at
Mount Sinai
New York, New York
Link to full program: bit.ly/3HPu4Lk
In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for PWH coinfected with HBV and HCV. Listen as she covers:
- How HIV-ASSIST supports ART selection in primary care
- Updates to viral hepatitis recommendations including:
- CDC HBV screening and testing recommendations
- AASLD simplified HCV treatment approach for PWH
- HIV-ASSIST for managing HIV/HBV coinfections, including ensuring that NRTIs that are effective for both HIV and HBV are included in an ART regimen and alerting the user when an additional HBV treatment is needed
- HIV-ASSIST for managing HIV/HCV coinfections, including showing how the HIV-ASSIST tool incorporates drug‒drug interaction considerations from the University of Liverpool HIV Drug Interaction Checker
Carolyn Chu, MD, MSc, FAAFP, AAHIVS
Chief Clinical Officer
National Clinician Consultation Center
Professor
Clinical Family Community Medicine
University of California, San Francisco
San Francisco, California
Link to full program: bit.ly/3pwaH2Y
In this episode, Amanda Binkley, PharmD, BCIDP, AAHIVP, and Nimish Patel, PharmD, PhD, AAHIVP, discuss clinically relevant data on long-acting ART from CROI 2023, including:
- LA CAB + RPV in San Francisco’s Ward 86 Safety Net Clinic Serving Publicly Insured PWH
- SOLAR: Randomized Switch to LA CAB + RPV From BIC/FTC/TAF
Amanda Binkley, PharmD, BCIDP, AAHIVP
Clinical Pharmacy Specialist
Infectious Disease
Department of Pharmacy
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Nimish Patel, PharmD, PhD, AAHIVP
Professor
Department of Clinical Pharmacy
Skaggs School of Pharmacy & Pharmaceutical Sciences
University of California
La Jolla, California
Link to full program: bit.ly/3ZjSFhg
In this episode, Christine Katlama, MD, and Babafemi Taiwo, MBBS, discuss optimizing ART for people with HIV who are treatment experienced or failing a current ART regimen, including:
- Recycling agents from the NRTI, NNRTI, INSTI, and PI classes in salvage ART regimens
- Maintaining NRTIs in second-line and salvage ART regimens, including the use of 3TC, TFV, and ABC
- ART regimen simplification
- When to perform genotypic resistance testing, including for PWH who have been off ART
- When to perform DNA genotyping for archived resistance testing
- Considering LA CAB + RPV with prior NNRTI exposure, ART resistance, or past adherence concerns with oral ART
- Using boosted DRV + DTG in salvage regimens
- Switching from boosted PIs to INSTIs in PWH receiving second-line therapy
- Second-line regimens with LA CAB + RPV failure
Christine Katlama, MD
Professor
Sorbonne University APHP Paris
Head, HIV/Hepatitis Clinical and Research Unit
Department of Infectious Diseases
Paris, France
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Link to full program: https://bit.ly/3Z44Gq3
In this episode, Sonya Krishnan, MD, MHS, discusses using HIV-ASSIST to aid in the selection of an ART regimen for a virologically suppressed PWH who is planning a pregnancy. Listen as she covers:
- How to input patient specific factors into the HIV-ASSIST tool
- Discussion of available education sheets to review the data and recommendations for her current ART regimen in pregnancy
- An explanation of why some regimens are ranked lower because of adherence factors such as increased pill burden or dosing frequency
- Guidelines informing the HIV-ASSIST output, including DHHS and IAS-USA, and the frequency with which updates are incorporated
- How to use the HIV-ASSIST output to guide regimen selection in pregnancy
- Use of the HIV-ASSIST tool in shared decision-making and patient counseling
Sonya Krishnan, MD, MHS
Assistant Professor
Division of Infectious Diseases
Johns Hopkins University
Baltimore, Maryland
Link to full program:
bit.ly/3pwaH2Y
In this episode, Ian Frank, MD, discusses long-acting HIV treatment with cabotegravir plus rilpivirine for people with HIV, including:
- Efficacy data with every-8-week dosing
- Real-world use in people with viremia
- Initiation and continuation strategies
- Virologic failure data
- Safety information
Presenter:
Ian Frank, MD
Associate Chief
Division of Infectious Diseases
Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
To download the slides: https://bit.ly/3HX1GGn
To view the full online program: https://bit.ly/3ZjSFhg
In this episode, Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI, discusses new data on COVID-19 presented at ECCMID 2023, including:
- Treatment in special populations
- REDPINE: remdesivir in people with renal impairment hospitalized for COVID-19 pneumonia
- Remdesivir and readmission for COVID-19 in immunocompromised patients
- Molnupiravir vs nirmatrelvir plus ritonavir for COVID-19 with hematologic malignancy
- Management of patients with severe disease
- RECOVERY: higher-dose vs standard-dose corticosteroids for hospitalized patients with COVID-19
- Real-world study of tocilizumab vs baricitinib for severe COVID-19
- Novel antivirals
- Ensitrelvir
- Bemnifosbuvir
- Novel vaccines
- NB2155
- AZD2816/AZD1222
- qNIV/CoV2373
- GRT-R910
- NVX-CoV2373 in people with HIV
Faculty:
Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI
Professor of Microbial Diseases
Centre for Experimental Pathogen Host Research
University College Dublin
Dublin, Ireland
Content based on an online CME/CE program supported by independent educational grants from Gilead Sciences, Inc. and Novavax.
Link to full program:
bit.ly/3niXGJ6
Link to downloadable slides:
bit.ly/3LUFejG
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:
- Current COVID-19 landscape
- Rapid antigen tests and PCR tests
- Risk stratification of patients who have a positive SARS-CoV-2 test
- Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)
- Long COVID
Presenters:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Trinh P. Vu, PharmD, BCIDP
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmaceutical Services
Emory University Hospital Midtown
Atlanta, Georgia
To download the slides: bit.ly/3oHKC09
To view the full online program: bit.ly/4201xcO
In this episode, David van Duin, MD, PhD, FIDSA, FAST, discusses new data on complicated clinical infections presented at ECCMID 2023, including:
- Gram-negative resistance
- Pharmacokinetic and clinical outcomes in patients receiving meropenem/vaborbactam for KPC-producing carbapenem-resistant Enterobacterales infections
- Comparative study of cefiderocol- vs colistin-containing regimens for CRAB VAP with concomitant bacteremia
- Real-world use of imipenem/cilastatin/relebactam for the treatment of infections caused by multidrug-resistant organisms
- Antimicrobial stewardship
- Safety and efficacy of antibiotic de-escalation from an antipseudomonal β-lactam in patients with Enterobacterales BSIs in SIMPLIFY
- The SOAB study comparing clinical outcomes of switching to oral antibiotics after IV lead-in therapy vs continuing IV therapy in patients with Enterobacterales BSIs
- Data from REGARD-VAP on outcomes of shortened antibiotic treatment for VAP guided by clinical criteria
- Investigational agents
- Open-label study following ATTACK of patients with colistin-resistant CRAB infections receiving sulbactam/durlobactam
- Summary of findings from EAGLE-2 and EAGLE-3 of gepotidacin for uncomplicated UTI treatment
- Post hoc DOOR analysis of SURE-2 of sulopenem for the treatment of complicated UTIs
Faculty:
David van Duin, MD, PhD, FIDSA, FAST
Professor of Medicine
Director, Immunocompromised Host Infecious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina
Content based on an online CME/CE program supported by an independent educational grant from Shionogi Inc.
Link to full program: https://bit.ly/3niXGJ6
Link to downloadable slides: https://bit.ly/3Hx0ppn
In this episode, Tracey Piparo, PA-C, and Renslow Sherer, MD, discuss cases of nonhospitalized patients with COVID-19, including:
- Young, healthy patient with no risk factors
- Young, healthy patient with risk factors
- Older patient with immunocompromise
- Older patient with renal dysfunction
- Patient experiencing hypoxia
Presenters:
Tracey Piparo, PA-C
Department of Palliative Medicine
RJWBarnabas
New Brunswick, New Jersey
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
To download the slides: bit.ly/44cgH0q
To view the full online program: https://bit.ly/4201xcO
In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:
- Barriers to HDV screening, including limitations to AASLD guideline recommendations
- Use of double reflex testing to improve HDV diagnosis
- Considerations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDV
- Updated CDC recommendations for HBV screening for all adults using a triple panel test
- Staging advanced liver disease in patients with HDV
- Indications for HDV treatment, including patients with low ALT levels and advanced or progressive liver disease
- Treatment landscape for HDV
- Personal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosis
- Updates on novel HDV therapies, including:
- Summary of efficacy data on bulevirtide from clinical trials
- Interpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib
Link to full program:
bit.ly/3yp1Lxf
In this episode, Joseph Lim, MD; Mindie H. Nguyen, MD, MAS, AGAF, FAASLD; and Jennifer Wild, MS, BSN, RN, OCN, discuss strategies for overcoming barriers to HBV care in Asian American people, including:
- HBV-related stigma
- Language barriers
- Health insurance navigation
Presenters:
Joseph Lim, MD
Professor of Medicine
Director, Clinical Hepatology
Vice-Chief, Section of Digestive Diseases
Yale University School of Medicine
New Haven, Connecticut
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (GI & Hepatology, Liver Transplant)
Professor of Epidemiology & Population Health (By Courtesy)
Director of Hepatology Fellowship
Director of Hepatology Clerkship
Stanford University Medical Center
Palo Alto, California
Jennifer Wild, MS, BSN, RN, OCN
Clinical Nurse
UCSF Helen Diller Family Comprehensive Cancer Center
GI Medical Oncology, Outpatient Hepatobiliary Program
Oakland, California
Link to downloadable slides: please link to VM401 downloadable slides when ready
Link to program: please link to HEP 2023 HBV Key Communities VM (PRP5676) when ready
In this episode, Essa Mohamed, PhD; Daouda Ndiaye; and Ponni Perumalswami, MD, MS, discuss strategies for overcoming barriers to HBV care in African immigrant people, including:
- HBV awareness and misconceptions
- HBV-related stigma
- Language barriers
- Health insurance navigation
Presenters:
Essa Mohamed, PhD
Clinical Researcher
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota
Daouda Ndiaye
Patient Navigator
Ponni Perumalswami, MD, MS
Associate Professor of Internal Medicine
Division of Gastroenterology and Hepatology
University of Michigan
Ann Arbor, Michigan
Link to program: bit.ly/3L3Kz6l
In this episode, Daniel R. Kuritzkes, MD, discusses considerations for patients experiencing weight gain on antiretroviral therapy, including:
• Commonly implicated antiretroviral therapy regimens and patient populations
• Guideline recommendations for management of weight gain
Presenter:
Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts
To download the slides:
bit.ly/3odUA9C
To view the full online program:
bit.ly/3ZjSFhg
In this episode, Isolde Butler, MD, and Brenda E. Crabtree Ramírez, MD, discuss rapid ART initiation for people newly diagnosed with HIV, including:
- The HIV care continuum in the United States and Latin America
- Barriers to HIV diagnosis, including stigma, discriminatory laws and policies, social determinants of health, and lack of access to healthcare
- Factors that predict delayed care linkage and inconsistent HIV care and treatment
- Improved clinical outcomes that have been shown with rapid ART initiation, first in low- and middle-income countries and now worldwide
- Recommendations for rapid ART—and regimen choices—from the DHHS, IAS-USA, CENSIDA, EACS, and WHO
- Recommendations for transitioning from PrEP to ART when someone seroconverts while receiving either oral PrEP or LA CAB for PrEP
- Barriers to rapid ART initiation in their individual care settings
- The future of LA injectable ART for initial treatment and rapid initiation
Isolde Butler, MD
Chief Medical Officer
CrescentCare
New Orleans, Louisiana
Brenda E. Crabtree Ramírez, MD
Assistant Professor, HIV Program
Department of Infectious Diseases
Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán
Mexico City, Mexico
Link to full program: bit.ly/3HPu4Lk
In this episode, Daniel R. Kuritzkes, MD, discusses considerations for rapid initiation of antiretroviral therapy in patients who are newly diagnosed with HIV, including:
- Recommended regimens
- Management of patients previously receiving PrEP
- Timing of laboratory testing
Presenter:
Daniel R. Kuritzkes, MD
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts
To download the slides:
https://bit.ly/3odUA9C
To view the full online program:
https://bit.ly/3ZjSFhg
In this episode, 2 HIV experts from the Asia-Pacific region share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.
Specifically, the faculty discuss the role of newer innovations in HIV, including 2-drug oral antiretroviral therapy (ART) regimens, 2-drug long-acting injectable ART, and long-acting HIV pre-exposure prophylaxis in HIV care in the Asia-Pacific region, as well as the implications of weight gain with ART and important considerations related to the unique challenges associated with caring for the aging population of people with HIV in the region.
Presenters:
Anchalee Avihingsanon, MD, PhD
HIV-NAT, Thai Red Cross AIDS Research Centre
Pathumwan, Bangkok, Thailand
Senior Clinical Trial
Medicine
Bangkok, Thailand
Reena Rajasuriar, BPharm, MPharm, PhD
Associate Professor
Department of Medicine
University of Malaya
Kuala Lumpur, Malaysia
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare.
Link to full program:
bit.ly/3Hz0jNa
In this episode, Angela Branche, MD, and Helen Y. Chu, MD, MPH, discuss the clinical presentation of respiratory syncytial virus (RSV) in adults and the importance of early detection, including:
- Clinical symptoms and presentation
- Complications, including exacerbations of cardiopulmonary diseases
- Use of medical resources compared with other respiratory viruses
- Diagnostic approaches and challenges
- Treatment and management of RSV disease
- Clinical impact of RSV awareness
Faculty:
Angela Branche, MD
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York
Helen Y. Chu, MD, MPH
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
School of Medicine
Seattle, Washington
Link to full program:
bit.ly/3nb25xe
Link to downloadable slides:
bit.ly/3TsXym5
In this episode, Angela Branche, MD, and Helen Y. Chu, MD, MPH, discuss the impact of respiratory syncytial virus (RSV) and describe those at risk for severe RSV disease, including:
- RSV prevalence and seasonality
- RSV burden throughout life, including burden in older adults
- Comorbidities that increase the risk of RSV complications
- RSV transmission in the hospital and care home setting
- Implications of risk factors for severe RSV on prevention and treatment
Faculty:
Angela Branche, MD
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
University of Rochester
Rochester, New York
Helen Y. Chu, MD, MPH
Associate Professor of Medicine
Division of Allergy & Infectious Diseases
University of Washington
School of Medicine
Seattle, Washington
Link to full program:
bit.ly/3nb25xe
Link to downloadable slides:
bit.ly/3TsXym5
In this episode, José R. Arribas, MD, and Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP, discuss optimizing antiretroviral therapy (ART) for people with HIV who are treatment experienced or failing a current ART regimen, including:
- The use of proviral DNA genotyping for switching therapy
- Maintaining nucleos(t)ide reverse-transcriptase inhibitors after a first failure
- The role of zidovudine in salvage regimens
- The use of twice-daily darunavir with protease inhibitor resistance and twice-daily dolutegravir with integrase strand transfer inhibitor resistance
- Simplification of regimens and long-acting therapies for people with HIV who are highly treatment experienced
- Drug‒drug interactions that may warrant dosing changes to avoid resistance development
- When to consider antiretrovirals with novel mechanisms of action, such as fostemsavir, ibalizumab, and lenacapavir
- The logistics of dosing, administration, and development of a complete ART regimen that includes novel mechanism antiretrovirals
- Addressing psychosocial factors to increase the chance of success on a new ART regimen
- Drug‒drug interactions with novel mechanism agents
- How common ART resistance is for people with HIV in their own practices
- The possibility of using long-acting cabotegravir plus rilpivirine in people with viremia in the future
- Addressing low-level viremia
José R. Arribas, MD
Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain
Melissa Badowski, PharmD, MPH, FIDSA, FCCP, BCIDP, BCPS, AAHIVP
Clinical Associate Professor
Section of Infectious Diseases Pharmacotherapy
Department of Pharmacy Practice
University of Illinois at Chicago, College of Pharmacy
Chicago, Illinois
Link to full program:
bit.ly/3Z44Gq3
In this episode, Darrell H. S. Tan, MD, FRCPC, PhD, and Kenric Ware, PharmD, AAHIVP, discuss considerations for HIV pre-exposure prophylaxis (PrEP) persistence, including:
- The PrEP continuum of care in the United States, including inequities in PrEP uptake and persistence by race
- CDC PrEP guidance regarding PrEP indications
- PrEP eligibility by regimen
- Summary of renal, bone, and weight outcomes with different PrEP options
- Data on HIV acquisition following PrEP discontinuation
- Drug concentrations and recommendations for stopping long-acting cabotegravir for PrEP
- Expanding PrEP options to facilitate adherence and persistence
- Providing PrEP by telehealth
Presenters:
Darrell H. S. Tan, MD, FRCPC, PhD
Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael’s Hospital
Toronto, Canada
Kenric Ware, PharmD, AAHIVP
Associate Professor
Department of Pharmacy Practice
South University
Savannah, Georgia
Chairperson, Pharmacist
Board of Directors
Joseph H. Neal Health Collaborative
Columbia, South Carolina
Link to full program:
https://bit.ly/3HPu4Lk
In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, and Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, answer questions including:
- Strategies to improve disparities in pre-exposure prophylaxis (PrEP) access in difficult-to-reach populations
- Key remaining questions related to PrEP options for cisgender women and people who inject drugs
- Concerns about resistance at seroconversion in patients with suboptimal PrEP compliance
- Implementation of molecular screening for patients receiving PrEP
- Expectations for weight gain and patient counseling points
Presenters:
Carolyn Chu, MD, MSc, FAAFP, AAHIVS
Chief Medical Officer
American Academy of HIV Medicine
Chief Clinical Officer
National Clinician Consultation Center
Samantha Strong, PharmD, BCACP, AAHIVP, CDCES
Clinical Director of Pharmacy
Nevada Health Centers
Las Vegas, Nevada
Link to full program:
https://bit.ly/3Fqdgs9
In this episode, Maria Buti, MD, and Richard H. Davis, PA-C, address key considerations when screening, diagnosing, and treating patients with hepatitis delta virus (HDV), such as:
- Barriers to screening
- HDV screening based on patient risk factors
- Universal screening for all patients with positive hepatitis B surface antigen (HBsAg)
- Reflex testing
- Availability of commercial testing
- Monitoring suggestions in HBsAg positive and HDV antibody positive patients with negative HDV RNA
- Limitations to evaluating advanced fibrosis in patients with HDV
- Data on novel HDV therapies (eg, bulevirtide and lonafarnib)
- Extending HDV therapy (eg, peginterferon) based on treatment response
- Stopping rules (eg, HDV RNA negativity, HBsAg loss) for discontinuing HDV therapy
Faculty:
Maria Buti, MD
Professor of Medicine
Hospital Universitario Vall d’Hebron
Barcelona, Spain
Richard H. Davis, PA-C
Senior PA
Gastroenterology
University of Florida
UF Health
Gainesville, Florida
Link to full program:
http://bit.ly/3yp1Lxf
In this episode, Latesha Elopre, MD, MSPH, discusses key considerations to barriers to PrEP uptake, including:
- Addressing disparities among racial and ethnic minority populations
- Understanding the concept of intersectionality
- Tackling multiple levels of intersectionality
- Individual (eg, self-stigma, mental health)
- Network (eg, access to PrEP services)
- Community (eg, racism, stigma, poverty)
- Social and structural (eg, laws/policies)
- Epidemic (eg, population level of viremia)
Presenter:
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ZjSFhg
Follow along with the slides:
https://bit.ly/3YmeRWy
In this episode, Darcey Wooten, MD, discusses updated guidance and rationale for monitoring for new HIV infections in people receiving long-acting PrEP, including:
- Testing both Ag/Ab and HIV-1 RNA
- Steps to take when a person receiving long-acting PrEP develops a new HIV infection
Presenter:
Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California
To download the slides:
https://bit.ly/3Jb1ofX
To view the full online program:
https://bit.ly/3ZjSFhg
In this episode, Darcey Wooten, MD, discusses the long-acting HIV treatment agent lenacapavir for treatment-experienced people with HIV, including:
- Efficacy data
- Initiation strategies
- Virologic failure data
- Safety information
Presenter:
Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California
To download the slides:
http://bit.ly/3Jb1ofX
To view the full online program:
https://bit.ly/3ZjSFhg
In this episode, Nancy Reau, MD, and Lydia Tang, MBChB, discuss how to increase linkage to care rates for persons with hepatitis D virus, including:
- Updates on currently low rates of linkage to care
- Barriers preventing patients with HBV/HDV
coinfection from engaging in care - Interventions to increase retention in care for patients with HDV
Faculty:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Lydia Tang, MBChB
Assistant Professor
Department of Infectious Diseases
University of Maryland School of Medicine
Institute of Human Virology
Baltimore, Maryland
Link to full program:
https://bit.ly/41oYawr
Follow along with the slides at:
https://bit.ly/3XW6m4g
In this episode, Coleman I. Smith, MD, and Lydia Tang, MBChB, discuss how to screen for hepatitis delta virus (HDV), including:
- Algorithm for evaluation of HDV
- Diagnosis of different stages of HDV infection
- Strategies to increase HDV testing rates
Faculty:
Coleman I. Smith, MD
Professor of Medicine
Hepatologist
Georgetown Transplant Institute
Georgetown University
Washington, DC
Lydia Tang, MBChB
Assistant Professor
Department of Infectious Diseases
University of Maryland School of Medicine
Institute of Human Virology
Baltimore, Maryland
Link to full program:
http://bit.ly/41oYawr
Follow along with the slides at:
http://bit.ly/3XW6m4g
In this episode, Jill Blumenthal, MD, MAS, and William R. Short, MD, MPH, AAHIVS, address key considerations when evaluating ART safety and tolerability in pregnant people, those trying to conceive, and transgender individuals, such as:
- Approaching patients trying to conceive on nonpreferred ART regimens (eg, 2-drug regimens like LA CAB and RPV)
- Optimizing the use of the Antiretroviral Pregnancy Registry
- Addressing unique barriers to ARV adherence in transgender individuals with HIV (eg, drug formulation considerations for ARV medications and gender-affirming hormone therapy, sperm banking or egg harvesting, drug coverage considerations)
Faculty:
Jill Blumenthal, MD, MAS
Associate Professor of Medicine
Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Link to full program:
http://bit.ly/3PM3nYe
Link to downloadable slides:
http://bit.ly/3WgYycz
In this episode, Canadian HIV experts share their thoughts on some of the most important new insights from HIV treatment and prevention research over the past year.
Specifically, the faculty discuss treatment strategies for patients with a history of NRTI resistance based on findings from the 2SD and NADIA trials; the latest data informing the use of 2-drug oral and injectable treatment regimens; prevention approaches for HIV and other sexually transmitted infections based on findings from the DoxyPEP, HPTN 083, and HPTN 084 trials; and other emerging innovations in HIV care.
Presenters:
Jean-Guy Baril, MD
Associate Professor
Family Medicine
Université de Montreal
Montreal, Quebec, Canada
Alexander Wong MD, FRCPC
Associate Professor
Department of Medicine
University of Saskatchewan
Regina, Saskatchewan, Canada
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.
Link to full program:
http://bit.ly/3YD8T4E
In this episode, 2 Australian HIV experts share their thoughts on some of the most important HIV insights gained during the past year in the context of HIV care in Australia.
Specifically, the faculty discuss the continued dominance of second-generation INSTI-based regimens as mainstay HIV therapy in Australia, including in both 2-drug and 3-drug oral regimens; the emergence of 2-drug long-acting injectable therapy as a switch strategy; key aspects of successfully expanded oral PrEP programs in the region; the potential role of long-acting injectable PrEP; and key new advances in HIV cure research.
Presenters:
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia
Don Smith, MD
Conjoint Professor
School of Population Medicine
University of New South Wales
Senior Staff Specialist
Albion Centre
South Eastern Sydney Local Health Network
Sydney, Australia
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.
Link to full program:
http://bit.ly/3YD8T4E
In this episode, 2 HIV experts from Latin America share their thoughts on the current status of HIV prevention strategies in the region, including recent successes and ongoing challenges. Specifically, the faculty discuss:
- Barriers that limit PrEP availability in many regions of Latin America despite the high need among vulnerable and at-risk groups
- Successful expansion of PrEP access in Brazil
- Key findings from the prospective ImPrEP study evaluating implementation of same-day oral PrEP among men who have sex with men and transgender women in Brazil, Mexico, and Peru
- What long-acting PrEP could mean for at-risk groups in Latin America when it becomes available
- Important considerations for PrEP among TGW
Presenters:
Claudia P. Cortes MD
Associate Professor
Infectious Diseases
Universidad de Chile
Santiago, Chile
Beatriz Grinsztejn MD, PhD
Diretora, STD/HIV Clinical Research Laboratory
Instituto Nacional de Infectologia Evandro Chagas
Oswaldo Cruz Foundation
Rio de Janeiro, Brazil
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. and ViiV Healthcare.
Link to full program:
http://bit.ly/3YD8T4E
In this episode, 2 European HIV experts share their thoughts on some of the most important new antiretroviral therapy insights from HIV research over the past year.
Specifically, the faculty discuss findings from real-world and long-term studies of 2-drug oral regimens, the latest on 2-drug long-acting injectable therapy, how 2-drug options fit into rapid start strategies, and other new and emerging innovations in HIV treatment, including the availability of lenacapavir for multidrug-resistant HIV treatment and resumption of islatravir clinical development.
Presenters:
Jürgen K. Rockstroh, MD
Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany
Alexandra Calmy, MD, FMH, PhD
HIV/AIDS Unit Director
Infectious Diseases Division
Geneva University Hospitals
University of Geneva
Geneva, Switzerland
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. andViiV Healthcare.
Link to full program:
http://bit.ly/3Hz0jNa
In this episode, Alba Azola, MD, and Monica Verduzco-Gutierrez, MD, discuss diagnosis and management of long COVID, including:
- Definitions of post COVID conditions
- Diagnosis, including symptoms and clinical presentation
- Epidemiology
- Risk factors
- Possible treatment options
- Clinical guidance statements
Presenters:
Alba Azola, MD
Assistant Professor
Department of Physical Medicine and Rehabilitation
Johns Hopkins
Co-Director
Johns Hopkins Post Acute COVID Team Clinic
Baltimore, Maryland
Monica Verduzco-Gutierrez, MD
Professor and Distinguished Chair
Department of Rehabilitation Medicine
University of Texas Health Science Center at San Antonio
Director, UT Health COVID-19 Recovery Clinic
Department of Rehab Medicine
UT Health San Antonio
San Antonio, Texas
Link to full program:
https://bit.ly/3Gn4tXO
Links to Consensus Guidance Statements on Assessment and Treatment of Post-Acute Sequelae of COVID-19:
Autonomic Dysfunction:
https://bit.ly/3GHeUGY
Cardiovascular Complications:
https://bit.ly/3CmupkX
Cognitive Symptoms:
https://bit.ly/3X9tnkw
Fatigue:
https://bit.ly/3ihiLRQ
Respiratory Sequelae:
https://bit.ly/3IrUkMc
In this episode, Kenric Ware, PharmD, AAHIVP, discusses the role of college campuses in HIV pre-exposure prophylaxis (PrEP) uptake for adolescents, including the following.
- PrEP awareness and education
- Venues for ongoing PrEP conversations, including in-person dormitory discussions, virtual webinars, and social media conversations
- Campus health clinics that are safe and trusting and minimize stigma
- Individualized approaches, including:
- Engaging local students in discussions of regional barriers and facilitators to PrEP uptake on their campus
- Recruiting PrEP ambassadors with social capital on campus, such as student athletes or sorority or fraternity leaders
- Identifying faculty and administrator PrEP champions to amplify and provide continuity and support to student PrEP messaging
Kenric Ware, PharmD, AAHIVP
Associate Professor
Department of Pharmacy Practice
South University
Savannah, Georgia
Chairperson, Pharmacist
Board of Directors
Joseph H. Neal Health Collaborative
Columbia, South Carolina
See the full program at:
http://bit.ly/3WhbBvZ
In this episode, Eric Florence, MD, PhD, discusses how clinics can prepare for the implementation of long-acting injectable antiretroviral therapy, including:
- Clinical infrastructure
- Ensuring adequate space and injection equipment
- Maintaining drug supply and temperature requirements
- Staffing
- Ensuring there are staff able to focus on the implementation of LA ART, including well-trained nurses to administer the injections
- Implementing a system for scheduling follow-up injections and providing patient reminders
- Having knowledgeable staff available to answer patient questions on their LA ART
Eric Florence, MD, PhD
Physician
Internal Medicine, Infectious Diseases & Tropical Medicine
University Hospital of Antwerp
Edegem, Brussels, Belgium
See the full program at:
https://bit.ly/3CsSvdX
In this episode, Marta Boffito, MD, PhD, FRCP, and Jens D. Lundgren, MD, DMSc, address key considerations when evaluating antiretroviral therapy safety and tolerability in aging patients and those with possible cardiometabolic toxicities, including:
- Monitoring for cardiometabolic syndromes (eg, lipid panels, coronary artery calcification scores)
- Approaching antiretroviral-related weight gain in clinical practice
- Interpreting results from RESPOND on cardiovascular risk with integrase strand transfer inhibitors
- Collaborating with other specialties (eg, cardiologists, dietitians) to provide a multidisciplinary approach for managing comorbidities, including prevention and management
Faculty:
Marta Boffito, MD, PhD, FRCP
Consultant Physician/Professor
HIV/Research
Chelsea and Westminster Hospital
Imperial College London
London, United Kingdom
Jens D. Lundgren, MD, DMSc
Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Link to full program:
http://bit.ly/3PM3nYe
Link to downloadable slides:
http://bit.ly/3WgYycz
In this episode, Jens D. Lundgren, MD, DMSc, and Barbara Rath, MD, PhD, HDR, discuss emerging insights on outpatient management of acute COVID-19 and long COVID in Europe, including:
- Current COVID-19 variant and subvariant landscape
- COVID-19 treatments, including antivirals and monoclonal antibodies
- ESCMID COVID-19 treatment guidelines
- Long COVID causes and pathophysiology
- Prevention and management of long COVID
Presenters:
Jens D. Lundgren, MD, DMSc
Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Barbara Rath, MD, PhD, HDR
Co-founder and Chair
Vaccine Safety Initiative, Berlin, Germany/USA
Research Director
Université de Bourgogne-Franche-Comté, France
Executive Board Member
ESGREV (Respiratory Virus Study Group for ESCMID)
ISIRV Chair
ISIRV-Epidemiology Group
Follow along with the downloadable slideset at:
https://bit.ly/3IN1ScA
Link to full program:
http://bit.ly/3kb8pn4
In this episode, Laurence Slama, MD, PhD, describes some of the ways that her clinic is attempting to make IM injections of long-acting antiretroviral therapy more sustainable long term. She explains the logistics of how she has allowed for patients to receive their long-acting cabotegravir and rilpivirine doses through community nurses after receiving the first 3 doses in a clinical setting. She also discusses some of the benefits and challenges of this kind of flexible system for patients and healthcare professionals.
Laurence Slama
Doctor
Department of Infectious Diseases
Hôtel Dieu, APHP
Paris, France
See the full program at:
https://bit.ly/3CsSvdX
In this episode, Jill Blumenthal, MD, MAS, discusses HIV pre-exposure prophylaxis (PrEP) considerations for transgender and nonbinary individuals, including:
- Providing gender-affirming care
- Integrating PrEP and gender care
- Taking a sexual history and addressing sexual health
- PrEP efficacy and options for transgender individuals, including FTC/TDF, FTC/TAF, and long-acting CAB
- The importance of reassuring transgender individuals that data suggest there are no drug–drug interactions between gender-affirming hormone therapy and any of the PrEP options
Jill Blumenthal, MD, MAS (she/hers)
Associate Professor of Medicine
Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California
See the full program at:
https://bit.ly/3WhbBvZ
In this episode, Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, discusses optimizing HIV pre-exposure prophylaxis (PrEP) selection and persistence for men who have sex with men (MSM), including:
- Disparities in PrEP uptake for MSM
- What healthcare professionals can do to address disparities in PrEP uptake
- Providing PrEP within a program that includes sexual health and primary care services, in addition to prescribing PrEP
- PrEP medication options for MSM
- Helping patients access PrEP medications
- Barriers to PrEP persistence
- Strategies for aiding in PrEP persistence, including:
- Increasing access to healthcare professionals through text messaging and telemedicine
- Ensuring a welcome and sex-positive environment
- Partnering with pharmacists and community health workers for follow-up
Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN
Professor
School of Nursing
Johns Hopkins University
Nurse Practitioner
Department of Infectious Diseases
John G. Bartlett Specialty Practice
Baltimore, Maryland
See the full program at:
https://bit.ly/3WhbBvZ
Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 treatments and the possibility for antiviral resistance, including:
- Treatment resistance mechanisms
- COVID-19 testing
- COVID-19 treatments, including antivirals and monoclonal antibodies
Presenters:
Fernando Carnavali, MD
Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Site Director
COVID Center of Excellence Satellite-Ansonia
Mount Sinai Health
New York, New York
Rasika Karnik, MS, MD
Assistant Professor
Division of Primary Care
Department of Internal Medicine
University of Chicago
Medical Director
Post-COVID Recovery Clinic
Chicago, Illinois
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Joseph Torrisi, PharmD, BCIDP
Clinical Pharmacy Specialist
Infectious Diseases
Pharmacy
Grady Health System
Atlanta, Georgia
Link to slides:
https://bit.ly/3hXMgId
Link to full program:
https://bit.ly/3G271KL
Fernando Carnavali, MD; Rasika Karnik, MS, MD; and Renslow Sherer, MD, discuss long COVID, including:
- Long COVID prevention strategies, including COVID-19 vaccination
- Long COVID treatment approaches
- Strategies for management of patients with long COVID
Presenters:
Fernando Carnavali, MD
Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Site Director
COVID Center of Excellence Satellite-Ansonia
Mount Sinai Health
New York, New York
Rasika Karnik, MS, MD
Assistant Professor
Division of Primary Care
Department of Internal Medicine
University of Chicago
Medical Director
Post-COVID Recovery Clinic
Chicago, Illinois
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Link to slides:
https://bit.ly/3hXMgId
Link to full program:
https://bit.ly/3G271KL
In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes a review of the following studies on ART and weight gain:
- ADVANCE: men vs women receiving DTG + FTC/TAF, DTG + FTC/TDF, and EFV + FTC/TDF
- Comparison of ART regimens (eg, INSTI-, NNRTI- and PI-based regimens) in a pooled analysis of 8 phase III randomized controlled trials
- GEMINI-1 and GEMINI-2: DTG + 3TC vs DTG + FTC/TDF
Presenter:
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides:
https://bit.ly/3PYy1zn
Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 rebound, including:
- Prevalence of COVID-19 rebound
- COVID-19 rebound and antiviral use
- Management of COVID-19 rebound
Presenters:
Fernando Carnavali, MD
Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Site Director
COVID Center of Excellence Satellite-Ansonia
Mount Sinai Health
New York, New York
Rasika Karnik, MS, MD
Assistant Professor
Division of Primary Care
Department of Internal Medicine
University of Chicago
Medical Director
Post-COVID Recovery Clinic
Chicago, Illinois
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Joseph Torrisi, PharmD, BCIDP
Clinical Pharmacy Specialist
Infectious Diseases
Pharmacy
Grady Health System
Atlanta, Georgia
Link to slides:
https://bit.ly/3hXMgId
Link to full program:
https://bit.ly/3G271KL
In this episode, Princy N. Kumar, MD, FIDSA, MACP, discusses key considerations for selecting ART in treatment-naive persons with HIV. Her discussion includes:
- DHHS Treatment Guideline recommendations
- Choosing among first-line recommended integrase inhibitors
- Recommended regimens for rapid ART start
- Select key studies in treatment-naïve adults:
- AMBER study of virologic response with DRV/COBI/FTC/TAF vs DRV/COBI + TFC/TDF
- DRIVE-AHEAD and DRIVE-FORWARD efficacy study results, including resistance analyses of DOR + 2 NRTIs vs EFV or (DRV + RTV) + 2 NRTIs
- Safety and efficacy results from GEMINI-1 and GEMINI comparing DTG + 3TC vs DTG + FTC/TDF
- The current/possible role of boosted PIs and NNRTIs
- Selection considerations between TDF and TAF
Presenter:
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides:
https://bit.ly/3PYy1zn
Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss how to ethically prioritize patients for COVID-19 treatment when treatment supplies may be limited, including insights on:
- Risk stratification
- Medication acquisition
- Drug interactions
Presenters:
Fernando Carnavali, MD
Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Site Director
COVID Center of Excellence Satellite-Ansonia
Mount Sinai Health
New York, New York
Rasika Karnik, MS, MD
Assistant Professor
Division of Primary Care
Department of Internal Medicine
University of Chicago
Medical Director
Post-COVID Recovery Clinic
Chicago, Illinois
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Joseph Torrisi, PharmD, BCIDP
Clinical Pharmacy Specialist
Infectious Diseases
Pharmacy
Grady Health System
Atlanta, Georgia
Link to slides:
https://bit.ly/3hXMgId
Link to full program:
https://bit.ly/3G271KL
In this episode, Tamera Coyne-Beasley, MD, MPH, discusses strategies to address barriers to improve meningococcal vaccination rates by addressing social determinants of health and minimizing vaccine inequities, such as:
- Working closely with members of the community, including community-based organizations and adolescent and young adult influencers
- Involving all youth when designing vaccination outreach and messaging programs
- Creating and evaluating the use of technology
- Using graphics, voices, and videos, appealing to all languages, and learning styles
- Acknowledging that racism exists in medicine and medical history
- Informing individuals that many children, including undocumented immigrants and those who are uninsured or underinsured, may be eligible for free meningococcal vaccines through the Vaccines for Children program
- Seeking ways to address the shortage of healthcare professionals
Faculty:
Tamera Coyne-Beasley, MD, MPH
Derrol Dawkins, MD Endowed Chair in Adolescent Medicine
Vice-Chair, Pediatrics
Professor of Pediatrics and Internal Medicine
Division Director
Adolescent Medicine
University of Alabama at Birmingham
Children's of Alabama
Birmingham, Alabama
Link to full program:
https://bit.ly/3T0GLG2
Fernando Carnavali, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss how new COVID-19 vaccines may affect risk stratification, including:
- Omicron-specific vaccine
- Role of vaccination in risk stratification
Presenters:
Fernando Carnavali, MD
Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Site Director
COVID Center of Excellence Satellite-Ansonia
Mount Sinai Health System
New York, New York
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Joseph Torrisi, PharmD, BCIDP
Clinical Pharmacy Specialist
Infectious Diseases
Pharmacy
Grady Health System
Atlanta, Georgia
Link to slides:
https://bit.ly/3WDYeFK
Link to full program:
https://bit.ly/3WJdIbs
In this episode, an international expert panel shares their thoughts on what will be needed from future long-acting HIV treatment and prevention strategies to address populations who are not eligible for currently available long-acting options. The faculty members also discuss important considerations for leveraging long-acting HIV approaches to address care inequities across different populations.
Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; essential considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection, such as the role of the lead-in phase, new guideline recommendations for monitoring during PrEP, and patient care and follow-up after PrEP discontinuation; and important considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium.
Presenters:
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Yvonne Gilleece, MB BCh, BAO
Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy
Darrell H. S. Tan, MD, FRCPC, PhD
Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada
Content based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3P3uPBc
In this episode, Carolyn Chu, MD, MSc, FAAFP, AAHIVS, discusses improving HIV pre-exposure prophylaxis accessibility and availability for PWID, including by:
- Integrating PrEP with services that PWID are already aware of and/or connected to (eg, harm reduction/syringe services and substance use disorder treatment programs, peer-based training/education initiatives, healthcare for the homeless programs, and emergency departments)
- Staffing PrEP programs with people who are trusted by PWID and delivering PrEP in settings where patients feel respected, comfortable, and safe
- Tailoring prescribing practices and interventions (eg, same-day medication initiation, on-site pharmacies and/or medication storage, and intensive outreach and navigation) to support the care needs of PWID
Carolyn Chu, MD, MSc, FAAFP, AAHIVS
Chief Medical Office
American Academy of HIV Medicine
See the full program at:
https://bit.ly/3WhbBvZ
In this episode, Monica Gandhi, MD, MPH, and Chloe Orkin, MBChB, FRCP, MD, discuss considerations for monkeypox, now called mpox, in people with HIV, including:
- The history of monkeypox (mpox)
- The current monkeypox (mpox) outbreak
- What we knew about monkeypox (mpox) in PWH prior to the current outbreak
- Data in PWH from an international case series of monkeypox (mpox)
- CDC data regarding monkeypox (mpox) in PWH
- Monkeypox (mpox) treatment recommendations
- Drug–drug interaction considerations between tecovirimat for monkeypox (mpox) and ART
- Monkeypox (mpox) vaccination recommendations for PWH
- Global access to monkeypox (mpox) treatments and vaccines
- Whether monkeypox (mpox) is a sexually transmitted infection and the implications of that
- Ongoing research on monkeypox (mpox) in PWH
Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Link to full program:
https://bit.ly/3HPu4Lk
In this episode, Annette Haberl, MD, and William R. Short, MD, MPH, AAHIVS, discuss when to consider an ART switch during pregnancy, including:
- Current DHHS, EACS, WHO, BHIVA, and German/Austrian guidelines for the use of ARVs in pregnancy
- What data and recommendations for the use of ARVs during pregnancy are currently missing from the guidelines
- Available data on newer ARVs in the ARV pregnancy registry
- Pharmacokinetic data for newer ARVs including BIC/FTC/TAF and LA CAB + RPV in pregnancy
- Recommendations for 2-drug ART regimens in pregnancy
- What to do when someone becomes pregnant on a newer ART regimen that is not yet recommended by the guidelines
Annette Haberl, MD
Physician
Head of HIV and Women
HIVCENTER Frankfurt
Department of Infectious Disease
Hospital of the Johann Wolfgang Goethe University
Frankfurt, Germany
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Link to full program:
https://bit.ly/3HPu4Lk
In this episode, Stephane De Wit, MD, PhD, discusses the benefits of long-acting antiretroviral therapy (ART) for migrant populations in Europe—and specifically in Belgium. He also addresses some of the challenges of accessing and following up with those populations.
Dr De Wit describes some of the ways that the Belgian healthcare system is set up to improve access to ART. He then explains some of the disease parameters for considering expanding the use of long-acting ART to patients who are not virologically suppressed. Finally, Dr De Wit offers some thoughts about the future of long-acting ART to migrant populations in Belgium.
Stephane De Wit, MD, PhD
Former Head
Infectious Diseases
Saint Pierre University Hospital
Brussels, Belgium
See the full program at:
https://bit.ly/3HIMAoF
When it comes to managing adults with HBV, should age factor into your treatment decision—or is it important to treat everyone, regardless of age?
Listen as Dr George Lau discusses these questions and more for strategizing the monitoring and treatment of older adults with HBV.
Presenter:
George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA)
Chairman
Humanity and Health Medical Group
Hong Kong, China
Chair, Professor, and Co-Director
Liver Diseases & Transplant Centre
The Fifth Medical Centre of Chinese PLA General Hospital
Beijing, China
Link to full program:
https://bit.ly/3fg9fwB
In this episode, Nancy Reau, MD, and Coleman I. Smith, MD, discuss the burden of undiagnosed hepatitis delta virus (HDV) infection and who should be tested, including:
- Epidemiology of HDV infection
- Clinical course of HDV infection
- Populations at high risk of HDV infection
- Guidelines for HDV testing
Faculty:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Coleman I. Smith, MD
Professor of Medicine
Hepatologist
Georgetown Transplant Institute
Georgetown University
Washington, DC
Link to full program:
https://bit.ly/3WmJnzi
Follow along with the slides at:
https://bit.ly/3NpAYI1
In this episode, Winnie Sseruma and Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, discuss some of the barriers to genuinely patient-centered HIV care in Africa and offer calls to action for healthcare professionals for responding to patient preferences.
They discuss the efforts to improve patient-centered HIV care in the foundations and organizations for which they work. They also address issues related to stigma around HIV and complacency and lack of visibility for HIV.
You will then hear them talk through differentiated service delivery in South Africa and Mozambique as models for other parts of Africa. They focus on HIV prevention and some of the difficulties of reaching certain populations to better communicate effective prevention practices.
They end with a discussion about the importance of documenting the experiences and stories of people living with HIV.
Winnie Sseruma
International Development Consultant
London, United Kingdom
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Link to full program:
https://bit.ly/3Fxsfkz
In this episode, Iskandar Azwa, MBChB, and patient advocate Andrew Tan Tze Tho discuss barriers to genuinely patient-centered HIV care in Malaysia and the surrounding region and offer calls to action for healthcare professionals for responding to patient preferences.
They discuss health literacy programs and other forms of effective health communication, especially with respect to disparate communities. They also address the prevalence of late presentation in Malaysia and the importance of getting people tested and into care earlier.
They then discuss the urgency of rapid initiation of antiretroviral therapy, discrepancies in access to health services, and stigma and discrimination.
Finally, they discuss the issues preventing newer antiretrovirals from being more readily available to people in the region; the importance of maintaining and refining patient-focused, differentiated care in the face of such disparities; and the role of advocates and healthcare professionals in helping to drive those improvements.
Iskandar Azwa, MBChB
Associate Professor
Infectious Diseases, Faculty of Medicine
University of Malaya
Kuala Lumpur, Malaysia
Andrew Tan Tze Tho
President
Kuala Lumpur AIDS Support Services Society (KLASS)
Kuala Lumpur, Malaysia
Link to full program:
https://bit.ly/3Fxsfkz
In this episode, Jill Blumenthal, MD, MAS, and Jennifer Cocohoba, PharmD, share how they manage possible antiretroviral (ARV)-associated toxicities in transgender individuals, including:
- Strategies on how to approach different ARV-related toxicities
- Other factors to consider when assessing possible ARV-related toxicities (eg, weight gain, cardiovascular disease), such as gender-affirming care and nonmedication risk factors (eg, smoking, life stressors)
- Clinically relevant drug–drug interactions related to HIV and gender-affirming care
- Methods to reduce barriers to ART adherence
Faculty:
Jill Blumenthal, MD, MAS
Associate Professor of Medicine
Infectious Diseases and Global Public Health
University of California, San Diego
San Diego, California
Jennifer Cocohoba, PharmD
Professor
Department of Clinical Pharmacy
University of California, San Francisco
Pharmacist
Women’s HIV Program
University of California San Francisco Medical Center
San Francisco, California
Link to full program:
https://bit.ly/3PM3nYe
Follow along with the slides at:
https://bit.ly/3NpAYI1
In this episode, Marion Elligsen, BScPhm, MSc, RPh, ACPR; Keith S Kaye, MD, MPH; and Andrew Shorr, MD, MPH, MBA, discuss key considerations for selecting empiric antibiotic regimens in patients with HABP/VABP in the intensive care unit, including:
- The role of novel β-lactam/β-lactamase inhibitor combinations
- Use of clinical predictions scores (eg, Drug Resistance in Pneumonia [DRIP] score) to predict risk for pneumonia caused by multidrug-resistant pathogens
- Application of rapid diagnostic testing in critically ill patients with pneumonia, including current limitations
- Implementation of advanced antibiograms and clinical prediction scores
- Clinical utility of biomarkers for pneumonia (eg, procalcitonin)
- Application of updated nosocomial pneumonia classifications in clinical practice
Faculty:
Marion Elligsen, BScPhm, MSc, RPh, ACPR
Practice-Based Researcher
Sunnybrook Research Institute
Antimicrobial Stewardship Pharmacy Lead
Department of Pharmacy
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Keith S. Kaye, MD, MPH
Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Andrew Shorr, MD, MPH, MBA
Director
Pulmonary and Critical Care Medicine
Medstar Washington Hospital Center
Washington, DC
Content based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.
Link to full program:
https://bit.ly/3HaZpYw
Link to downloadable slideset:
https://bit.ly/3UxHoqr
In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:
- Hepatitis B
- Prevention of HBV vertical transmission when HBIg is unavailable
- Therapeutic vaccination for HBV cure
- Antiviral therapy to prevent HCC in patients with CHB in the indeterminate phase
- Hepatitis delta
- HDV prevalence in ethnically diverse, urban, safety-net populations
- Bulevirtide ± pegIFN-α2a for chronic HDV in the French cATU study
- Bulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di study
- HDV functional cure with lonafarnib-based therapy
- Hepatitis C
- Integrated community HCV service for PWUD: the ITTREAT study
- Helios-3 study of treatment of people with HCV by specialists or nonspecialists
- Risk of HCC after SVR in patients with HCV
Presenter:
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany
Follow along with the downloadable slideset at:
https://bit.ly/3FxIOwZ
Link to full program:
https://bit.ly/3Y1tD6f
In this episode, Nancy Reau, MD, shares her thoughts on the most practice-changing viral hepatitis data from AASLD 2022, including:
- Novel therapeutics for HBV
- HCV management strategies
- HDV screening and linkage to care
- Fatty liver disease in persons with viral hepatitis
- Use of statins to decrease morbidity and mortality in persons with liver disease
Presenter:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director
Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Link to full program:
https://bit.ly/3Y1tD6f
In this episode, Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, discuss new HIV data presented at IDWeek and HIV Glasgow 2022, including
- Prevention strategies
- LA therapies
- Investigational agents
Presenters:
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Content based on an online CME/CE program supported by an independent educational grant from Gilead Sciences, Inc.;
Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Link to full program:
https://bit.ly/3iFEF0T
In this episode, Jason Gallagher, PharmD, and Emily Heil, PharmD, MS, BCIDP discuss landmark clinical trials of COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound phenomenon, including:
- EPIC-HR study of nirmatrelvir plus ritonavir
- PINETREE study of remdesivir
- MOVe-OUT and Panoramic studies of molnupiravir
- COVID-19 rebound in treated and untreated patients
Presenters:
Jason Gallagher, PharmD
Clinical Professor
School of Pharmacy
Temple University
Clinical Pharmacy Specialist
Infectious Diseases
Temple University Hospital
Philadelphia, Pennsylvania
Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland
In this episode, Princy N. Kumar, MD, and Paul E. Sax, MD, discuss new COVID-19 data from IDWeek 2022, including:
- COVID-19 vaccines, including omicron BA.1 bivalent booster
- Risk factors for breakthrough COVID-19 infections
- COVID-19 diagnostics, including digital droplet PCR
- COVID-19 therapeutics, including:
- Nirmatrelvir plus ritonavir
- Tixagevimab plus cilgavimab
- Baricitinib
- Tocilizumab
- Inhaled interferon β-1a
- COVID-19 therapeutics and outcomes in patients with immunocompromise
- Long COVID
Presenters:
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Follow along with the downloadable slideset at:
http://bit.ly/3gkJI67
Link to full program:
http://bit.ly/3TSVthM
In this episode, Nneka Holder, MD, MPH, shares various strategies to improve meningococcal vaccine uptake in adolescent patients, including:
- Use of school vaccine mandates beyond entry requirements
- Promote more frequent visits by incorporating immunization platforms and using text or email reminders to bring patients back to the office
- Schedule follow-up visits before patients leave the office to increase retention
- Increase access and convenience by:
- Implementing quick, immunization-only visits
- Promoting use of alternative vaccinations sites (eg, school gyms, local pharmacies) for meningococcal booster doses
- Address vaccine hesitancy, ensuring patients and parents have a voice in how their healthcare is managed
- Continue to bring up the importance of meningococcal vaccines at every visit even after vaccine refusal
Faculty:
Nneka Holder, MD, MPH
Associate Professor
Department of Pediatrics
MedStar Georgetown University Hospital
Washington, DC
Link to full program:
https://bit.ly/3T0GLG2
This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses solutions to expanding PrEP uptake. His discussion includes:
- Potential healthcare professional barriers to prescribing PrEP
- Addressing the gap in PrEP training for healthcare professionals
- Expanding PrEP options to facilitate adherence and persistence: today and in the near future
- Immediate PrEP initiation at New York City sexual health clinics
- Providing PrEP by telehealth
- Take-home points on expanding PrEP uptake
Presenter:
Timothy J. Wilkin, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Link to full program:
http://bit.ly/3UFUl2b
Follow along with the slides at:
https://bit.ly/3EcaYg0
This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses PrEP uptake for cisgender women. His discussion includes:
- Prevalence of PrEP use in cisgender women in the United States
- Barriers to PrEP uptake in cisgender women
- Implementation of PrEP within family planning clinics in Atlanta
- PrEP in pregnancy and breastfeeding
Presenter:
Timothy J. Wilkin, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Link to full program:
http://bit.ly/3UFUl2b
Follow along with the slides at:
http://bit.ly/3TDOPM8
This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses barriers to PrEP uptake for people who inject drugs. His discussion includes:
- PrEP uptake and recommendations for people who inject drugs
- Project SHE: integrating PrEP with community-based syringe services for women who inject drugs
Presenter:
Timothy J. Wilkin, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Link to full program:
http://bit.ly/3UFUl2b
Follow along with the slides at:
https://bit.ly/3EcaYg0
This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, focuses on transgender women. His discussion includes:
- Barriers to PrEP uptake in transgender women
- High PrEP adherence among transgender women and transfeminine individuals in a real-world healthcare setting in New York City
Presenter:
Timothy J. Wilkin, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Link to full program:
http://bit.ly/3UFUl2b
Follow along with the slides at:
https://bit.ly/3EcaYg0
This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses barriers to PrEP uptake in the context of racial inequities, specifically for Black and Latinx communities. His discussion includes:
- Inequities in PrEP uptake in Black and Hispanic and Latinx people compared with White people
- Structural barriers to PrEP adoption
- Kaiser Permanente study (2012-2019): PrEP continuum of care and new HIV infections
- Ele[MEN]t study: PrEP persistence and discontinuation in young Black men who have sex with men
- Creating change: education of patients and healthcare professionals to address inequities in PrEP uptake
Presenter:
Timothy J. Wilkin, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at:
https://bit.ly/3EcaYg0
This episode is part of a larger discussion that comes from “Partnering With Patients: Overcoming Barriers to HBV Care in Asian Communities in the US.” Hear from Thuan Vu, MD, as he discusses linkage to care after HBV diagnosis in Asian communities from a provider’s perspective. And listen to discussions with Jennifer Wild, MSN, BSN, RN, OCN, and Melinda Tran as they consider his story from a patient advocacy point of view.
Topics include barriers to linkage to care like social stigma, lack of insurance coverage, financial support, and a lack of physicians who speak the patient’s native language.
Link to full program:
https://bit.ly/3Gf7NWo
In this episode, Paul E. Sax, MD, discusses long-acting (LA) injectables for HIV treatment, including:
- Guidance on the use of LA cabotegravir (CAB) + rilpivirine (RPV)
- Risk factors for virologic failure of LA CAB + RPV
- The ATLAS-2M study
- Combined clinical trials of LA CAB + RPV
- Practical considerations for LA CAB + RPV
- Implementation of LA CAB + RPV
- Switching to LA CAB + RPV without an oral lead-in, including a discussion of the FLAIR extension study
- Supporting candidates for LA antiretroviral therapy (ART)
- Discussion of an implementation study of LA CAB + RPV in patients with challenges to oral ART adherence in San Francisco
- Future LA ART
- The investigational LA HIV capsid inhibitor lenacapavir (LEN)
- LEN resistance from the CAPELLA and CALIBRATE studies
- LEN injection-site reactions in the CAPELLA and CALIBRATE studies
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at:
http://bit.ly/3Gh9AKG
In this episode, Paul E. Sax, MD, discusses the latest recommendations and options for HIV pre-exposure prophylaxis (PrEP), including:
- CDC PrEP guideline 2021 updates for oral PrEP
- The ANRS IPERGAY study: on-demand oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) PrEP in men who have sex with men who are at high risk for HIV infection
- A review of the HPTN 083 and 084 studies: efficacy and safety of long-acting (LA) injectable cabotegravir (CAB) vs daily oral FTC/TDF for PrEP
- 1-year follow-up after unblinding for HPTN 083 and 084
- LA CAB for PrEP: monitoring and safety
- Stopping LA CAB for PrEP
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at:
https://bit.ly/3Gh9AKG
In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, discusses strategies for and importance of HIV care engagement and reengagement for those who have fallen out of care. Her overview includes:
- WHO Global Health Strategy on HIV
- Longitudinal HIV care trajectories
- Promotion of successful care and antiretroviral therapy (ART) adherence
- Differentiated service delivery
- Improving care and ART adherence in high-risk groups
- Patient perspectives on ART persistence
Presenter:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Panelists:
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD
Chief and Director
VHS-Infectious Diseases Medical Centre
Director
Chennai Antiviral Research and Treatment (CART) Clinical Research Site
Voluntary Health Services
Chennai, India
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Follow along with the slides:
https://bit.ly/3dSNoum
Link to full program:
https://bit.ly/3AE2AV1
This episode is part of a larger discussion that comes from “Partnering With Patients: Overcoming Barriers to HBV Care in Asian Communities in the US.” First, Melinda Tran discusses treatment and retention of HBV care in Asian Communities in the US with Jennifer Wild, MS, BSN, RN, OCN, and Thuan Vu, MD. Their conversation offers an interesting mix of insights from the point of view of patient advocates and healthcare providers.
Topics include barriers to treatment—like a lack of insurance coverage and financial support, complexities in treatment guidelines, psychosocial factors—and addressing practical solutions to these barriers.
Link to full program
http://bit.ly/3Gf7NWo
Patient advocate Bright Ansah shares some issues she encountered while seeking treatment after her diagnosis with HBV, including limited follow-up on lab results and a lack of compassion from her healthcare providers, and rushed health appointments.
Bright’s story opens up a conversation about broader concerns about HBV treatment and retention in care with Janet Afoakwah and William Amiteye, fellow patient advocates on the panel, and Patricia D. Jones, MD, MSCR, who offers a healthcare provider’s perspective. They also discuss practical solutions to those barriers, including ways to establish trust with the patient, emphasizing active listening and compassionate care during appointments, and collaborating with patients on their options and next steps.
Link to full program:
http://bit.ly/3Gf7NWo
Listen as patient advocate William Amiteye uses his own experience as a Tanzanian immigrant to discuss important barriers to effective HBV screening and diagnosis, including limited knowledge about HBV from his healthcare providers, a lack of compassion toward his diagnosis from those same providers, and a limited awareness of HBV from patients in general.
His story opens up an interesting and important discussion with another patient advocate on the panel, Janet Afoakwah, and Patricia D. Jones, MD, MSCR, who provides a provider’s perspective on the topic.
Link to full program:
http://bit.ly/3Gf7NWo
In this episode, Renslow Sherer, MD, and Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, discuss patient cases that illustrate key concepts for managing ambulatory patients with acute COVID-19 infection, including:
- A young, otherwise healthy patient
- An older patient with multiple comorbidities
- A patient with immunocompromise
- A patient requiring emergency department-level care
Presenters:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN
Professor
School of Nursing
Johns Hopkins University
Nurse Practitioner
Department of Infectious Diseases
John G. Bartlett Specialty Practice
Baltimore, Maryland
To download the slides:
http://bit.ly/3G9IrJx
To view the full online program:
https://bit.ly/3TqnNIX
This is 1 of 6 short episodes taken from a webinar on barriers and solutions to expanding pre-exposure prophylaxis (PrEP) uptake in the comprehensive program “Contemporary HIV Treatment and Prevention 2022.” In this episode, Timothy J. Wilkin, MD, MPH, discusses barriers to PrEP uptake for adolescents. His discussion includes:
- How PrEP is underused in adolescents and young adults
- Healthcare professional barriers to provision of PrEP for adolescents
- A systematic review and meta-analysis of adherence to PrEP in adolescents and young adults
- Barriers to adherence in adolescents and young adults
- Interventions to support PrEP adherence in adolescents
Presenter:
Timothy J. Wilkin, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at:
https://bit.ly/3EcaYg0
In this episode, hear Marta Boffito, MD, PhD, FRCP, and Julian Falutz, MD, FRCPC, discuss their approach to minimizing antiretroviral (ARV)-related intolerances in older patients with HIV, including:
- Consequences of polypharmacy
- Deprescribing ARV and non-ARV medications
- Complications associated with aging (eg, geriatric syndromes such as falls, frailty, multimorbidity)
- Mediations to avoid, such as anticholinergic medications, to minimize drug–drug interactions and risk of developing geriatric syndromes
Faculty:
Marta Boffito, MD, PhD, FRCP
Consultant Physician/Professor
HIV/Research
Chelsea and Westminster Hospital
Imperial College London
London, United Kingdom
Julian Falutz, MD, FRCPC
Associate Professor of Medicine
Department of Medicine
McGill University School of Medicine
Director
Comprehensive HIV and Aging Initiative
Chronic Viral Illness Service
McGill
Montreal, Quebec, Canada
Link to full program:
https://bit.ly/3PM3nYe
Follow along with the slides at:
https://bit.ly/3NpAYI1
In this episode, Marc Thompson and Tristan J. Barber, MA, MD, FRCP, discuss some of the barriers to genuinely patient-centered HIV care in the United Kingdom and offer calls to action for healthcare professionals for responding to patient preferences. They discuss barriers to HIV testing and effectively communicating the benefits of testing to disparate communities. They also talk through the difficulties in maintaining patient engagement in HIV care and the value of using peer support workers in HIV clinics. You will then hear Marc and Dr Barber talk through treatment and prevention practices. They focus on the importance of messaging around U=U: that treatment can make a patient’s HIV undetectable, and therefore their HIV is untransmissible. They end with a discussion about changing treatment paradigms and how to keep patients informed and empowered—not overwhelmed—by those changes to help ensure lasting health outcomes.
Marc Thompson
Director, The Love Tank
Co-founder, Prepster
London, United Kingdom
Tristan J. Barber, MA, MD, FRCP
Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom
Link to full program:
https://www.clinicaloptions.com/hiv/programs/2022/what-pts-want-hiv
An RSV vaccine, if approved, may reduce disease burden in older adults. In this recap of the most common questions from a symposium at the Family Medicine Experience 2022 conference, listen as we discuss when an RSV vaccine may be approved and how to overcome barriers to the implementation of vaccines for older adults in primary care settings.
Hear answer to questions such as:
- When might potential RSV vaccines be available, and when might the Advisory Committee on Immunization Practices make recommendations on their use?
- How will the vaccine roll out? Who would receive the vaccine first?
- If approved, what will the RSV vaccination schedule be?
- How can we overcome vaccine hesitancy?
Presenters
John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel College of Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania
Chair, Department of Family and Community Medicine
Abington-Jefferson Health
Abington, Pennsylvania
Laura Hurley, MD, MPH
Associate Professor of Medicine
Division of General Internal Medicine
Department of Medicine
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Primary Care Physician
Division of General Internal Medicine
Department of Medicine
Denver Health
Denver, Colorado
Pamela Rockwell, DO, FAAFP
Professor
Family Medicine
University of Michigan Medical School
Ann Arbor, Michigan
View the full program at:
https://bit.ly/3Wt87GI
In this episode, Deondre Moore and Samantha V. Hill, MD, MPH, discuss some of the barriers to genuinely patient-centered HIV care in the United States and offer calls to action for healthcare professionals for responding to patient preferences. They talk through some of the barriers that patients face, from struggling with unfamiliar medical terminology, to healthcare professional biases, to more structural problems like housing and food scarcity. They also discuss strategies that healthcare professionals can incorporate to provide more comprehensive, inclusive, collaborative HIV care.
Samantha V. Hill, MD, MPH
Assistant Professor
Division of Adolescent Medicine
Department of Pediatrics
The University of Alabama at Birmingham
Birmingham, Alabama
Deondre Moore
U.S. Partnerships and Community Engagement Manager
Prevention Access Campaign
Houston, Texas
Link to full program:
https://bit.ly/3fsWuij
In this episode, Samantha Strong, PharmD, BCACP, AAHIVP, CDCES, discusses closing the HIV pre-exposure prophylaxis (PrEP) gap for Black cisgender women, including:
- Racial inequities in PrEP access
- Addressing barriers to PrEP for cisgender women such as lack of education and awareness, low perceived risk of HIV, healthcare professional bias, and medical mistrust
- Closing the PrEP gap through education, normalizing sexual health conversations, and decreasing stigma to empower women
Samantha Strong, PharmD, BCACP, AAHIVP, CDCES
Clinical Director of Pharmacy
Nevada Health Centers
Las Vegas, Nevada
See the full program at:
https://bit.ly/3WhbBvZ
When it comes to managing older adults with hepatitis B virus (HBV), what comorbidity, comedication, and adherence issues should be considered?
Listen as Graham R. Foster, FRCP, PhD, discusses these considerations and more for strategizing the monitoring and treatment of older adults with HBV.
Presenter:
Graham R. Foster, FRCP, PhD
Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom
Link to full program:
https://bit.ly/3fg9fwB
In this episode, Latesha Elopre, MD, MSPH, discusses closing the HIV pre-exposure prophylaxis (PrEP) gap for Black men who have sex with men (MSM), including:
- Racial inequities in PrEP access
- Considering strategies to address barriers to PrEP uptake and persistence among Black MSM
- Considering individualized PrEP options
- On-demand oral emtricitabine/tenofovir disoproxil fumarate (2:1:1)
- Injectable cabotegravir
- Empowering patients to take control of their PrEP care by providing choices for optimal adherence
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama
For the full program, visit:
https://bit.ly/3VGrN9L
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:
- Rapid antigen tests and PCR tests
- Risk stratification of patients who have a positive SARS-CoV-2 test
- Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)
- Monoclonal antibody treatment (bebtelovimab)
- Long COVID
Presenters:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Trinh P. Vu, PharmD, BCIDP
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmaceutical Services
Emory University Hospital Midtown
Atlanta, Georgia
To download the slides:
https://bit.ly/3TkT7sJ
To view the full online program:
https://bit.ly/3TqnNIX
In this episode, Timothy J. Wilkin, MD, MPH, provides a case-based overview of switching antiretroviral therapy in a patient with viral suppression on their current regimen who has a history of virologic failure with drug-resistance mutations. Key findings from 2 relevant studies—the SWITCHMRK trial and Study 380-4030—are reviewed. The case discussion also highlights several other challenges that can be encountered in the switch setting, including incomplete immune recovery, comorbidities, and gastrointestinal intolerability of some antiretroviral drugs.
Presenter:
Timothy J. Wilkin, MD, MPH
Professor Medicine
Division of Infectious Diseases
Weill Medical College of Cornell University
New York, New York
Content based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3VIsDTg
Follow along with the slides at
https://bit.ly/3DdP3F6
In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:
- Switching with prior or unknown resistance
- Data on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studies
- The impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 study
- A post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistance
- Data from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184V
- A retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat’AIDS Cohort
- Switching to long-acting ART
- Guidance on candidates for LA CAB + RPV
- Data on risk factors for virologic failure with LA CAB + RPV
- Considering an ART switch after weight gain
- Data on weight gain after ART initiation by ARV class and drug
- Mean change in weight by sex at Week 96 in the ADVANCE study
- DHHS guideline recommendations regarding weight gain with ART
Tristan J. Barber, MA, MD, FRCP
Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom
Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California
In this episode, Lilian Abbo, MD, FIDSA; Julie Ann Justo, PharmD, MS; and David van Duin, MD, PhD, FIDSA, FAST, discuss key concepts about extraintestinal pathogenic Escherichia coli, including:
- Diverse strains and virulence factors associated with invasive disease
- Antimicrobial resistance profiles seen in clinical practice
- Various disease manifestations
- Prevalence and burden of invasive infections
- Populations at risk
- Risk factors for multidrug-resistant strains
- Emerging vaccine technologies
- Active clinical trials
- Benefits of vaccines and the challenges associated with development
- Importance of antimicrobial stewardship and potential role of vaccines to reduce antimicrobial resistance
Program Director:
Lilian Abbo, MD, FIDSA
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida
Faculty:
Julie Ann Justo, PharmD, MS
Clinical Associate Professor
Department of Clinical Pharmacy and Outcomes Sciences
University of South Carolina College of Pharmacy
Infectious Diseases Clinical Pharmacy Specialist
Department of Pharmacy
Prisma Health Richland Hospital
Columbia, South Carolina
David Van Duin, MD, PhD, FIDSA, FAST
Professor of Medicine
Director, Immunocompromised Host Infectious Diseases Program
Division of Infectious Diseases
University of North Carolina
Chapel Hill, North Carolina
Content based on a CME program supported by an educational grant from Janssen Therapeutics.
Follow along with a downloadable slideset at:
https://bit.ly/3eG29Bn
Link to full program:
https://bit.ly/3eFHfCl
In this podcast, Gary S. Marshall, MD, summarizes the burden of meningococcal disease and the importance of immunization, including:
- The unpredictability and severity of meningococcal disease
- Differences between meningococcal serogroups and available vaccines
- Current meningococcal vaccine recommendations, distinguishing between routine vs shared clinical decision-making recommendations
- Vaccine recommendations in high-risk populations
- Use of immunization platforms to help complete age-appropriate vaccines, including the MenACWY and MenB vaccine, in adolescents and young adults
Faculty:
Gary S. Marshall, MD
Professor of Pediatrics
Division of Pediatric Infectious Diseases
University of Louisville School of Medicine
Louisville, Kentucky
Link to full program:
https://bit.ly/3T0GLG2
In this episode, Cristina Mussini, MD, shares her approach to caring for aging patients with HIV. This includes not just focusing on their HIV, but their over well-being, such as:
- Maintaining a healthy weight, eating healthy and staying mobile
- Overcoming the obstacle of stigma from society and self-stigma
- Empowering patients to care for themselves
- In women who are often caregivers most of their life:
- Encouraging self-care
- Staying up to date with preventive care such as cancer screenings (eg, mammography, annual Pap smear, and colonoscopy)
- Teaching patients to love themselves
- Making sure the patient knows you truly care for them
Faculty:
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy
Link to full program:
https://bit.ly/3KkF4iZ
How do we define “older” in our older patients living with hepatitis B virus (HBV)? What monitoring and treatment options should be considered for these older patients with chronic HBV infection?
Listen as Nancy Reau, MD, discusses strategies and considerations for monitoring and treating older adults with HBV, illustrated with a patient case.
Presenter:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Link to full program:
https://bit.ly/3T1UImw
In this episode, listen to Priscilla Y. Hsue, MD, and Jens D. Lundgren MD, DMSc, discuss the latest data about ARV-related weight gain and cardiometabolic toxicities in PWH. Hear faculty:
- Review risk factors associated with significant weight gain
- Consider possible implications of weight gain and cardiometabolic toxicities
- Share their approaches to ARV-related weight gain and/or cardiometabolic toxicities
Faculty:
Priscilla Y. Hsue, MD
Professor of Medicine
University of California at San Francisco
San Francisco General Hospital
San Francisco, California
Jens D. Lundgren, MD, DMSc
Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Link to full program:
https://bit.ly/3PM3nYe
In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:
- Prevention strategies
- Oral therapies
- LA therapies
- Cure
- COVID-19 in PWH
Faculty
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Follow along with the slides at
bit.ly/3SLuhBq
In this episode, Roger Bedimo, MD, MS, FACP, discusses key considerations for switching ART in virologically suppressed patients who are pregnant or trying to conceive. His discussion includes:
- DHHS Perinatal Guideline recommendations
- French Perinatal Cohort study on the implications of viral suppression when changing ART in the first trimester of pregnancy
- IMPAACT 2010 Update on the safety and efficacy of DTG vs EFV and TDF vs TAF in pregnancy
- DolPHIN-2 study of virological suppression with DTG- vs EFV-based ART started in late pregnancy
Presenter:
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3UYTF8Q
Follow along with the slides at
https://bit.ly/3CqhrmU
In this podcast, Melanie Reese, a woman aging with HIV, shares her perspectives on the added challenges faced by older women with HIV—an underserved, underresourced, and underresearched group—and talks about potential solutions that should be considered, such as:
- Listen and prioritize concerns brought to you by older women with HIV to improve trust in you and the medical profession
- Promote self-advocacy for women to improve their interactions with healthcare professionals, such as opening the dialogue about sexual health
- Support mental health by ensuring a baseline neurologic exam to monitor for any cognitive decline
- Emphasize the importance of self-care and prioritizing oneself
- Address psychosocial issues by finding ways for patients to connect with others
- Advocate to change policies, standards of care, and laws that govern all places that care for those who are aging and need assistance in care
Faculty
Melanie Reese
Subject Matter Expert, HIV Aging
Technical Expert Panel
Health Resources and Services Administration
HIV/AIDS Bureau
Baltimore, Maryland
Link to full program:
https://bit.ly/3KkF4iZ
In this episode, listen to Dorothy Onyango, patient and patient activist, share her views on the many barriers encountered by aging patients with HIV living in resource-limited settings and the need to work on solutions to overcome such barriers, including:
- The major burden of poverty affecting access to care/medications, healthcare services (eg, treatment for noncommunicable diseases, home-based care), and social support
- The added social obstructions to HIV care for older women (eg, sexual reproductive health rights)
- Potential solutions to support the aging population with HIV to encourage good health and wellness such as:
- Self-advocacy to provide a voice for patients, especially women
- A comprehensive public health response
- Policy changes, including a budget line in the national budget, to ensure the rights of older people
- AIDS-friendly prevention initiatives (eg, affordable/accessible condoms)
- Income-generating activities to help older patients with HIV become economically sound
Faculty:
Dorothy Onyango
Chief Executive Officer
Women Fighting AIDS in Kenya
Founding Member, International Community of Women Living With HIV
Former Chair, Pan African Women’s Coalition
Former Board Member, Kenya National AIDS Council
Nairobi, Kenya
Link to full program:
https://bit.ly/3yIkntc
In this episode, an international expert panel shares their thoughts on key considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection.
Topics include anticipated patient interest in this new paradigm, the role of the oral lead-in phase, new guideline recommendations for monitoring during PrEP, patient care and follow-up after PrEP discontinuation, and remaining unanswered questions.
Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; key considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.
Presenters:
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Yvonne Gilleece, MB BCh, BAO
Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy
Darrell H. S. Tan, MD, FRCPC, PhD
Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada
Content based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3P3uPBc
In this podcast, Jonathan Appelbaum, MD, FACP, AAHIVS, summarizes the many medical challenges faced by aging people with HIV, including:
- Underrepresentation of older patients in medical research
- Consequences of early experiences in the epidemic such as late HIV diagnosis and low CD4+ cell count nadir, incomplete or short-lived virologic suppression with early regimens, and toxicity associated with early antiretroviral agents
- Added challenges of multimorbidity and psychosocial challenges, especially mental health issues, loneliness, and social isolation
- The need to provide care for the aging HIV population using a holistic approach
- Gaps in the current healthcare system in providing optimal care for aging people with HIV
Faculty:
Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida
Link to full program:
https://bit.ly/3KkF4iZ
In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses strategies for successful antiretroviral therapy (ART) initiation. Her overview includes:
- Recommendations for rapid ART
- First-line ART regimens for treatment-naive people with HIV
- IMEA 055 FAST study
- STAT study
- DIAMOND study
- Antiretroviral resistance mutations
- Patient perspectives on the importance of rapid ART initiation
Presenter:
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Panelists:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD
Chief and Director
VHS Infectious Diseases Medical Centre
Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site
Voluntary Health Services
Chennai, India
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Follow along with the slides:
https://bit.ly/3dSNoum
Link to full program:
https://bit.ly/3AE2AV1
In this episode, Babafemi Taiwo, MBBS, discusses strategies for reaching people with HIV who are not yet diagnosed. His overview includes:
- HIV diagnosis by global region
- Disparities in serostatus awareness
- Patient perspective on importance of HIV testing
- Barriers to HIV diagnosis
- Complications from late HIV diagnosis
- Strategies to improve rates of HIV testing
Presenter:
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Panelists:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD
Chief and Director
VHS Infectious Diseases Medical Centre
Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site
Voluntary Health Services
Chennai, India
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Follow along with the slides:
https://bit.ly/3PJRthD
Link to full program:
https://bit.ly/3AE2AV1
In this episode, Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD, discusses the importance of linking people to care after a positive HIV diagnosis. His overview includes:
- HIV care continuum
- Factors that delay linkage to care
- Organized strategies to improve linkage to care for people with HIV
- Interventions that may improve linkage to care for people with HIV
- Patient perspective on how to engage patients in their HIV care
Presenter:
Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD
Chief and Director
VHS Infectious Diseases Medical Centre
Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site
Voluntary Health Services
Chennai, India
Panelists:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Follow along with the slides:
https://bit.ly/3PJ4iJ8
Link to full program:
https://bit.ly/3AE2AV1
In this episode, hear Dr. Jean Rene Anderson and Dr. William Short discuss special factors to consider when selecting HIV treatments during pregnancy, including:
- Key elements involved in evaluating ARV medications during pregnancy (eg, efficacy, pharmacokinetic, and safety data)
- Approach to optimizing ART regimens prior to and during pregnancy
Faculty:
Jean Rene Anderson, MD
Professor
Department of Gynecology and Obstetrics
Johns Hopkins University
Director, Johns Hopkins HIV Women's Health Program
Johns Hopkins Medical Institutions
Baltimore, Maryland
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Link to full program:
https://bit.ly/3PM3nYe
You can think of the “D” in HDV as standing for difficult, disadvantaged, and dangerous. Hepatitis delta virus (HDV) is difficult to diagnose, is often diagnosed in disadvantaged patient populations, and leads to dangerous sequelae.
Listen as Dr. Kosh Agarwal and Dr. Graham R. Foster and discuss challenges and opportunities for linking patients to care after a positive test for HDV.
Presenters:
Kosh Agarwal, MD
Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
King's College Hospital NHS Foundation Trust
London, United Kingdom
Graham R. Foster, FRCP, PhD
Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom
Link to full program:
https://bit.ly/3tlxa0H
In this episode, an international expert panel shares their thoughts on key considerations at the operational level for incorporating long-acting injectable antiretroviral therapy into the HIV treatment armamentarium. Topics include the duration of injection appointments in real-world settings, managing additional patient volume/workload (particularly the key role of nurses), and preventing and addressing planned and unplanned missed doses. Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including:
- Key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience
- Long-acting HIV pre-exposure prophylaxis
- What is still needed in long-acting HIV care to further address patient needs and inequities across subgroups
Presenters:
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Yvonne Gilleece, MB, BCh, BAO
Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy
Darrell H. S. Tan, MD, FRCPC, PhD
Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada
Content based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3P3uPBc
In this episode, an international expert panel shares their thoughts on key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, including selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience. Subsequent episodes in this 4-part series will cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including operational planning, clinic impact, and handling missed doses with long-acting antiretroviral therapy for treatment; long-acting HIV pre-exposure prophylaxis; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.
Presenters:
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Yvonne Gilleece, MB, BCh, BAO
Honorary Clinical Professor in HIV Medicine and Sexual Health
Department of Global Health & HIV
Brighton & Sussex Medical School
Consultant in HIV Medicine and Sexual Health
HIV Department
University Hospitals Sussex NHS Foundation Trust
Brighton, United Kingdom
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy
Darrell H. S. Tan, MD, FRCPC, PhD
Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada
Content based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3P3uPBc
In this episode, hear HIV activist Marc Thompson share his perspectives on aging with HIV including:
- His early experiences after receiving his diagnosis
- Persisting issues of the HIV epidemic including stigma and discrimination
- Changes in healthcare with the advent of HIV treatment
- Added issues of aging with HIV like polypharmacy, multimorbidity, and mental health concerns (eg, loneliness, social isolation)
- Actions needed to improve the path for the future: addressing opportunities to expand research, improve collaboration between HIV and other healthcare professionals and gain wisdom and knowledge from others aging with HIV
Presenter:
Marc Thompson
Director, The Love Tank
Link to full program:
https://bit.ly/3yIkntc
You can also join Marc Thompson and a panel of patient advocates and healthcare professionals in person or in a live simulcast as they discuss healthy aging with HIV at our live symposium at AIDS 2022 in Montreal, Quebec, Canada. They will discuss the challenges faced by older people with HIV, including medical and nonmedical issues, and specific challenges faced by subgroups of older patients such as women and patients in resource-limited settings.
In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:
- Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studies
- HBV cure from the Everest Project in China
- HDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertension
- HCV retreatment in patients with prior direct-acting antiviral therapy failure
Presenter:
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany
Follow along with the downloadable slideset at:
https://bit.ly/3yJAruD
Link to full program:
https://bit.ly/3AjCNBC
In this episode, Nancy Reau, MD, discusses new viral hepatitis data from EASL 2022, including:
- Novel therapeutics for HBV
- Therapeutic vaccination for HBV
- Emerging treatment options for HDV
- HCV care cascade
- HCC monitoring after HCV cure
Presenter:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Follow along with the downloadable slideset at:
https://bit.ly/3yJAruD
Link to full program:
https://bit.ly/3IeUapm
In this episode, Carla S. Coffin, MD, MSc, shares her thoughts on the different investigational approaches under evaluation for their potential to achieve HBV cure, including entry inhibitors, capsid inhibitors, siRNAs, immune modulators, TLR agonists, therapeutic vaccines, and checkpoint inhibitors.
Presenter:
Carla S. Coffin, MD, MSc
Professor of Medicine
Division of Gastroenterology and Hepatology
Department of Medicine
University of Calgary
Medical Director of Calgary Liver Unit
Division of Gastroenterology and Hepatology
Department of Medicine
Foothills Medical Centre
Calgary, Alberta, Canada
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation.
Link to full program:
https://bit.ly/3OGHvOv
In this episode, Yvette Raphael provides her perspectives and advice as an individual living with HIV in South Africa for more than 20 years. She shares her experiences and ideas for how to improve processes related to HIV diagnosis, care linkage, and treatment.
Presenter:
Yvette Raphael
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3tmgozy
In this episode, Pietro Lampertico, MD, PhD, discusses what to do when treatment for hepatitis B virus (HBV) infection is not indicated, covering topics such as:
- The different phases of chronic HBV infection
- Which patients in different phases require immediate HBV treatment and which can be monitored without therapy
- The critical importance of ongoing monitoring for patients who do not meet indications for immediate therapy
- The tests and frequency that should be used for monitoring patients not receiving HBV treatment
Presenter:
Pietro Lampertico, MD, PhD
Professor of Gastroenterology
Director, Division of Gastroenterology and Hepatology
IRCCS Ca Granda Policlinico Hospital
University of Milan
Milan, Italy
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation.
Link to full program:
https://bit.ly/3OGHvOv
In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores the data and recommendations for HIV postexposure prophylaxis (PEP).
Listen as she gives perspectives on:
- The CDC algorithm for evaluation and treatment of
potential HIV exposures - The CDC guideline preferred and alternative PEP antiretroviral therapy regimens
- Data for the use of the single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide for PEP
- Recommended laboratory monitoring with PEP
- The initiation of pre-exposure prophylaxis following a course of PEP, when appropriate
Presenter:
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York
Follow along with the slides at:
https://bit.ly/3NBVXWN
See the entire program at:
https://bit.ly/3fOl0XX
In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for transgender people with HIV (PWH).
Listen as she gives perspectives on:
- Department of Health and Human Services (DHHS) guideline recommendations for transgender PWH
- Providing HIV care within a gender-affirmative care model, including discussion of strategies, barriers, and facilitators
- Gender-affirmative hormone therapy options
- Drug–drug interaction potential between gender-affirmative hormone therapy and antiretroviral therapy
- Recommended laboratory monitoring while receiving gender-affirming hormone therapy
- The cascade of care for transgender PWH and barriers to engagement and retention in care
Presenter:
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York
Follow along with the slides at:
https://bit.ly/3wOdKVo
Link to full program:
https://bit.ly/3fOl0XX
In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for choosing antiretroviral therapy (ART) for pediatric patients.
Listen as she gives perspectives on:
- Department of Health and Human Services (DHHS) guideline recommendations for infants at risk for perinatal HIV transmission
- DHHS guideline–recommended ART regimens for children
- The ODYSSEY A and B studies evaluating dolutegravir-based ART in children and adolescents
- Data for the use of the fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide in children and adolescents
- Key ART and management considerations for adolescents and young adults with HIV
Presenter:
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York
Follow along with the slides at:
https://bit.ly/3wMur29
Link to full program:
https://bit.ly/3fOl0XX
In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses:
Principles for antiviral agent use in nonhospitalized patients
- Preferred and alternative treatment options
- Treatment prioritization when there are logistical or supply constraints
Outpatient remdesivir use
- PINETREE data (adult patients)
- CARAVAN data (pediatric patients)
- FDA approval and treatment candidacy
Therapeutic updates
- Ivermectin and the TOGETHER study
- Monoclonal antibody use during current omicron era
Presenter:
Sharon R. Lewin, AO, FRACP, PhD, FAHMSZ
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia
Review the downloadable slideset at:
https://bit.ly/3FXc90w
In this episode, Dexter James Wiseman, MD, discusses immunology and RSV vaccine development for older adults, including:
- Need for a vaccine
- Economic burden of RSV
- Reasons for poor outcomes in older adults
- Investigational vaccines
Presenter:
Dexter James Wiseman, MD
Clinical Research Fellow
NHLI
Imperial College
Physician
Respiratory Medicine
Royal Brompton Hospital
London, United Kingdom
Review the downloadable slideset and the full program at:
https://bit.ly/3ydC8Ri
In this episode, Dexter James Wiseman, MD, discusses the impact and diagnosis of RSV in older adults, including:
- Risk factors for poor outcomes
- RSV vs influenza outcomes
- RSV symptoms
- RSV diagnostics
Presenter:
Dexter James Wiseman, MD
Clinical Research Fellow
NHLI
Imperial College
Physician
Respiratory Medicine
Royal Brompton Hospital
London, United Kingdom
Review the downloadable slideset and the full program at:
https://bit.ly/3ydC8Ri
In this episode, Dexter James Wiseman, MD, discusses the epidemiology and risk factors for RSV in older adults, including:
- Overview
- Disease burden based on age
- Seasonality
- Impact in care facilities
- Effects of the COVID-19 pandemic
Presenter:
Dexter James Wiseman, MD
Clinical Research Fellow
NHLI
Imperial College
Physician
Respiratory Medicine
Royal Brompton Hospital
London, United Kingdom
Review the downloadable slideset and the full program at:
https://bit.ly/3ydC8Ri
In this episode, listen as Robert G. Gish, MD, discusses key information on comparing current HBV vaccine formulations, and learn the best immunization practices for routine vaccination, including in special situations.
Presenter:
Robert G. Gish, MD
Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno
School of Medicine
Reno, Nevada
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director
Hepatitis B Foundation
Washington, DC
Review the downloadable slidesets at:
https://bit.ly/3LJPPLz
Link to full program:
https://bit.ly/3OZ50Ta
In this episode, learn about the importance of identifying adults at risk for reduced hepatitis B virus (HBV) seroprotection and applying current HBV vaccine recommendations in special populations. Listen as Robert G. Gish, MD, discusses key information on the identification and evaluation of patients who have chronic health conditions and therefore may be at risk for nonresponse to available vaccines.
Presenter:
Robert G. Gish, MD
Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno
School of Medicine
Reno, Nevada
Clinical Professor
University of California Skaggs School of
Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director
Hepatitis B Foundation
Washington, DC
Review the downloadable slidesets at:
https://bit.ly/3KPiJZz
Link to full program:
https://bit.ly/3OZ50Ta
In this episode, learn about the importance of hepatitis B virus (HBV) vaccination in adults. Listen as Robert G. Gish, MD, discusses key data on the burden and impact of HBV infection, and strategies to overcome barriers to HBV vaccination.
Robert G. Gish, MD
Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno
School of Medicine
Reno, Nevada
Clinical Professor
University of California Skaggs School of
Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director
Hepatitis B Foundation
Washington, DC
Review the downloadable slidesets at:
https://bit.ly/3l1ZD8h
Link to full program:
https://bit.ly/3LMZn8E
Hepatitis delta virus (HDV) is the most severe form of viral hepatitis, yet many patients go undiagnosed. Increasing HDV awareness is an important step to correct this and ensure that at-risk patients receive screening and then treatment and monitoring following a positive test. Hear Grace LH Wong, MD, and Ming-Lung Yu, MD, PhD, discuss a call to action to increase healthcare professional and patient awareness of HDV.
Presenters:
Grace LH Wong, MD
Professor
Director, Medical Data Analytics Centre (MDAC)
Deputy Director, Center for Liver Health
Assistant Dean (Learning Experience), Faculty of Medicine
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong
Ming-Lung Yu, MD, PhD
Chair Professor
Hepatobiliary Division
Department of Internal Medicine and Hepatitis Center
Kaohsiung Medical University
Visiting Staff
Hepatobiliary Division
Department of Internal Medicine
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
Link to full program:
https://bit.ly/3tlxa0H
In this episode, Norah Terrault, MD, MPH, and a patient who has been cured of hepatitis C virus (HCV) infection discuss the importance of universal HCV testing for all adults, as well as the ease of curative therapies and the benefits of living with improved liver function post cure.
This insightful discussion underscores how perceptions around HCV transmission risks and lack of symptoms serve as barriers to adequate screening and diagnosis, preventing curative treatment for many people with undiagnosed disease. The conversation also highlights the critical role of patient education and self-advocacy related to HCV infection, including what patients need to know and expect following cure.
Presenters:
Shelley Rossell
Norah Terrault, MD, MPH
Professor of Medicine
Chief of Gastrointestinal and Liver Diseases
University of Southern California
Los Angeles, California
Content is based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation.
Link to full program:
https://bit.ly/3OGHvOv
In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss novel therapies for HIV prevention and treatment, including:
- Prevention
- Cabotegravir for pre-exposure prophylaxis (PrEP) with the latest results from the HPTN 083 and HPTN 084 studies
- Novel PrEP therapies in development, including islatravir and lenacapavir
- Initial therapy
- Lenacapavir for initial therapy with results from the CALIBRATE study
- Switch strategies
- Cabotegravir as a switch strategy with the latest results from the ATLAS-2M study, evaluating Q4W vs Q8W dosing, data on direct-to-inject without the oral lead-in, and data to date in pregnancy
- Heavily treatment–experienced patients
- Currently available novel therapies for heavily treatment–experienced patients, including fostemsavir and ibalizumab
- Lenacapavir for heavily treatment–experienced patients with results from the CAPELLA study
Presenters:
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/3vWhjHj
Link to full program:
https://bit.ly/3fOl0XX
In this podcast, Dr Dominique Laurent Braun discusses his micro-elimination program, the Swiss HCVree trial, designed to prevent hepatitis C virus (HCV) transmission among HIV-positive men who have sex with men. The study employed a test-and-treat approach to eliminate HCV infection in this key target population and could be a model for other countries to eliminate HCV infection in certain populations.
Presenter:
Dominique Laurent Braun, MD
Senior Staff Physician
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
University of Zurich
Zurich, Switzerland
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.
Link to full program:
https://bit.ly/3OGHvOv
Antiviral agents continue to be effective against different strains of SARS-CoV-2 when used early in the disease course. In this episode, learn about the role of antiviral agents in hospitalized and high-risk nonhospitalized patients with COVID-19 and in different age groups. Listen as David A. Wohl, MD, discusses when and how to use IV and oral antiviral agents including:
- Nirmatrelvir + ritonavir
- Remdesivir
- Molnupiravir
Presenter:
David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases
Clinical Trials Unit
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Review the downloadable slidesets at:
https://bit.ly/3Ou4tbE
Link to full program:
https://bit.ly/3EBdf38
The place of monoclonal antibodies in COVID-19 is changing. In this episode, learn about their role in prophylaxis of patients who are at high risk of complications from acquiring COVID-19 or treatment of high-risk patients who have a mild to moderate COVID-19 infection. Listen as Gregory Huhn, MD, MPHTM, discusses when and how to use monoclonal antibodies including:
- Bebtelovimab
- Cilgavimab/tixagevimab
- Sotrovimab
Presenter:
Gregory Huhn, MD, MPHTM
Associate Professor
Department of Infectious Diseases
Rush University Medical Center
Senior Director of HIV Services
Department of Infectious Diseases
Cook County Health
Chicago, Illinois
Review the downloadable slidesets at:
https://bit.ly/3xOfu1A
Link to full program:
https://bit.ly/3EBdf38
In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and a patient with previous injection drug use who has been cured of HCV infection discuss critical barriers that are preventing more people with current or previous injection drug use from receiving appropriate HCV care.
This insightful discussion underscores the negative effects of stigma toward people who inject drugs that exist in many clinical settings, the important role that socioeconomic factors such as transportation access and stable housing play in preventing access to HCV care, the effects of insufficient staffing at many addiction treatment centers, and the need for creative solutions to overcome these barriers.
Presenter:
Oluwaseun Falade-Nwulia, MBBS, MPH
Associate Professor
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Attending
Division of Infectious Diseases
Johns Hopkins Hospital
Baltimore, Maryland
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation.
Link to full program:
https://bit.ly/3KmJvZt
In this episode, Renslow Sherer, MD, discusses what is known to date regarding long COVID, also known as postacute sequelae of COVID-19 infection, including:
- Possible causes and risk factors
- Signs and symptoms
- Clinical management
- Treatment options under consideration
- Role of vaccination
Presenter:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Review the downloadable slideset and the full program at:
https://bit.ly/3Ix8uZg
In episode 7 of a series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss:
- Role of family history in risk of hepatocellular carcinoma (HCC)
- Surveillance for HCC
- Steps to take when diagnosed with HCC
- How to live a healthy life after HCC diagnosis and treatment
Presenter:
Ming-Lung Yu, MD, PhD
Chair Professor
Hepatobiliary Division
Department of Internal Medicine and Hepatitis Center
Kaohsiung Medical University
Visiting Staff
Hepatobiliary Division
Department of Internal Medicine
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/37GY0cm
Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection.
In this episode, Vikramjit Mukherjee, MD, discusses the role and timing of these treatment options, including:
- High-titer convalescent plasma
- Corticosteroids
- Interleukin-6 inhibitors (eg, tocilizumab)
- Janus kinase inhibitors (eg, baricitinib)
Presenter:
Vikramjit Mukherjee, MD
Assistant Professor of Medicine
Division of Pulmonary, Critical Care, & Sleep Medicine
New York University School of Medicine
Director, Medical Intensive Care Unit
Bellevue Hospital
New York, New York
Review the downloadable slidesets at:
https://bit.ly/35NNb7Q
Link to full program:
https://bit.ly/35SrxQ0
In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including:
- When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infections
- EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infections
- Considerations for the administration of ART to patients who are unable to swallow or critically ill and intubated
- Treatment of Kaposi sarcoma and considerations for starting ART to avoid drug–drug interactions with Kaposi sarcoma treatment
- Considerations for starting ART with cytomegalovirus and the risk for IRIS from cytomegalovirus
- Discussion of treatment of cytomegalovirus and overlapping toxicities between its treatment and ART
- When to start ART with cryptococcal meningitis and the data to support delayed treatment initiation with this particular opportunistic infection
- EACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of cryptococcal meningitis specifically
- Treatment of cryptococcal meningitis and managing drug–drug interactions between ART and antifungal therapy
Presenters:
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics
University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/3uktrm1
Link to full program:
https://bit.ly/3q2DlGd
In this episode, Heiner Wedemeyer, MD, discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.
Presenter:
Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology and Endocrinology
Hannover Medical School
Hannover, Germany
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation.
Link to full program:
https://bit.ly/3KmJvZt
Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in rural settings, including facing up to stigma, getting access to experienced medical practitioners, and searching for information and peer support.
Presenter:
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.
Link to full program:
https://bit.ly/3KmJvZt
In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including:
- Discussion of the PrEP gap and racial and gender disparities in PrEP access
- CDC, EACS, and WHO guidance on PrEP eligibility
- PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir
- Data from clinical trials on the efficacy of FTC/TDF daily for men including Partners PrEP, TDF2, iPrEx, iPrEx OLE, and PROUD
- Data from the ANRS IPERGAY study on the use of FTC/TDF on demand
- Data from the DISCOVER trial on the use of FTC/TAF for PrEP
- Data from the HPTN 083 study on the use of long-acting cabotegravir as PrEP for cisgender men
- Clinical monitoring and considerations during PrEP use
Presenters:
Latesha Elopre, MD
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama
Karine Lacombe, MD, PhD
Professor
UMR-S1136
Sorbonne University
Head, Infectious Diseases Department
St Antoine Hospital, AP-HP
Paris, France
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/3uqPje3
Link to full program:
https://bit.ly/3q2DlGd
In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender women, including:
- Discussion of the PrEP gap and racial and gender disparities in PrEP access
- CDC, EACS, and WHO guidance on PrEP eligibility
- PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir
- Data from phase III trials on the efficacy of FTC/TDF daily for women including Partners PrEP, TDF, VOICE, and FEM-PrEP
- Pharmacokinetic data of FTC/TDF and FTC/TAF in the female genital tract and discussion of why on-demand dosing of FTC/TDF is not recommended in cisgender women
- Data and recommendations for the use of the dapivirine ring from ASPIRE and The Ring Study and their open-label extensions, DREAM and HOPE
- Data from the HPTN084 study on the use of long-acting cabotegravir as PrEP for cisgender women
- Recommendations for the use of PrEP during pregnancy and breastfeeding
- Clinical monitoring and considerations during PrEP use
Presenters:
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
Assistant Dean of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama
Karine Lacombe, MD, PhD
Professor
UMR-S1136
Sorbonne University
Head, Infectious Diseases Department
St Antoine Hospital, AP-HP
Paris, France
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/36s2ovB
Link to full program:
https://bit.ly/3q2DlGd
In this episode, Graham R. Foster, FRCP, PhD, and Paul Y. Kwo, MD, share lessons learned in the management of HCC and liver transplantation the COVID-19 era, including:
• Global impact of HCC and strategies for maintaining HCC care in the COVID-19 era
• Characteristics of liver transplant recipients in the COVID-19 era
• Impact of COVID-19 pandemic period on liver transplant outcomes
• Impact of liver transplant status on COVID-19 outcomes
• Strategies for providing streamlined care for patients with liver cancer or liver transplantation in the COVID-19 era
Presenters:
Graham R. Foster, FRCP, PhD
Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Follow along with the slides at:
https://bit.ly/3HQ6dZ5
Link to full program:
https://bit.ly/3Bgyd5I
In this episode, Jason Schafer, PharmD, MPH, explores key considerations for the use of long-acting injectable pre-exposure prophylaxis (PrEP).
-
Listen as he gives his perspectives on:
-
The FDA approval of long-acting cabotegravir for PrEP
-
Healthcare professionals’ clinical concerns with long-acting injectable antiretroviral therapy
-
Considerations for long-acting cabotegravir as PrEP
-
Dosing and administration
- Managing missed doses
- Discontinuation
-
Delays in HIV diagnoses found in the HPTN 083 study in men
-
CDC recommendations for HIV screening while receiving PrEP
Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/3wugMOC
See the entire program at:
https://bit.ly/3q2DlGd
Hepatitis delta virus (HDV) is the most severe form of viral hepatitis and warrants new treatment options for better efficacy and tolerability. In part 2 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on new and emerging treatment options for HDV and rational use of these new agents. Their discussion includes:
- Assembly inhibitors (eg, lonafarnib)
- Entry inhibitors (eg, bulevirtide)
- Interferon lambda
- Nucleic acid polymers
- Small interfering RNA (siRNA) agents
Presenters:
Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology, and Endocrinology
Hannover Medical School
Hannover, Germany
Cihan Yurdadin, MD
Professor and Chief
Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey
Link to full program:
https://bit.ly/365VUlG
In this episode, Jeffrey Kwong, DNP, MPH, FAANP, FAAN, and Susan LeLacheur, DrPH, PA-C, AAHIVS, share insights on new HIV data from CROI 2022, including:
- Perinatal antiretroviral therapy exposure
- Investigational formulation of long-acting contraception combined with pre-exposure prophylaxis
- Monitoring with long-acting cabotegravir for pre-exposure prophylaxis
- Myocardial infarction risk by HIV status
Presenters:
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Professor
Division of Advanced Nursing Practice
Rutgers School of Nursing
Newark, New Jersey
Nurse Practitioner
Gotham Medical Group
New York, New York
Susan LeLacheur, DrPH, PA-C, AAHIVS
Professor
PA Studies
The George Washington University School of Medicine and Health Sciences
Washington, DC
Link to full program:
https://bit.ly/3tdkXfJ
In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:
- Epidemiology and burden of nosocomial bacterial pneumonia
- Patient-specific risk factors for MDR pathogens
- Improving outcomes with the use of antibiograms
- Recommended empiric therapy for clinically suspected VABP
- Antimicrobial resistance in HABP/VABP
- Algorithms for gram-negative organism antibiotic-susceptibility testing
- Using rapid diagnostic tests for HABP/VABP
- New antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:
- ASPECT-NP: ceftolozane/tazobactam vs meropenem
- REPROVE: ceftazidime/avibactam vs meropenem
- RESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenem
- RESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactam
- APEKS-NP: cefiderocol vs meropenem
- CREDIBLE-CR: cefiderocol vs best available therapy
Program Director:
Keith S. Kaye, MD, MPH
Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson
Medical School
New Brunswick, New Jersey
Faculty:
Lilian Abbo, MD, FIDSA
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida
Jason M. Pogue, PharmD
Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan
Content based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.
Follow along with a downloadable slideset at:
https://bit.ly/3CEop6h
Link to full program
https://bit.ly/3i781lf
In this episode, Fidelia Bernice, PharmD, and Jennifer Cocohoba, PharmD, share insights on new HIV data from CROI 2022, including:
- Islatravir tissue and plasma distribution after monthly oral dosing
- Pharmacokinetics, safety, and acceptability of a tenofovir vaginal ring
- PrEP and Hormone Therapy in Transgender Individuals
- Anticholinergic drug effects in older PWH
- Adherence in PWH
Presenters:
Fidelia Bernice, PharmD
Clinical Pharmacy Specialist, Infectious Diseases
Department of Pharmacy
University of Maryland Medical Center
Baltimore, Maryland
Jennifer Cocohoba, PharmD
Professor
Department of Clinical Pharmacy
University of California, San Francisco
San Francisco, California
Link to full program:
https://bit.ly/3tdkXfJ
In this episode, Jordan J. Feld, MD, MPH, and Nancy Reau, MD, share lessons learned in the testing and treatment of viral hepatitis in the COVID-19 era, including:
- Global impact of the COVID-19 pandemic on viral hepatitis testing and linkage to care
- Impact of COVID-19 pandemic on testing and treatment in the United States and Canada
- Innovative strategies to improve linkage to care of patients with viral hepatitis during the COVID-19 pandemic
Presenters:
Jordan J. Feld, MD, MPH
Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Follow along with the slides at:
https://bit.ly/3HQ6dZ5
Link to full program:
https://bit.ly/3Bgyd5I
In this episode, Jason Schafer, PharmD, MPH, explores the data for long-acting injectable pre-exposure prophylaxis (PrEP).
Listen as he gives his perspectives on the:
- PrEP pipeline and the importance of having options for patients with differing preferences
- FDA approval of long-acting cabotegravir for PrEP
- HPTN 083 and 084 studies of long-acting cabotegravir for PrEP compared with oral emtricitabine/tenofovir disoproxil fumarate
- Safety data on long-acting cabotegravir for PrEP
- CDC recommendations on the management of injection-site reactions with cabotegravir for PrEP
Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/3tbvEPK
See the entire program at:
https://bit.ly/3q2DlGd
In this episode, Daniel R. Kuritzkes, MD, and David A. Wohl, MD, discuss new HIV data from CROI 2022, including:
- Prevention strategies
- LA therapies
- Second-line therapies
- The VISEND study comparing dolutegravir-based antiretroviral therapy (ART) vs protease inhibitor–based ART for second-line therapy
- The NADIA study comparing dolutegravir with darunavir/ritonavir and tenofovir disoproxil fumarate with zidovudine for second-line therapy
- Comorbidities and cure
- ACTG A5324 (InMIND) study of ART intensification for cognitive impairment in people with HIV
- IMPAACT P1107 case of patient with loss of HIV-1–specific antibody response and viral detection following CCR5∆32/∆32 cord/haploidentical transplant
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, Global Infectious Diseases Clinical Trials Unit
University of North Carolina at Chapel Hill
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Follow along with an expanded slideset at:
https://bit.ly/3CItz0Z
Link to full program:
https://bit.ly/3tSpdAx
In this episode, Jason Schafer, PharmD, MPH, explores recommendations and data on managing antiretroviral therapy (ART) in the inpatient setting.
Listen as he gives his perspectives on:
- Antiretroviral stewardship to prevent medication errors in the inpatient setting and at transitions of care
- Renal and hepatic dosing considerations for ART
- Drug–drug interaction considerations between ART and medications commonly encountered in the inpatient setting
- Antiretroviral food effects
- Administration of antiretrovirals in persons with swallowing difficulties
Presenter:
Jason Schafer, PharmD, MPH
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/36h5tOC
See the entire program at:
https://bit.ly/3q2DlGd
Hepatitis delta virus (HDV) only exists in patients with hepatitis B virus (HBV) coinfection. In part 1 of this 2-part podcast series, hear Heiner Wedemeyer, MD, and Cihan Yurdaydin, MD, discuss their thoughts on serologic testing for both HDV and HBV and steps to take in monitoring, treating, and reassessing HBV in patients coinfected with HDV.
Presenters:
Heiner Wedemeyer, MD
Professor and Chairman
Department of Gastroenterology, Hepatology, and Endocrinology
Hannover Medical School
Hannover, Germany
Cihan Yurdaydin, MD
Professor and Chief, Department of Gastroenterology and Hepatology
Koç University Medical School
Istanbul, Turkey
Link to full program:
https://bit.ly/365VUlG
Episode 3 of this series features Anna Cristina L. dela Cruz, MD, in conversation with patient Melody Cheng about Melody’s decision to start hepatitis B virus (HBV) antiviral therapy during pregnancy. This podcast also discusses recommended approaches to preventing HBV transmission from mother to child, current recommendations on starting treatment for chronic HBV infection, and the issues around stopping treatment.
Presenter:
Anna Christina L. dela Cruz, MD
Associate Professor
Division of Digestive Diseases and Nutrition
Department of Internal Medicine
University of Kentucky
Lexington, Kentucky
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.
Link to full program:
https://bit.ly/3KmJvZt
Treatment options for hepatitis delta virus (HDV) are lacking, but many exciting agents are under investigation. Hear Drs Nancy Reau and Stefan Zeuzem discuss their thoughts on up-and-coming agents for treating HDV, and explore what questions need answering to most effectively use currently available and emerging therapies, which include:
- Bulevirtide
- Interferon λ
- Lonafarnib
Presenters:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany
Link to full program:
https://bit.ly/3tlxa0H
In episode 2 of this series, tune in to a conversation between Robert G. Gish, MD, and patient advocate Jacki Chen, PhD, about the potential benefits of simplifying our approach to treating patients with chronic hepatitis B. The conversation focuses on the stigma many patients experience following diagnosis and how access to treatment may reduce this.
Presenter:
Robert G. Gish, MD
Professor of Medicine
Loma Linda University
Loma Linda, California
Adjunct Professor of Medicine
Nevada School of Medicine
Las Vega, Nevada
Clinical Professor
University of Nevada Reno School of Medicine
Clinical Professor
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director
Hepatitis B Foundation
Washington, DC
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.
Link to full program:
https://bit.ly/3lSkSui
In this episode, Drs Norah Terrault, MD, MPH, and Grace LH Wong, MD, share lessons learned in the care of patients with hepatitis B virus (HBV) in the COVID-19 era, including:
- HBV cascade of care before vs during the pandemic
- Innovative strategies to improve HBV diagnosis and linkage to care
- Lessons learned in telemedicine
- Elimination through vaccination
- Management of HBV and COVID-19 coinfection
- Management of elevated liver enzymes in COVID-19
Presenters:
Norah Terrault, MD, MPH
Professor of Medicine
Chief of Gastrointestinal and Liver Diseases
University of Southern California
Los Angeles, California
Grace LH Wong, MD
Professor
Director, Medical Data Analytics Centre (MDAC)
Deputy Director, Center for Liver Health
Assistant Dean (Learning Experience), Faculty of Medicine
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong
Follow along with the slides at:
https://bit.ly/3HQ6dZ5
Link to full program:
https://bit.ly/3Bgyd5I
In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses what is known about the SARS-CoV-2 omicron variant, including:
Transmissibility and infectiousness
- Immune evasion
Disease severity
- Risks of hospitalization and death
Vaccine effectiveness
- 2- vs 3-dose vaccine effectiveness
- T-cell response
Presenter:
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia
Review the downloadable slidesets at:
https://bit.ly/32tp2BT
https://bit.ly/3JKyNLW
Link to full program:
https://bit.ly/3Ix8uZg
In episode 6 of an ongoing series of sharing sessions between a physician and patient, Tarik Asselah, MD, PhD, and his patient, who is living with chronic hepatitis B (CHB), discuss:
- Importance and goals of hepatitis B virus (HBV) treatment, with a call for broader access to treatment worldwide
- Screening for HBV, especially given the frequency of asymptomatic disease
- HBV vaccination as a preventive measure
- Living a healthy life and maintaining hope while living with CHB
Presenter:
Tarik Asselah, MD, PhD
Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris
Clichy, France
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3565S64
In this episode, Mark S. Sulkowski, MD, explores recommendations and data on treating HIV and hepatitis C virus (HCV) in patients who are coinfected.
Listen as he gives his perspectives on:
- Prioritization of both HIV and HCV treatment
- Efficacy of HCV direct-acting antivirals in people with HIV
- American Association for the Study of Liver Diseases/Infectious Diseases Society of America recommendations for first-line HCV treatment in HIV/HCV coinfection
- International guidance on first-line antiretroviral therapy
- HIV/HCV drug–drug interactions
- The Swiss HCVree Trial of HCV treatment as prevention in men who have sex with men with HIV
- Dependence of HCV elimination on the HIV care continuum for people who are HIV/HCV coinfected
Presenter:
Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Follow along with the slides at:
https://bit.ly/3oUi29g
Link to full program:
https://bit.ly/3fOl0XX
In this episode, Mark S. Sulkowski, MD, discusses his recommended approach for managing nonalcoholic steatohepatitis in patients with HIV, including recognizing nonalcoholic steatohepatitis, recommending lifestyle interventions, and considering pharmacologic approaches.
Presenter:
Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Content based on an online CME program supported by an educational grant from Theratechnologies Inc.
Link to full program:
https://bit.ly/3Gk7juJ
In this episode, Robert G. Gish, MD, and Pietro Lampertico, MD, PhD, share lessons learned in the care of patients coinfected with hepatitis B virus and hepatitis delta virus (HDV), including:
- Burden of HDV infection
- Chronic HDV infection and comorbidities
- Impact of COVID-19 on care of patients with chronic hepatitis B
- Screening for HDV and which assays to use
- Screening for viral hepatitis at a COVID-19 vaccination site
Presenters:
Robert G. Gish, MD, FAASLD, AGAF, FAST
Professor of Medicine
Loma Linda University
Loma Linda, California
Clinical Professor
University of Nevada Reno School of Medicine
Reno, Nevada
University of California Skaggs School of Pharmacy and Pharmaceutical Sciences
San Diego, California
Medical Director
Hepatitis B Foundation
Washington, DC
Pietro Lampertico, MD, PhD
Professor of Gastroenterology
Director, Division of Gastroenterology and Hepatology
IRCCS Ca Granda Policlinico Hospital
University of Milan
Milan, Italy
Follow along with the slides at:
https://bit.ly/3HQ6dZ5
Link to full program:
https://bit.ly/3Bgyd5I
In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for antiretroviral therapy (ART) use in older patients with renal and hepatic impairment.
- European AIDS Clinical Society guideline screening recommendations for kidney disease in people with HIV
- Antiretroviral dose adjustment recommendations based on estimated glomerular filtration rate
- Data on the use of full-dose lamivudine with renal impairment
- Data on the use of 2-drug nucleos(t)ide reverse-transcriptase inhibitor–sparing ART regimens, including GEMINI-1 and -2, TANGO, and SALSA for dolutegravir/lamivudine; SWORD-1 and -2 for dolutegravir/lamivudine; and ATLAS and FLAIR for long-acting cabotegravir plus rilpivirine
- US Department of Health and Human Services recommendations on the use of ART agents with hepatic impairment
- Recommendations from the American Gastroenterological Association on screening and diagnosis of nonalcoholic fatty liver disease (NAFLD)
- Prevalence of NAFLD, nonalcoholic steatohepatitis, and liver fibrosis in people with HIV
- Overlapping risk factors between HIV and NAFLD
Presenters:
Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida
Jens D. Lundgren, MD, DMSc
Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/3gAsu19
Link to full program:
https://bit.ly/3fOl0XX
In this episode, Jürgen K. Rockstroh, MD, and Giada Sebastiani, MD, discuss key strategies to appropriately screen for, identify, and manage nonalcoholic steatohepatitis in persons with HIV. They also answer pressing questions from healthcare professionals.
Presenters:
Jürgen K. Rockstroh, MD
Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany
Giada Sebastiani, MD
Associate Professor of Medicine
McGill University Health Centre
Division of Gastroenterology and Hepatology and Division of Infectious Diseases
Clinician Scientist
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada
Content based on an online CME program supported by an educational grant from Theratechnologies Inc.
Link to full program:
https://bit.ly/363orZ9
In this episode, Jürgen K. Rockstroh, MD, discusses his recommended approach for diagnosing nonalcoholic steatohepatitis in patients with HIV, the value of noninvasive diagnostic tests such as serum biomarkers and elastography, and how timely nonalcoholic fatty liver disease assessment and metabolic risk factor determination can result in early interventions.
Presenter:
Jürgen K. Rockstroh, MD
Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany
Content based on an online CME program supported by an educational grant from Theratechnologies Inc.
Link to full program:
https://bit.ly/3Gk7juJ
In this episode, John D. Baxter, MD, explores recommendations and data on the use of proviral DNA genotyping to inform antiretroviral therapy (ART) choice for patients who are treatment experienced.
Listen as he gives his perspectives on:
- US Department of Health and Human Services guideline recommendations on the use of proviral DNA genotyping
- US Department of Health and Human Services guideline recommendations and supporting data on switching ART with viral suppression and underlying drug resistance
- Study 380-4030 on outcomes with bictegravir- and dolutegravir-based ART in patients with preexisting nucleos(t)ide reverse-transcriptase inhibitor resistance
- The BRAAVE 2020 study on switching to bictegravir/emtricitabine/tenofovir alafenamide in Black persons with HIV, some of whom had baseline ART resistance
- Between-class ART switches with underlying resistance
- Susceptibility of tenofovir disoproxil fumarate and abacavir with thymidine analogue mutations
Presenter:
John D. Baxter, MD
Professor of Medicine
Division of Infectious Diseases
Department of Pathology
Cooper Medical School of Rowan University
Head, Division of Infectious Diseases
Cooper University Health Care
Camden, New Jersey
Follow along with the slides at:
https://bit.ly/3HmkSLc
See the entire program at:
https://bit.ly/3fOl0XX
In this episode, Rageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIV, and Solange L. Baptiste, ScM, discuss the burden of HIV among BIPOC and migrant communities and key strategies to reduce racial disparities in HIV care globally:
- Disproportionate impact of HIV among BIPOC communities and migrant populations globally
- Barriers to HIV testing, prevention, and treatment services among BIPOC communities and migrant populations
- Strategies to overcome health system–based and provider-based barriers to engagement with HIV care
Rageshri Dhairyawan, MBBS, BSc, FRCP, DipGUM, DFSRH, DipHIV
Honorary Senior Lecturer in HIV Medicine
Blizard Institute, Faculty of Medicine and Dentistry
Queen Mary University of London
Consultant Physician in HIV Medicine
Department of Infection and Immunity
Barts Health NHS Trust
London, United Kingdom
Solange L. Baptiste, ScM
Executive Director
International Treatment Preparedness Coalition
Bryanston, South Africa
Content based on a CME program supported by educational grants from AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP
To follow along, download the slides at:
https://bit.ly/3ngDrsv
Link to full program:
https://bit.ly/3gh6WXj
| In this episode, John D. Baxter, MD, explores recommendations and data on choosing antiretroviral therapy with transmitted drug resistance.Listen as he gives his perspectives on:* Initial response to antiretroviral therapy during primary HIV infection with baseline resistance * Data from the START study on treatment-naive patients with transmitted drug resistance by region and drug class * Recommendations from the US Department of Health and Human Services and International AIDS Society–USA guidelines on baseline genotype testing for integrase strand transfer inhibitor resistance * Considerations for the use of second-generation integrase strand transfer inhibitors and darunavir with transmitted drug resistance * Cases of transmitted multidrug-resistant HIV in patients receiving pre-exposure prophylaxis
Presenter:John D. Baxter, MDProfessor of MedicineDivision of Infectious DiseasesDepartment of PathologyCooper Medical School of Rowan UniversityHead, Division of Infectious DiseasesCooper University Health CareCamden, New JerseyFollow along with the slides at:https://bit.ly/3u7pjWqSee the entire program at: https://bit.ly/3fOl0XX |
The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:
- Direct-acting, small-molecule antiviral agents such as molnupiravir, nirmatrelvir + ritonavir, and remdesivir
- Monoclonal antibody treatments such as bamlanivimab + etesevimab, casirivimab + imdevimab, cilgavimab + tixagevimab, regdanvimab, and sotrovimab
Presenter:
Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts
Review the downloadable slidesets at:
https://bit.ly/3FXc90w
https://bit.ly/32tp2BT
Link to full program:
https://bit.ly/3Ix8uZg
In this episode, Samantha V. Hill, MD, MPH, and David Malebranche, MD, MPH, examine key facilitators to tackling racial inequities in HIV care, including:
- Barriers to HIV testing, prevention, and treatment services in BIPOC communities and migrant populations
- Facilitators to HIV testing, prevention, and treatment services in BIPOC communities and migrant populations
- Strategies to overcome health system–based and healthcare professional–based barriers to engagement with HIV care
Samantha V. Hill, MD, MPH
Assistant Professor
Division of Adolescent Medicine
Department of Pediatrics
The University of Alabama at Birmingham
Birmingham, Alabama
David Malebranche, MD, MPH
Internal Medicine Physician
HIV/Sexual Health Specialist
AIDS Healthcare Foundation (AHF) Medical Clinic
Atlanta, Georgia
Content based on a CME program supported by educational grants provided by AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP
To follow along, download the slides at:
https://bit.ly/3ngDrsv
Link to full program:
https://bit.ly/3gh6WXj
In this episode from the series “Key Decisions in HIV Care,” Daria Podlekareva, MD, PhD, and Mark S. Sulkowski, MD, discuss important considerations for ART use in patients with coinfections, including:
- DHHS testing and treatment recommendations for HBV in patients with HIV
- Data suggesting that tenofovir alone may not suppress HBV in all PWH
- Data from NA-ACCORD showing that incomplete HBV DNA suppression is associated with HCC in patients with HIV/HBV
- Data for the use of entecavir as an add-on therapy if an HIV ART regimen is not HBV active
- Data showing that lamivudine alone is associated with resistance in patients with HIV/HBV
- Discussion of HBV management in the setting of 2-drug regimens for HIV if the patient is coinfected
- Recommendations from the DHHS, EACS, and WHO to start ART as soon as possible in patients with TB/HIV coinfection
- Data from the SAPiT, ACTG A5221 STRIDE, and CAMELIA studies to show the benefits of early ART in patients with TB/HIV
- Recommendations from the EACS guidelines on what ART regimens are recommended with TB/HIV
- Drug-drug interaction considerations between ART and TB treatment
- Discussion of the prevention and management of TB-associated IRIS
Presenters:
Daria Podlekareva, MD, PhD
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with slides:
https://bit.ly/3zHySMO
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Karen Ha, MD, explores recommendations and data on the role of PIs in current practice.
Listen as she gives her perspectives on:
- DHHS guideline recommendations on the use of PI-based ART
- Data from the DIAMOND study on the use of boosted DRV for rapid initiation
- Data from the EARNEST and NADIA studies on the use of PI-based ART with NRTI resistance
- Considerations for the use of PIs in patients with cardiovascular risk, including data from the D:A:D study
- Key drug–drug interaction considerations with the use of PIs
Presenter:
Karen Ha, MD
Assistant Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Cooper University Hospital
Cooper Medical School of Rowan University
Camden, New Jersey
Follow along with the slides at:
https://bit.ly/3zvO6EB
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Karen Ha, MD, explores recommendations and data on the role of NNRTIs in current practice.
Listen as she gives her perspectives on:
- DHHS guideline recommendations on the use of NNRTI-based ART
- Weight gain data from the ADVANCE study, DRIVE-AHEAD, DRIVE-FORWARD, DRIVE-SHIFT, and a multivariate analysis of weight gain on ART
- Key food effects and drug–drug interaction considerations with the use of NNRTIs
Presenter:
Karen Ha, MD
Assistant Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Cooper University Hospital
Cooper Medical School of Rowan University
Camden, New Jersey
Follow along with the slides at:
https://bit.ly/3G2PS2p
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Renslow Sherer, MD, discusses key data on COVID-19 oral antiviral agents—molnupiravir and nirmatrelvir (PF-07321332) plus ritonavir—for nonhospitalized adults with mild to moderate COVID-19, including:
- EPIC-HR study of nirmatrelvir (PF-07321332) plus ritonavir
- Safety data
- Efficacy data
- MOVe-OUT study of molnupiravir
- Safety data
- Efficacy data
- Roles in treatment of COVID-19
- Timing of treatment
Presenter:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Review the downloadable slideset at:
https://bit.ly/31wi1Qi
Link to full program:
https://bit.ly/3EH2485
In this episode, Christian R. Pollard provides his perspectives as an individual taking daily oral HIV PrEP, including factors he considered in the decision to use PrEP, his experience with taking PrEP (daily pills and periodic laboratory testing), and his thoughts on what opportunities future PrEP options may offer.
Presenter:
Christian R. Pollard
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3AFvsZY
In this episode from the series “Key Decisions in HIV Care,” W. David Hardy, MD, and Josep M. Llibre, MD, PhD, discuss important considerations for ART use in the context of virologic failure and resistance, including:
- A discussion of the definitions of the following: highly treatment experienced, complex ART, multidrug-resistant HIV, and limited treatment options
- The scope of the problem, including data from the CNICS cohort
- DHHS and EACS guideline recommendations on the management of virologic failure and drug resistance, including recommendations for the use of genotypic and phenotypic genotyping and proviral DNA sequencing
- Construction of an optimized background regimen with discussion of the OPTIONS, DAWNING, NADIA, and VIKING-3 trials
- Novel treatment options, including ibalizumab and data from TMB-301/-311, fostemsavir and data from BRIGHTE, and lenacapavir and data from CAPELLA
Presenters:
W. David Hardy, MD
Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California
Josep M. Llibre, MD, PhD
Senior Consultant Physician and Clinical Researcher
Infectious Disease and “Fight against AIDS and Infectious Diseases Foundation”
Hospital Universitari Germans Trias i Pujol
Badalona
Barcelona, Spain
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/3z9AtL0
Link to full program:
https://bit.ly/2TXTYWx
Hear insights from 3 faculty experts as they present emerging data and guidelines and engage in discussion on patient-centered ART selection for people with HIV.
Topics include assessing treatment options; individualizing ART for women of childbearing potential and during pregnancy, patients with OIs, and during the COVID-19 pandemic; and new data on investigational ART strategies.
Learn how to:
- Apply the results of recent clinical studies and evolving treatment guidelines on the timing and choice of first-line ART and switch strategies and managing treatment-experienced patients with HIV
- Integrate individual patient factors such as drug–drug interactions, comorbidities, pregnancy status, adherence, and dosing preferences when selecting optimal ART
- Appropriately counsel patients regarding the anticipated clinical role of new and investigational ART regimens in individualized care
Presenters:
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Jean-Michel Molina, MD, PhD
Head of the Department of
Infectious Diseases
Saint-Louis Hospital, Assistance-Publique Hôpitaux de Paris
Professor of Infectious Diseases
University of Paris
Paris, France
Cristina Mussini, MD
Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases
Infectious Diseases Clinics
University Hospital
University of Modena and Reggio Emilia
Reggio Emilia, Italy
Follow along with the slides at:
https://bit.ly/329c8ZP
See the entire program at:
https://bit.ly/3FkRofM
In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for ART use in older PWH, including:
- DHHS, EACS, IAS, and WHO recommendations for first-line ART
- Virologic outcomes for older PWH in clinical trials and results from the HealthHIV Second Annual National Survey
- Polypharmacy and its potential consequences, including common non-ARV medications prescribed in the VACS cohort, drug–drug interactions with common concomitant medications, common comorbidities in older PWH, and drug–disease state interactions including renal and hepatic impairment
- Cardiovascular risk considerations including data from the D:A:D study and RESPOND cohort and lipid changes in the TANGO study of switching to DTG/3TC from TAF-based ART
Presenters:
Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida
Jens D. Lundgren, MD, DMSc
Professor
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/3miT6qH
See the entire program at:
https://bit.ly/2TXTYWx
Hepatitis delta is the most severe form of viral hepatitis, and many patients remain undiagnosed. In this episode, Maria Buti, MD, and Robert G. Gish, MD, discuss the prevalence and severity of hepatitis delta. Hear their personal experiences from the clinic and their call to action for universal screening of patients with hepatitis B for coinfection with hepatitis delta.
Presenters:
Maria Buti, MD
Professor of Medicine
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Robert G. Gish, MD
Professor of Medicine
Loma Linda University
Loma Linda, California
Medical Director
Hepatitis B Foundation
Washington, DC
Link to full program:
https://bit.ly/3E9xKSx
In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on patient specific factors associated with LA CAB plus RPV failure.
Listen as she gives her perspectives on:
- LA CAB plus RPV pharmacokinetic data
- DHHS guideline recommendations on which patients can be considered for LA CAB plus RPV
- Data from the ATLAS, FLAIR, and ATLAS-2M studies on patients with virologic failure and the factors that may have contributed
Presenter:
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove Campus
Downers Grove, Illinois
HIV/ID Clinical Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois
Follow along with the slides at:
https://bit.ly/3EfaSRX
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA), and Ming-Lung Yu, MD, PhD, discuss key racial inequities of care that lead to undertreatment for migrant populations and other racial minorities globally with or at risk for hepatitis B. In addition, they discuss plans to improve engagement across the care continuum and strategies to combat implicit racial biases that affect optimal HBV care.
Topics include:
- Differences in the burden of HBV globally
- Suboptimal engagement of HBV care
- Stigma associated with HBV care
- Key strategies for overcoming racial barriers
- First-hand patient stories
Geoffrey Dusheiko, FRCP, FRCP (Edin), FCP (SA)
Emeritus Professor of Medicine
Consultant Hepatologist
University College London Medical School
Professor
Liver Unit
Kings College Hospital
London, United Kingdom
Ming-Lung Yu, MD, PhD
Chair Professor
Hepatobiliary Division
Department of Internal Medicine and Hepatitis Center
Kaohsiung Medical University
Visiting Staff
Hepatobiliary Division
Department of Internal Medicine
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan
Kaohsiung City, Taiwan
Content based on a CME program supported by educational grants provided by AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP
To follow along, download the slides at:
https://bit.ly/3gWStjZ
Link to full program:
https://bit.ly/3kKIb9a
In this episode, Dalilah Restrepo, MD, discusses barriers to shingles vaccination and strategies to increase routine vaccine uptake in the COVID-19 era.
Using the latest data and expert guidance, this podcast covers topics such as:
- Shingles disease burden and increasing incidence over time
- Decline in shingles vaccination rates in the COVID-19 era
- National Vaccine Advisory Committee standards of care
- CDC guidance catching up after RZV dosing delays
- Strategies to increase shingles vaccine uptake
Presenter:
Dalilah Restrepo, MD
Infectious Diseases Specialist
Fountain Valley Hospital
Fountain Valley, California
Content based on a CME program supported by an educational grant from GlaxoSmithKline
Follow along with the downloadable slides at:
https://bit.ly/3pW7Bl8
Link to full program:
https://bit.ly/3o4PB8N
In this episode, Renslow Sherer, MD, discusses key data on COVID-19 vaccine efficacy, including:
- Third doses
- Booster doses
- Mixing and matching booster doses
Presenter:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Review the downloadable slideset at:
https://bit.ly/3Fl0yZV
Link to full program:
https://bit.ly/3EH2485
In this episode, Martin C. Mahoney, MD, PhD, discusses new data on vaccine-preventable diseases from IDWeek 2021, including:
- Pneumococcal disease
- Respiratory syncytial virus (RSV)
- Herpes zoster
- Influenza
Presenter:
Martin C. Mahoney, MD, PhD
Professor of Oncology
Department of Internal Medicine
Roswell Park Comprehensive
Cancer Institute
Buffalo, New York
Follow along with an expanded slideset at:
https://bit.ly/3Ev8ozr
Link to full program:
https://bit.ly/3BCHF2E
In this episode, Nancy Reau, MD, discusses new viral hepatitis data from AASLD 2021, including:
- HBV treatment in pregnancy
- Outcomes following HBV treatment withdrawal
- Progress toward an HBV cure
- HCV implementation science and current status of the cascade of care
- Hepatitis delta virus: understanding the clinical impact
- Phase III clinical trial updates for hepatitis delta virus, including data on bulevirtide
Presenter:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Follow along with the downloadable slideset at:
https://bit.ly/3d6NQRV
Link to full program:
https://bit.ly/3lputrT
In this episode, Tristan J. Barber, MA, MD, FRCP, discusses new HIV data from EACS 2021, including:
- First-line therapies
- BIC/FTC/TAF in a test-and-treat model in IMEA 055 FAST
- Week 144 data of ISL + DOR in treatment-naive patients from P011
- Switch Strategies
- Data on the use of DTG/3TC in patients with an M184V mutation from SOLAR 3D and the French Dat’AIDS Cohort
- Long-Acting Therapies
- Efficacy and safety of LA CAB + RPV by BMI
- Long-term follow-up of participants who discontinued LA CAB + RPV in the ATLAS, ATLAS-2M, and FLAIR trials
- Patient satisfaction with LA CAB + RPV from the CARISEL study
- Resistance and subgroup data from the CAPELLA study of lenacapavir in heavily treatment–experienced patients
- COVID-19 vaccination efficacy and the impact of the pandemic on viral suppression in PWH
Presenter:
Tristan J. Barber, MA, MD, FRCP
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
Honorary Associate Professor
Institute for Global Health
University College London
London, United Kingdom
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Follow along with an expanded slideset at:
https://bit.ly/32RCX4N
Link to full program:
https://bit.ly/3G2GknK
| In this episode, Dalilah Restrepo, MD, discusses expert guidance on vaccination for the prevention of shingles complications in the COVID-19 era.Contributor:Dalilah Restrepo, MDInfectious Diseases SpecialistFountain Valley HospitalFountain Valley, CaliforniaUsing a case study and the latest expert guidance, this podcast covers topics such as: * Expert guidance on maintenance of routine vaccination during the COVID-19 era * Common shingles complications in immunocompetent patients * Additional shingles complications in immunocompromised patients * Guidance on safe shingles vaccine delivery during the COVID-19 pandemic * CDC guidance catching up after RZV dosing delays
Content based on a CME program supported by an educational grant from GlaxoSmithKline.Follow along with the downloadable slides at: https://bit.ly/3r3AKx1Link to full program:https://bit.ly/3o4PB8N |
In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on strategies to address suboptimal CD4+ cell count response in people with HIV on suppressive ART.
Listen as he gives his perspectives on:
- The consequences of suboptimal CD4+ cell count response
- ART intensification
- ART switch strategies with data from the SPIRAL study
- Data on the addition of interleukin-2 from the SILCAAT and ESPIRIT studies
- DHHS guideline recommendations
Presenter:
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/3DC2bkP
See the entire program at:
https://bit.ly/2TXTYWx
| In this episode, Prof Ashley Brown, BSc, MD, FRCP, and Ahmed M. Elsharkawy, PhD, FRCP(UK), discuss key racial inequities of care that lead to undertreatment for migrant populations and other racial minorities globally with or at risk for hepatitis C.Topics include:* HCV Burden and Care Disparities in Specific Populations * Genotypes and Length of Infection in Ethnic Minorities * Primary Care Education and System-Related Barriers * Solutions to Overcome Barriers to HCV Care * First-hand Patient Stories
Prof Ashley Brown, BSc, MD, FRCPProfessor of Practice, Viral HepatitisDivision of Metabolism, Digestion and ReproductionImperial College LondonConsultant HepatologistLiver & Antiviral UnitImperial College Healthcare NHS TrustLondon, United KingdomAhmed M. Elsharkawy, PhD, FRCP(UK)Consultant Hepatologist and Honorary Senior LecturerLiver Unit and Biomedical Research CentreUniversity Hospitals BirminghamUniversity of BirminghamBirmingham, United KingdomContent based on a CME program supported by educational grants provided by AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP To follow along, download the slides at:https://bit.ly/36UDLViLink to full program:https://bit.ly/3kKIb9a |
In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity and the use of NRTI-sparing regimens with discussion of the GEMINI-1 and -2 studies of DTG/3TC and the SWORD-1 and -2 studies of DTG/RPV, and safety with long-acting injectables with specific discussion of the ATLAS and FLAIR studies of LA CAB plus RPV and the CUSTOMIZE study.
Presenters:
Fidelia Bernice, PharmD
Clinical Pharmacy Specialist
Infectious Diseases
Department of Pharmacy
University of Maryland Medical Center
Baltimore, Maryland
Aadia I. Rana, MD
Associate Professor of Medicine
Division of Infectious Diseases
University of Alabama at Birmingham
1917 Clinic
Birmingham, Alabama
Content based on a CME program supported by independent educational grants fromJanssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.
Link to full program:
https://bit.ly/3ydMtcL
In this episode, Tracy Zivin-Tutela, MD, discusses expert guidance on vaccination against shingles.
Tracy Zivin-Tutela, MD
Infectious Diseases Specialist
Department of Infectious Diseases
Fountain Valley Regional Hospital
Los Alamitos Medical Center
Fountain Valley, California
Using a case study and the latest expert guidance, this podcast covers topics such as:
- Counseling patients on benefits and efficacy of vaccination against shingles
- Vaccine safety
- Vaccination guidelines for adults with or without previous vaccination with zoster vaccine live or recalled childhood chickenpox
- Administration of vaccination with consideration for other routine vaccines for flu, pneumonia, COVID-19
Content based on a CME program supported by an educational grant from GlaxoSmithKline
Follow along with the downloadable slides at:
https://bit.ly/3kunxJr
Link to full program:
https://bit.ly/3o4PB8N
In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.
Listen as he gives his perspectives on:
- Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TC
- The SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patients
- Real-world experience with switching to DTG/RPV from the OPERA study
- The TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimen
- The SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimen
Presenter:
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/3n0Z8wU
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Gregory Dore, MBBS, PhD, FRACP, MPH, and Stacey Trooskin, MD, PhD, MPH, share lessons learned in the care of patients with HCV infection during the COVID-19 pandemic, including:
- Telehealth
- Treatment of PWID
- TEMPO pilot study
- MINMON study
Presenters:
Gregory Dore, MBBS, PhD, FRACP, MPH
Professor, Head
Viral Hepatitis Clinical Research Program
Kirby Institute
University of New South Wales
Infectious Diseases Physician
St. Vincent's Hospital
Sydney, Australia
Stacey Trooskin, MD, PhD, MPH
Chief Medical Officer
Philadelphia FIGHT Community Health Centers
Faculty
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Follow along with the slides at:
https://bit.ly/3naBUVj
Link to full program:
https://bit.ly/3F5bxG8
In this episode, hepatologist Giada Sebastiani, MD, discusses why the presence of obesity, metabolic syndrome, persistent elevation of ALT, or exposure to dideoxynucleoside analogues can trigger an evaluation for NAFLD and NASH, particularly in our aging population of patients with HIV with topics including:
- Metabolic factors
- HIV-related factors
- Which patients with HIV are at risk
Presenter:
Giada Sebastiani, MD
Associate Professor of Medicine
McGill University Health Centre
Division of Gastroenterology and Hepatology and Division of Infectious Diseases
Clinician Scientist
Research Institute of McGill University Health Centre
Montreal, Quebec, Canada
Content based on an online CME program supported by an educational grant from Theratechnologies Inc.
Link to full program:
https://bit.ly/3BYoXBP
In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.
Presenters:
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
HIV/ID Clinical Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois
Jonah Musa, MBBS, MSCI, PhD
Professor, Obstetrics and Gynecology
University of Jos
Honorary Consultant Obstetrician and Gynecologist
Jos University Teaching Hospital
Jos, Nigeria
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/3GRxpGQ
Link to full program:
https://bit.ly/2TXTYWx
In this episode, Renslow Sherer, MD, discusses new COVID-19 data from IDWeek 2021, including:
- Prevention of COVID-19
- ChAdOx1 nCoV-19
- Ad26.COV2.S
- Tixagevimab plus cilgavimab
- Outpatients with COVID-19
- Remdesivir IV
- Molnupiravir
- Hospitalized patients with COVID-19
- Baricitinib
- Lenzilumab
- Casirivimab plus imdevimab
- Long-term COVID-19 outcomes
- Sustained recovery
Presenter:
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Link to full program and downloadable slides:
https://bit.ly/3BCHF2E
In this episode, Oni Blackstock, MD, MHS, and Nina T. Harawa, PhD, MPH, discuss racial disparities in COVID-19 outcomes, including:
- Background on healthcare inequities among BIPOC
- COVID-19 racial disparities and the healthcare inequities driving them
- Overcoming barriers to optimal COVID-19 care among BIPOC
- Addressing concerns about COVID-19 vaccination
- Motivational interviewing principles and the brief negotiated interview to earn trust and increase vaccine acceptance
Presenters:
Oni Blackstock, MD, MHS
Founder and Executive Director
Health Justice
New York, New York
Nina T. Harawa, PhD, MPH
Professor of Medicine and Epidemiology
UCLA David Geffen School of Medicine
Charles R. Drew University of Medicine and Science
Policy Core Director
UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS)
Los Angeles, California
Link to full program and downloadable slides:
https://bit.ly/3blGA3R
In this episode, Nicholas Chamberlain, MD, provides an overview of the different antiretroviral drug formulations and dosing strategies in various stages of clinical development for long-acting HIV PrEP—advances that collectively offer the potential for highly individualized approaches to HIV biomedical prevention.
Presenter:
Nicholas Chamberlain, MD
Medical Director
AHF Healthcare Center – Atlanta Midtown
Department of Medicine
AIDS Healthcare Foundation
Atlanta, Georgia
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3AFvsZY
In episode 1 of an ongoing series of conversations between a physician and patient, Stacey Trooskin, MD, PhD, MPH, and patient advocate Brother Dan Palmer discuss approaches to improve access to HCV therapy. The conversation focuses on how barriers to care affected Dan’s health after his hepatitis C diagnosis and the strategies he employed to overcome them.
Presenter:
Stacey Trooskin, MD, PhD, MPH
Chief Medical Officer
Philadelphia FIGHT Community Health Centers
Faculty
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Content based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.
Link to full program:
https://bit.ly/3lSkSui
In this podcast episode, Paul E. Sax, MD, and Renslow Sherer, MD, discuss the clinical significance of new data on the prevention and treatment of COVID-19, including:
- COVID-19 in immunocompromised hosts
- Prime-Boost Strategy for COVID-19 vaccination
- COVID-19 surge effects
- Monoclonal antibody therapy for prevention and treatment
- Remdesivir update
- Repurposed drug, fluvoxamine
- What does the future of the pandemic look like?
Presenters:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Link to full program, including downloadable slidesets:
https://bit.ly/3zVTwYW
In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data to support the management of missed CAB plus RPV injections.
Listen as she gives her perspectives on:
- Prescribing information recommendations for managing missed injections of CAB plus RPV
- Pharmacokinetic modeling data to support management strategies for missed injections
- Data from the ATLAS and FLAIR studies on missed injections and patient outcomes
Presenter:
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove Campus
Downers Grove, Illinois
HIV/ID Clinical Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois
Follow along with the slides at:
https://bit.ly/30nJfaZ
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data on maternal weight gain associated with ART use in pregnancy.
Listen as she gives her perspectives on:
- IMPAACT 2010 data on maternal weight gain with DTG + FTC/TAF vs DTG + FTC/TDF vs EFV/FTC/TDF
- SMARTT study data on gestational weight gain by ART class
- Tsepamo Surveillance study data on maternal weight and birth outcomes among women receiving ART, as well as weight outcomes with DTG vs EFV
- DHHS Perinatal Guideline recommendations on dolutegravir and maternal weight gain
Presenter:
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove Campus
HIV/ID Clinical Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois
Follow along with the slides at:
https://bit.ly/3DusMQk
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Darcy Wooten, MD, discusses new HIV data from IDWeek 2021, including:
- A rapid test-and-treat program to start DTG/3TC in patients newly diagnosed with HIV (STAT)
- Efficacy when switching from 3-drug to 4-drug TAF-based regimens to DTG/3TC (TANGO)
- Virologic outcomes with 2-drug vs 3-drug ART regimens (Trio Health HIV Network Study)
- Metabolic complications in treatment-naive patients (Study 1489 and Study 1490)
- Resistance analysis of an investigational agent, lenacapavir (CALIBRATE)
- The Positive Perspectives Survey to evaluate the U=U Educational Campaign in North American patients
Presenter:
Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California
Link to full program:
https://bit.ly/3BCHF2E
During this episode, Lynora Saxinger, MD, FRCPC, CTropMed, updates listeners on the latest Emergency Use Authorizations and guideline recommendations for optimal clinical management of COVID-19. Gain practical insights on patient identification, risk stratification, and treatment.
Key points include:
- Treatment of COVID-19 can be broken into antiviral and immune-modulating therapies
- Each agent should be used at the correct disease stage to maximize benefit
- Antiviral medications and mAbs show the greatest promise early during COVID-19, before the host immune response is mounted
- Passive immunization with mAbs can prevent infection and severe disease—and mortality—if given early to hospitalized persons
- Operational challenges to using these medications exist, but given the epidemic of unvaccinated persons, these treatments become increasingly relevant to reduce burden on healthcare systems
Presenter:
Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta, Canada
Content based on an online CME program supported by an educational grant from Gilead Sciences, Inc.
Follow along with the slides at:
https://bit.ly/3BxQKtD
Link to full program:
https://bit.ly/3BwzdlC
In this episode from the series “Key Decisions in HIV Care,” Jason Halperin, MD, MPH, and Jürgen K. Rockstroh, MD, discuss important considerations in the rapid initiation of ART, including guideline recommendations and data supporting recommended ART regimen options for rapid initiation and emerging data for the 2-drug regimen dolutegravir/lamivudine for rapid start from the STAT study. Following their dialogue, the faculty field questions from healthcare professionals.
Presenters:
Jason Halperin, MD, MPH
Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana
Jürgen K. Rockstroh, MD
Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Follow along with the slides at:
https://bit.ly/2XWPuBi
Link to full program:
https://bit.ly/2TXTYWx
In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores the data to support the use of tenofovir alafenamide in pregnancy.
Listen as she gives her perspectives on:
- DHHS guideline recommendations for the use of TAF in pregnancy
- Pharmacokinetic data to support adequate TAF concentrations throughout pregnancy
- Available antiretroviral pregnancy registry information on the use of TAF in pregnancy
- Data from the IMPAACT 2010 study to support the use of a TAF-containing regimen in pregnancy
Presenter:
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy
Downers Grove Campus
HIV/ID Clinical Pharmacist
Northwestern Memorial Hospital
Chicago, Illinois
Follow along with the slides at:
https://bit.ly/3ofTHLr
Link to full program:
https://bit.ly/2TXTYWx
In this episode, Tracy Zivin-Tutela, MD, discusses factors that put your patients at risk for shingles and its complications.
Tracy Zivin-Tutela, MD
Infectious Diseases Specialist
Department of Infectious Diseases
Fountain Valley Regional Hospital
Los Alamitos Medical Center
Fountain Valley, California
Using a case study and the latest data, this podcast covers topics such as:
- Pathophysiology and epidemiology
- Disease burden and potential complications in older patients, including postherpetic neuralgia
- Risk factors, including age, immunosenescence, chronic diseases, unvaccinated status
Content based on a CME program supported by an educational grant from GlaxoSmithKline
Follow along with the downloadable slides at:
https://bit.ly/3ENbcbP
Link to full program:
https://bit.ly/3o4PB8N
In this episode, Jason Halperin, MD, MPH, explores the data to support rapid ART initiation in patients with OUD.
Listen as he gives his perspectives on:
- DHHS guidelines for rapid initiation of ART and specific recommendations for patients with substance use disorders
- SAMSHA recommendations for the treatment of OUD
- Medications that are recommended for the treatment of OUD, including drug–drug interaction considerations with ART
- Data to support the treatment of OUD to improve HIV viral suppression rates
In addition, hear his patient’s perspective on the importance of receiving treatment for his OUD and HIV together.
Presenter:
Jason Halperin, MD, MPH
Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana
Follow along with the slides:
https://bit.ly/3kE5Wzq
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Jason Halperin, MD, MPH, explores the data to support rapid ART initiation in adolescent patients.
Listen as he gives his perspectives on:
- DHHS and IAS-USA guidelines for rapid initiation and specific recommendations for adolescents and young adults
- CrescentCare data comparing the virologic outcomes for patients 18-24 years of age compared with those aged 25 years or older
- Data to suggest that rapid ART upholds equity
In addition, hear his patient’s perspective on the importance of rapid initiation of ART to prevent transmission to others and the burden it lifted for him.
Presenter:
Jason Halperin, MD, MPH
Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana
Follow along with the slides at:
https://bit.ly/39xL5r0
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Colleen Kelley, MD, MPH, discusseskey features and available safety and efficacy data on investigational long-acting HIV pre-exposure prophylaxis strategies that are in late stages of clinical development.
Presenter:
Colleen Kelley, MD, MPH
Atlanta, Georgia
Colleen Kelley, MD, MPH, has disclosed that she has received funds for research support from Gilead Sciences, Moderna, Novavax, and ViiV Healthcare.
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program: https://bit.ly/3AFvsZY
In this second of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including data on investigational antiretroviral agents, lenacapavir and islatravir, and alternative dosing of BPaL for MDR-TB.
This episode includes discussion of:
- An extension of FLAIR, demonstrating virologic efficacy and safety of long-acting CAB plus RPV at Week 124
- A Week 26 safety and efficacy analysis of CAPELLA, a study of lenacapavir in heavily treatment–experienced PWH
- CALIBRATE, a study of the safety and efficacy of lenacapavir in treatment-naive PWH
- A Week 96 safety analysis of Protocol 011, evaluating islatravir plus DOR in treatment-naive patients
- A Week 24 safety and pharmacokinetic analysis of Protocol 016, evaluating oral islatravir once monthly for PrEP
- ZeNix, a phase III trial of pretomanid, bedaquiline, and linezolid (BPaL) in patients with highly resistant TB
Presenters:
Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Shobha Swaminathan, MD
Associate Professor
Division of Infectious Diseases
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey
Follow along with the slides at:
https://bit.ly/3hvRN5b
Content based on an online CME program supported by an educational grant from ViiV Healthcare.
In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including:
- Rationale for use of mAb
- Potential for resistance to mAb
- Single vs combination therapy with mAb
- Challenges in implementation of mAb as treatment or prevention
- Bamlanivimab
- Sotrovimab
- Casirivimab plus imdevimab
Link to full program, including downloadable slidesets: https://bit.ly/3zVTwYW
Presenters:
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
Faculty Medicine Dentistry and Health Sciences
University of Melbourne and Royal Melbourne Hospital
Consultant Infectious Diseases Physician
Department of Infectious Diseases
Royal Melbourne Hospital and Alfred Hospital
Melbourne, Australia
Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts
Sharon R. Lewin, AO, FRACP, PhD, FAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.
Arthur Kim, MD, has disclosed that he has served on the drug and safety monitoring board for Kintor.
In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH.
This episode includes discussion of:
- A Global Clinical Platform that evaluated outcomes of PWH hospitalized with COVID-19
- A post hoc analysis of TANGO, evaluating the virologic and metabolic outcomes when switching to DTG/3TC vs continued 3- or 4-drug TAF-based regimens
- A Week 48 analysis of SALSA, demonstrating virologic efficacy and favorable safety profile of switching to DTG/3TC vs continuing a 3-drug ART regimen
Presenters:
Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Shobha Swaminathan, MD
Associate Professor
Division of Infectious Diseases
Department of Medicine
Rutgers New Jersey Medical School
Newark, New Jersey
Follow along with the slides at:
https://bit.ly/3hvRN5b
Content based on an online CME program supported by an educational grant from ViiV Healthcare.
In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:
- BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients
- TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNA
- BRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA
- VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNA
- SWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistance
- DAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIs
- BRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agent
In addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.
Presenter:
Geeta Gupta, MD
Professor
Director, AIDS Education and Training Center
University of California, Irvine
Orange, California
Follow along with the slides at:
https://bit.ly/3zxKBfL
Content based on an online CME program supported by an educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
In this episode, Mindie H. Nguyen, MD, MAS, AGAF, FAASLD, and Lewis R. Roberts, MB ChB, PhD, examine the HBV burden and care disparities in specific populations, including Asian Americans and foreign-born immigrants, and strategies to address barriers to care.
Presenters:
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine
Department of Gastroenterology and Hepatology
Stanford University Medical Center
Palo Alto, California
Lewis R. Roberts, MB ChB, PhD
Professor of Medicine and Consultant
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota
Content based on a CME program supported by educational grants provided by AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP
To follow along, download the slides at:
https://bit.ly/3gWStjZ
Link to full program:
https://bit.ly/3kKIb9a
In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:
- BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients
- TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNA
- BRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA
- VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNA
- SWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistance
- DAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIs
- BRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agent
In addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.
Presenter:
Geeta Gupta, MD
Professor
Director, AIDS Education and Training Center
University of California, Irvine
Orange, California
Follow along with the slides at:
https://bit.ly/3zxKBfL
Content based on an online CME program supported by an educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from:
- BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-experienced patients
- TMB-301, a study that added the monoclonal antibody ibalizumab in pretreated patients with multidrug-resistant HIV and demonstrated significant decreases in HIV-1 RNA
- BRIGHTE, which showed that the addition of fostemsavir in heavily treatment–experienced patients with HIV led to a significant decrease in HIV-1 RNA
- VIKING-3, a study that demonstrated the addition of DTG dosed BID in INI-resistant patients was effective in decreasing HIV-1 RNA
- SWITCHMRK, a study that showed underlying resistance matters when deciding to switch regimens in a treatment-experienced, virologically suppressed patient, especially when switching to a regimen with a low barrier to resistance
- DAWNING, a study that demonstrated that DTG, when added to 2 NRTIs, was superior to RTV-boosted LPV in patients with virologic failure on an NNRTI plus 2 NRTIs
- BRAAVE, which evaluated safety and efficacy of switching to BIC/FTC/TAF in Black patients virologically suppressed on 2 NRTIs plus a third agent
In addition, Dr. Gupta reviews current DHHS ART guideline recommendations related to managing virologic failure, including drug resistance testing and drug selection, as well as switching recommendations in patients with viral suppression and underlying drug resistance.
Presenter:
Geeta Gupta, MD
Professor
Director, AIDS Education and Training Center
University of California, Irvine
Orange, California
Follow along with the slides at:
https://bit.ly/3zxKBfL
Content based on an online CME program supported by an educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
In this episode, Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.
Listen as he gives his perspectives on:
- Weight gain following ART initiation by ARV class and ARV drug
- Results of the ADVANCE and GEMINI-1 and -2 studies, with exploration of weight, risk of CVD and diabetes
- BMI changes in PWH
- DHHS and IAS-USA guidelines for initial therapy
Presenter:
Joseph J. Eron, MD
Professor of Medicine and Epidemiology
University of North Carolina
School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Follow along with the slides at:
https://bit.ly/3DyLgA3
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, David Malebranche, MD, MPH, discusses modifying ART in virologically suppressed patients, including switching ART in a patient with daily pill fatigue, switching ART to avoid comorbidities and simplifying ART in the context of known multidrug resistance. The overview will include analyses from:
- The ATLAS and FLAIR studies in which long-acting intramuscular CAB + RPV was initiated after initial virologic suppression with oral therapy
- D:A:D study data that found cumulative use of RTV-boosted DRV, but not RTV-boosted ATV, was independently associated with a small but progressively increasing risk of CVD events
- The SWORD-1 and -2 evaluating the switch to DTG + RPV vs continuation of baseline ART in virologically suppressed adults
- The TANGO study that compared switching to DTG/3TC vs continuing a TAF-based 3-drug regimen
- The DAWNING study that showed favorable outcomes for treatment-experienced patients switched to DTG containing regimens with an M184V mutation, whether the regimen contained emtricitabine or lamivudine or not
- Study 380-4030 that showed noninferiority in maintenance of viral suppression when switching to BIC/FTC/TAF from DTG + FTC/(TAF or TDF)
- BRAAVE 2020 that evaluated the impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH
In addition, Dr. Malebranche reviews current recommendations by the DHHS regarding considerations when switching regimens in virologically suppressed patients and switching regimens in patients with viral suppression and drug resistance.
Presenter:
David J. Malebranche, MD, MPH
Internal Medicine Physician
HIV/Sexual Health Specialist
Clinician, AIDS Healthcare Foundation (AHF) Medical Clinic
Atlanta, Georgia
Follow along with the slides at:
https://bit.ly/3kseOqk
Content based on an online CME program supported by an educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from:
- The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year period
- The DIAMOND study analyzing virologic efficacy and safety at 48 weeks after initiating DRV/COBI/FTC/TAF within 24 hours of HIV infection diagnosis
- A rapid ART start program in young PWH in New Orleans that demonstrated achievement of viral suppression in fewer than 30 days and no discontinuations due to adverse events
- The ATLAS (including ATLAS-2M) and FLAIR studies that demonstrated efficacy and safety of long-acting injectable CAB plus RPV
- SWORD-1 and SWORD-2 that demonstrated switching to a 2-drug regimen of DTG plus RPV in virologically suppressed adults was safe and effective
- GEMINI-1 and GEMINI-2 that demonstrated noninferiority of DTG plus 3TC compared with DTG plus FTC/TDF
- TANGO that demonstrated safety and efficacy of switching to DTG/3TC in virologically suppressed adults receiving a TAF-based regimen
In addition, Dr. Sax reviews current recommendations by the DHHS, WHO, and IAS-USA regarding these emerging therapies and treatment paradigms.
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Follow along with the slides at:
https://bit.ly/3zdPwm2
Content based on an online CME program supported by an educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of:
- The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC
- The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC
- An extension of the FLAIR study, evaluating efficacy and safety of long-acting CAB plus RPV in treatment-naive patients
- The CUSTOMIZE study, an implementation effectiveness study that evaluated the feasibility of implementing provision of long-acting CAB plus RPV in the clinic setting
- The HPTN 084 study of PrEP using CAB vs TDF plus FTC in sexually active cisgender women
- The CALIBRATE and CAPELLA studies of long-acting lenacapavir in treatment-naive and treatment-experienced patients, respectively
In addition, Drs. Cocohoba and Schafer discuss key considerations of these medications, including cost and acquisition logistics.
Presenters:
Jennifer Cocohoba, PharmD
Professor
Department of Clinical Pharmacy
University of California, San Francisco
San Francisco, California
Jason Schafer, PharmD
Professor and Vice Chair
Jefferson College of Pharmacy
Thomas Jefferson University
Philadelphia, Pennsylvania
Content based on conference coverage of IAS 2021 with educational rant support from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp.; and ViiV Healthcare.
Link to full program:
https://bit.ly/3z8SBnC
In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including:
- WHO Global Clinical Platform: COVID-19 outcomes in PWH
- 2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO)
- Investigational antiretroviral use
- CAB LA + RPV LA in treatment-naive PWH (FLAIR)
- Investigational antiretroviral agents
- LEN (CAPELLA, CALIBRATE)
- ISL (P011, P016)
- Alternative BPaL dosing in treatment of drug-resistant TB (ZeNix)
Babafemi Taiwo, MBBS
Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP.; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Follow along with an expanded slideset at:
https://bit.ly/3syWD5T
Link to full program:
https://bit.ly/3z8SBnC
During this episode, Darrell H. S. Tan, MD, FRCPC, PhD, discusses approved and guideline-recommended oral HIV PrEP regimens and provides key insights on determining PrEP candidacy as well as important considerations for specific populations/clinical scenarios, including adolescents, pregnancy/breastfeeding, and transgender individuals.
Presenter:
Darrell H. S. Tan, MD, FRCPC, PhD
Associate Professor
Division of Infectious Diseases
University of Toronto
Clinician-Scientist
Division of Infectious Diseases
St. Michael’s Hospital
Toronto, Canada
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3AFvsZY
In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels. Their conversation highlights a need for patient education and shared decision-making.
Presenter:
Anna Christina L. dela Cruz, MD
Associate Professor
Division of Digestive Diseases and Nutrition
Department of Internal Medicine
University of Kentucky
Lexington, Kentucky
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3u196yK
In episode 4 of an ongoing series of sharing sessions between a physician and patient, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, discusses hepatitis B diagnosis and treatment with his patient, Mark. The conversation focuses on Mark’s missed HBV diagnosis and likely reactivation following treatment for rheumatoid arthritis and raises awareness for needed improvements to communication between multidisciplinary healthcare teams.
Presenter:
Geoffrey M. Dusheiko MD, FCP(SA), FRCP
Emeritus Professor of Medicine
University College London School of Medicine
Kings College Hospital
London, United Kingdom
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3u196yK
In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and Joseph K. Lim, MD, examine the HCV burden and care disparities in specific populations, including Black, Hispanic, Asian, American Indian, and Alaska Native persons, and strategies to address barriers to care.
Oluwaseun Falade-Nwulia, MBBS, MPH
Associate Professor
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Attending
Division of Infectious Diseases
Johns Hopkins Hospital
Baltimore, Maryland
Joseph K. Lim, MD
Professor of Medicine
Director, Clinical Hepatology
Vice-Chief
Section of Digestive Diseases
Yale University School of Medicine
New Haven, Connecticut
Content based on a CME program supported by educational grants provided by AbbVie, Gilead Sciences, Inc., and Janssen Therapeutics, Division of Janssen Products, LP
To follow along, download the slides at:
https://bit.ly/36UDLVi
Link to full program:
https://bit.ly/3kKIb9a
In this episode, Stefan Zeuzem, MD, discusses exciting new data on viral hepatitis reported at the virtual EASL 2021, including new findings on treatment of HDV, treatment of HBV and HCV in children, linking patients to care, and new molecules being investigated for HBV cure.
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany
Content based on a CME program supported by educational grants provided by AbbVie, Antios Therapeutics, and Gilead Sciences, Inc.
To follow along, download the slides at:
https://bit.ly/3rl8AeS
Link to full program:
https://bit.ly/3ky46QK
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode,Drs Elizabeth Bukusi, Peter Godfrey-Faussett, and Nina Russell discuss promising advances in the field of HIV vaccine research and how we can prepare for optimal rollout of an eventual HIV vaccine.
Presenters:
Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD , PGD (Research Ethics), MBE (Research Ethics), CIP
Senior Principal Clinical Research Scientist
Center for Microbiology Research
KEMRI
Research Professor
Departments of Global Health and Obstetrics and Gynecology
University of Washington,
Nairobi, Kenya
Seattle, Washington
Peter Godfrey-Faussett, MBBS, FRCP(UK)
Science Advisor
United Nations Joint Programme on HIV (UNAIDS)
Professor of Infectious Diseases and International Health
London School of Hygiene and Tropical Medicine
London, United Kingdom
Nina Russell, MD
Director for TB and HIV Prevention
Bill & Melinda Gates Foundation
Seattle, Washington
Link to full series:
https://bit.ly/2UgrQ12
Link to the HIV unmuted series from IAS: https://hivunmuted.iasociety.org/
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
In this podcast, Spencer H. Durham, PharmD, BCPS, BCIDP; Stefan Gravenstein, MD, MPH; and Barbara Resnick, PhD, CRNP, discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults. Following their dialogue, the faculty field questions from healthcare professionals.
Presenters:
Spencer H. Durham, PharmD, BCPS, BCIDP
Associate Clinical Professor of Pharmacy Practice
Director, Alumni & Professional Affairs Clinical Affairs & Outreach
Auburn University Harrison School of Pharmacy
Auburn, Alabama
Stefan Gravenstein, MD, MPH
Director
Division of Geriatrics and Palliative Medicine
The Warren Alpert Medical School of Brown University
Providence, Rhode Island
Barbara Resnick, PhD, CRNP
Professor
School of Nursing
University of Maryland
Nurse Practitioner
Roland Park Place
Baltimore, Maryland
Content based on an online CME program supported by educational grants from Janssen Therapeutics, Division of Janssen Products, LP.
Link to full program:
https://bit.ly/3kvr8ro
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Swati Gupta and Mr. Marc Dixneuf discuss how to broaden global advocacy and increase investment for an HIV vaccine.
Presenters:
Swati Gupta, DrPH, MPH
Vice President and Head of Emerging Infectious Diseases and Scientific Strategy
International AIDS Vaccine Initiative
New York, New York
Marc Dixneuf, PhD
Director General
AIDES
Pantin, France
Special Commentator:
Jonathan Weber, MB, BChir, PhD, FRCP, FRCPath, FMed Sci
Dean of the Faculty of Medicine
Imperial College
London, United Kingdom
Link to full series:
https://bit.ly/3ytytMY
Link to the HIV unmuted series from IAS:
https://bit.ly/3f5qC0d
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
In this episode, Jehan Budak, MD, discusses the use of HIV-ASSIST, a free, online, decision-support tool to inform ART selection.
Jehan Budak, MD
Assistant Professor
Division of Allergy & Infectious Diseases
University of Washington
Seattle, Washington
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Theratechnologies; and ViiV Healthcare.
Link to full program:
https://bit.ly/33RZ9Zy
In this episode, Latesha Elopre, MD, MSPH, explains how to initiate pre-exposure prophylaxis (PrEP), including in underserved communities, with examples on overcoming barriers and improving access.
Listen as she gives her perspectives on:
- Evidence for PrEP efficacy in the DISCOVER study
- Recommendations in MSM, heterosexual men and women, injection drug users, and adolescents and adults weighing more than 77 lb
- CDC guidance
- How PrEP is underused, including racial/ethnic disparities
- Strategies to overcoming barriers
Presenter:
Latesha Elopre, MD, MSPH
Assistant Professor
Division of Infectious Diseases
Director of Diversity and Inclusion
General Medical Education
University of Alabama at Birmingham
Birmingham, Alabama
Follow along with the slides at:
https://bit.ly/3ABCNL8
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of:
- ATLAS and FLAIR studies of long-acting injectable CAB + RPV
- ATLAS 2M dosing study
- FDA approval and DHHS statement on use of long-acting injectable ART
- Studies on whether an oral lead-in is needed
Presenter:
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Follow along with the slides at:
https://bit.ly/3hNfHII
See the entire program at:
https://bit.ly/2TXTYWx
In this episode, Joseph J. Eron, Jr., MD, and Darcy Wooten, MD, share insights on HIV antiretroviral therapy safety and tolerability including recent data on weight gain and metabolic implications with INSTIs and NRTIs as well as the latest updates and recommendations on dolutegravir and pregnancy.
Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California
Content based on a CME program supported by independent educational grants from Janssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare
Link to full program:
https://bit.ly/3ydMtcL
Listen to expert insights from Joseph J. Eron, Jr., MD, on exciting data about investigational agents (dapivirine ring, islatravir, lenacapavir, broadly neutralizing antibodies) for next-generation HIV prevention.
Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Link to full program:
https://bit.ly/3ux6FF8
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this episode, Dr. Susan Buchbinder and Mr. Jontraye Davis discuss what has been learned and built through the past 40 years of HIV vaccine research, including how HIV vaccine scientific advancements and infrastructure were critical to the success of developing a COVID-19 vaccine.
Presenters:
Susan Buchbinder, MD
Clinical Professor
Departments of Medicine, Epidemiology and Biostatistics
University of California, San Francisco
Director, Bridge HIV
San Francisco Department of Public Health
San Francisco, California
Jontraye Davis, MHA, PMD Pro
Community Program Manager
FHI 360
Adjunct Instructor
North Carolina Central University
Durham, North Carolina
Special Commentator:
Jerome H. Kim, MD
Director General
International Vaccine Institute
Seoul, South Korea
Link to full series:
https://bit.ly/3ytytMY
Link to the HIV unmuted series from IAS:
https://bit.ly/3f5qC0d
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
In this episode, David A. Wohl, MD, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.
David A. Wohl, MD
Professor of Medicine
School of Medicine
Site Leader, AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director, HIV Services
North Carolina Department of Correction
Raleigh, North Carolina
Link to full program:
https://bit.ly/3ux6FF8
In this episode, Roger Bedimo, MD, MS, FACP; Princy N. Kumar, MD, FIDSA, MACP; and Brian Wood, MD, answer healthcare professionals’ most pressing questions on caring for heavily treatment–experienced patients with HIV.
Faculty:
Roger Bedimo, MD, MS, FACP
Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas
Princy N. Kumar, MD, FIDSA, MACP
Professor of Medicine and Microbiology
Chief, Division of Infectious Diseases and Tropical Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC
Brian Wood, MD
Associate Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington
Seattle, Washington
Content based on an online CME/CPE-certified program supported by educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3g8aBHs
In this episode, the first in a yearlong series on Key Decisions in HIV Care, Daniel R. Kuritzkes, MD, and Chloe Orkin, MBChB, FRCP, MD, discuss important considerations when switching ART in patients with viral suppression on their current regimen, including guideline recommendations and data supporting different switch regimen options such as single-tablet triple therapy, 2-drug oral regimens, doravirine-based regimens, and long-acting injectable therapy. Following their dialogue, the faculty field questions from healthcare professionals.
Presenters:
Daniel R. Kuritzkes, MD
Chief, Division of Infectious
Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.
Link to full program:
https://bit.ly/2TXTYWx
Listen to expert insights from W. David Hardy, MD, on current options for pre-exposure prophylaxis and exciting new data on next-generation HIV prevention.
W. David Hardy, MD
Scientific and Medical Consultant
Adjunct Clinical Professor of Medicine
Division of Infectious Diseases
Keck School of Medicine of USC
Los Angeles, California
Content based on a CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic. In this first episode, Dr. Linda-Gail Bekker and Ms. Maureen Luba discuss why an HIV vaccine remains the ultimate game-changer to ending the epidemic and the gaps it will address in the expanding HIV prevention landscape.
Presenters:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Chief Operating Officer
Desmond Tutu HIV Foundation
Deputy Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Maureen Luba
Africa Region Advocacy Advisor
Global Advocacy for HIV Prevention
AIDS Vaccine Advocacy Coalition
Link to full series:
https://bit.ly/3ytytMY
Link to the HIV unmuted series from IAS:
https://bit.ly/3f5qC0d
Content is part of a CME-certified educational program that is supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
In this episode, Daniel R. Kuritzkes, MD, and Michelle S. Cespedes, MD, MS, discuss new ART data from virtual CROI 2021.
Michelle S. Cespedes, MD, MS
Associate Professor of Medicine
Division of Infectious Disease
Department of Medicine
Icahn School of Medicine at Mount Sinai
Attending Physician
Mount Sinai Medical Center
New York, New York
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content based on a CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
In this episode, Ethel D. Weld, MD, PhD, demonstrates the use of HIV-ASSIST, a free, online, decision support tool to inform ART selection.
Ethel D. Weld, MD, PhD
Assistant Professor of Medicine, Pharmacology, & Molecular Sciences
Division of Clinical Pharmacology
Department of Infectious Diseases
Johns Hopkins University School of Medicine
Attending Physician
Inpatient HIV Service
General Infectious Diseases Consult Services
Johns Hopkins Hospital
Baltimore, Maryland
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Theratechnologies; and ViiV Healthcare.
Link to full program:
https://bit.ly/33RZ9Zy
In episode 3 of an ongoing series of sharing sessions between a physician and patient, Jordan J. Feld, MD, MPH, and Wendy, who is living with chronic hepatitis B, discuss the challenges of determining the best time to start treatment. The conversation focuses on incorporating shared decision-making, particularly for cases that are not straight forward and do not fit into an one specific category outlined by the guidelines.
Presenter:
Jordan J. Feld, MD, MPH
Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3u196yK
In this episode, William R. Short, MD, MPH, AAHIVS, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Content based on a CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/3ux6FF8
In Part 4 of this 4-part series, listen to Howard Grossman, MD, and Cristina Mussini, MD, answer healthcare professionals’ questions on vaccine recommendations, bone health and fragility fractures, and racial disparities and social determinants that affect caring for patients aging with HIV.
Presenters:
Howard Grossman, MD
Clinical Affiliate Assistant Professor
Department of Integrated Medical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida
Medical Director, West Palm Beach, Wilton Manors, and Key West
Midway Specialty Care
Wilton Manors, Florida
Cristina Mussini, MD
Head, Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Disease
Infectious Disease Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy
Content based on an online CME/CE/CPE-certified program supported by educational grants from Gilead Sciences, Inc.; Merck Sharp & Dohme Corp.; and ViiV Healthcare.
Link to full program:
http://bit.ly/32JD145
In this episode, Drs José R. Arribas, Andrew Carr, and Lynora Saxinger discuss simplification strategies for a virologically suppressed patient with HIV and a complex ART treatment history.
Presenters:
José R. Arribas, MD
Research Director, HIV and Infectious Diseases
Hospital La Paz IdiPAZ
Madrid, Spain
Andrew Carr, MBBS, MD, FRACP, FRCPA
Professor of Medicine
University of New South Wales
Director, HIV and Immunology Unit
St Vincent’s Hospital
Sydney, Australia
Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency
Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta
Canada
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3xdgcTk
In this episode, Drs José R. Arribas, Andrew Carr, and Lynora Saxinger discuss ART safety and management in a woman who wishes to conceive.
Presenters:
José R. Arribas, MD
Research Director, HIV and Infectious Diseases
Hospital La Paz IdiPAZ
Madrid, Spain
Andrew Carr, MBBS, MD, FRACP, FRCPA
Professor of Medicine
University of New South Wales
Director, HIV and Immunology Unit
St Vincent’s Hospital
Sydney, Australia
Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency
Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta
Canada
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3xdgcTk
In this episode, Drs José R. Arribas, Andrew Carr, and Lynora Saxinger discuss weight gain concerns for a patient with initiating ART.
Presenters:
José R. Arribas, MD
Research Director, HIV and Infectious Diseases
Hospital La Paz IdiPAZ
Madrid, Spain
Andrew Carr, MBBS, MD, FRACP, FRCPA
Professor of Medicine
University of New South Wales
Director, HIV and Immunology Unit
St Vincent’s Hospital
Sydney, Australia
Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency
Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta
Canada
Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/3xdgcTk
In episode 2 of an ongoing series of sharing sessions between a physician and patient, Robert Gish, MD, FAASLD, and patient advocate, Alan Wang, discuss stigma as a barrier to optimal HBV care and treatment. The conversation focuses on how stigma affected Alan’s engagement with his care and strategies to overcome stigma as a barrier to HBV care.
Presenter:
Robert Gish, MD, FAASLD
Medical Director
Hepatitis B Foundation
Medical Director
Asian Pacific Health Foundation
San Diego, California
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3u196yK
| In episode 1 of this ongoing series, listen to a conversation between Grace LH Wong, MD, and her patient, Ms. Chan, on the shared decision for Ms. Chan to start treatment for hepatitis B infection during her pregnancy.Presenter:Grace LH Wong, MDProfessorDivision of Gastroenterology and HepatologyDepartment of Medicine and TherapeuticsThe Chinese University of Hong KongHonorary ConsultantDivision of Gastroenterology and HepatologyDepartment of Medicine and TherapeuticsPrince of Wales HospitalHong KongContent based on an online CME program supported by an independent educational grant from Gilead Sciences. |
Link to full program:
https://bit.ly/3u196yK
In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses exciting new HIV data reported at the virtual CROI 2021, including new findings on HIV PrEP, HIV and COVID-19, ART in pregnancy and the postpartum period, as well as on the comparative efficacy of various ARV regimens.
Presenter:
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Link to full program:
http://bit.ly/3eUPAj9
In episode 17 of this series, Arthur Kim, MD, provides a brief update on the latest COVID-19 treatment options and guidelines. After the update, Dr. Kim answers questions submitted by healthcare professionals on various aspects of COVID-19.
Presenter:
Arthur Kim, MD
Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Dr. Bekker discusses results from key studies reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, and implantable options. In addition, Dr. Bekker will discuss several studies evaluating different aspects of PrEP implementation and acceptance as well as considerations for multipurpose prevention strategies.
Presenter:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Content based on a CME program supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Link to full program:
http://bit.ly/3s41GtM
In this episode, Dr. Jens Lundgren discusses results from key studies reported at the IAS COVID-19 Conference: Prevention, including new findings on potential SARS-CoV-2 suppressive therapies, strategies for vaccination and mass testing, and interventions to prevent transmission of COVID-19 while maintaining desired outcomes in HIV care.
Jens D. Lundgren, MD, DMSc
Professor
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Content based on a CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
http://bit.ly/3avWfhs
In this episode, Part 16 of an ongoing series, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, provides a brief update on emerging COVID-19 variants and their potential impacts on vaccine efficacy. After the update, Professor Lewin answers questions submitted by healthcare professionals on various aspects of COVID-19.
Presenter:
Sharon R. Lewin, AO, FRACP, PhD, FAHMS
Director, The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Part 3 of a 4-part series, Dr. Monica Gandhi, Dr. Rajesh Gandhi, and Dr. Josep Llibre discuss key health challenges faced by aging patients with HIV and answer clinicians’ questions on HIV treatment considerations and on prevention, screening, and treatment of common age-related comorbidities.
Presenters:
Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California
Rajesh T. Gandhi, MD
Professor of Medicine
Department of Infectious Diseases
Harvard Medical School
Physician, Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts
Josep M. Llibre, MD, PhD
Senior Consultant Physician and Clinical Researcher
Department of Infectious Diseases
Lluita Contra La SIDA Foundation
University Hospital, Germans Trias i Pujol
Badalona
Barcelona, Spain
Content based on an online CME/CE/CPE-certified program supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and ViiV Healthcare.
Link to full program:
http://bit.ly/32JD145
In this episode, Part 15 of an ongoing series, Roger Paredes, MD, PhD, provides a brief update on emerging COVID-19 variants and their potential impacts on the pandemic. After the update, Dr. Paredes answers clinician questions on various aspects of COVID-19.
Presenter:
Roger Paredes, MD, PhD
Section Chief, Infectious Diseases Department
Germans Trias i Pujol University Hospital
Head of the Microbial Genomics Group
IrsiCaixa AIDS Research Institute
Badalona, Catalonia, Spain
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Part 14 of an ongoing series, Vikramjit Mukherjee, MD, provides a brief update on COVID-19 mortality trends, including the latest data on overall and in-hospital fatality rates. After the update, Dr. Mukherjee answers clinician questions on various aspects of COVID-19.
Presenter:
Vikramjit Mukherjee, MD
Assistant Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
New York University School of Medicine
Director, Medical Intensive Care Unit
Bellevue Hospital
New York, New York
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
http://bit.ly/3eDoJF0
In this episode, Joseph J. Eron, Jr., MD; and Daniel R. Kuritzkes, MD; discuss evolving issues in first-line antiretroviral therapy, including 2-drug therapy, weight gain, and safety during conception and pregnancy.
Presenters:
Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology
University of North Carolina
School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
http://bit.ly/34fVILZ
In this episode, the third in a 3-part series on Ending the HIV Epidemic, Judith Feinberg, MD, and Kenneth Mayer, MD, discuss the important role of HIV pre-expsoure prophylaxis (PrEP) for preventing HIV infection among at-risk individuals and critical strategies for effective PrEP implementation among principle populations, including men who have sex with men and transgender women, heterosexual cisgender women, and people who inject drugs. Following their dialogue, the faculty field clinician questions on HIV prevention.
Presenters:
Judith Feinberg, MD
Professor
Attending Physician
Departments of Medicine and Behavioral Medicine & Psychiatry
West Virginia University School of Medicine
Morgantown, West Virginia
Kenneth Mayer, MD
Infectious Disease Attending
Beth Israel Deaconess Medical Center
Professor of Medicine
Harvard Medical School
Medical Research Director
Fenway Community Health
Boston, Massachusetts
Content based on an online CME program supported by educational grants from Gilead Sciences and ViiV Healthcare and produced in collaboration with PCE and HealthHIV.
Link to full program:
http://bit.ly/3263Q1s
| In this episode, Roger Bedimo, MD, MS, FACP, and Eric S. Daar, MD, discuss caring for heavily treatment–experienced patients with HIV, including assessment of virologic failure and current treatment options for patients with multiclass drug resistance.Presenters:Roger Bedimo, MD, MS, FACP Professor of MedicineDivision of Infectious Diseases University of Texas Southwestern Medical Center Section ChiefDivision of Infectious Diseases Department of Internal Medicine VA North Texas Health Care System Dallas, TexasEric S. Daar, MDChiefDivision of HIV Medicine Harbor-UCLA Medical Center Professor of MedicineDavid Geffen School of Medicine at UCLA Los Angeles, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare. |
Link to full program:
http://bit.ly/34fVILZ
In this episode, Part 13 of an ongoing series, Jens D. Lundgren, MD, DMSc, provides a brief update monoclonal antibody treatments for COVID-19, including the FDA Emergency Use Authorization for bamlanivimab and discusses the recently released information on COVID-19 vaccine efficacy. After the update, Professor Lundgren answers clinician questions on various aspects of COVID-19.
Presenter:
Jens D. Lundgren, MD, DMSc
Professor
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
| In this episode, the second in a 3-part series on Ending the HIV Epidemic, Jason Halperin, MD, MPH, and Aadia I. Rana, MD, discuss treatment as prevention, the critical infrastructure needed to implement rapid ART, the importance of routinely assessing for barriers to care, and real-time monitoring strategies that improve patient adherence and engagement. Following their dialogue, the faculty field clinician questions on HIV treatment and retention in care.Presenters:Jason Halperin, MD, MPHAssistant Professor of MedicineDepartment of Infectious DiseasesTulane UniversityInfectious Disease PhysicianCrescentCareNew Orleans, LouisianaAadia I. Rana, MDAssociate Professor of MedicineDivision of Infectious Diseases The University of Alabama at Birmingham 1917 ClinicBirmingham, AlabamaContent based on an online CME program supported by educational grants from Gilead Sciences and ViiV Healthcare and produced in collaboration with PCE and HealthHIV. |
Link to full program:
https://bit.ly/3263Q1s
| In this episode, Dr. Terrault discusses results from key viral hepatitis studies reported at the American Association for the Study of LiverDiseases (AASLD) 2020 annual conference, The Liver Meeting Digital Experience, including new findings on HBV treatment and management, hepatocellular carcinoma risk, and emerging approaches to HCV care in underserved populations.Presenter:Norah Terrault, MD, MPHProfessor of MedicineChief of Gastrointestinal and Liver DiseasesUniversity of Southern CaliforniaLos Angeles, CaliforniaContent based on a CME program supported by an independent educational grant from Gilead Sciences, Inc. |
Link to full program:
https://bit.ly/37bBrce
In this episode, Brian Wood, MD, discusses HIV treatment safety and tolerability data from 2020 conferences and addresses how he manages ARV-associated weight gain his patients and how the latest data on ART safety during conception and pregnancy impact his treatment recommendations.
Presenters:
Brian Wood, MD
Associate Professor of Medicine
Division of Allergy and Infectious Diseases
University of Washington
Seattle, Washington
Content based on an online CME/CE/CPE-certified program supported by educational grants from Janssen Therapeutics, Division of Janssen Products, LP.
Link to full program:
https://bit.ly/38YZVrz
In this episode, Part 2 of an 4-part series, Dr. Jonathan Appelbaum, Dr. Howard Grossman, and Professor Jürgen Rockstroh discuss key health challenges faced by aging patients with HIV and answer clinicians’ questions on HIV treatment considerations and on prevention, screening, and treatment of common age-related comorbidities.
Presenters:
Jonathan Appelbaum MD, FACP, AAHIVS
Laurie L. Dozier Jr, MD, Education Director
Professor of Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida
Howard Grossman, MD
Clinical Affiliate Assistant Professor
Department of Integrated Medical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Florida
Medical Director, West Palm Beach, Wilton Manors, and Key West
Midway Specialty Care
Wilton Manors, Florida
Jürgen Rockstroh, MD
Professor of Medicine
University of Bonn
Bonn, Germany
Content based on an online CME/CE/CPE-certified program supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and ViiV Healthcare.
Link to full program:
https://bit.ly/32JD145
In this episode, Dr. Joseph Eron and Dr. Jason Halperin discuss caring for complex HIV cases, including patients with underlying resistance or comorbidities.
Presenters:
Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Jason Halperin, MD, MPH
Assistant Professor of Medicine
Department of Infectious Diseases
Tulane University
Infectious Disease Physician
CrescentCare
New Orleans, Louisiana
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/34fVILZ
In this episode, Part 12 of an ongoing series, David Heymann, BA, MD, DTM&H, provides a brief update on strategies for moving forward and living safely within the continued COVID-19 pandemic. After the update, Professor Heymann answers clinician questions on various aspects of COVID-19.
Presenter:
David Heymann, BA, MD, DTM&H
Professor of Infectious Disease Epidemiology
London School of Hygiene & Tropical Medicine
London, England
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, the first in a 3-part series on Ending the HIV Epidemic, Lisa K. Fitzpatrick, MD, MPH, MPA, and David Malebranche, MD, MPH, discuss strategies to expand early HIV testing, maximize patient engagement in HIV care, navigate emerging clusters of HIV infection, and combat HIV-related stigma. Following their dialogue, the faculty field clinician questions on HIV diagnosis and management.
Presenters:
Lisa K. Fitzpatrick, MD, MPH, MPA
Professorial Lecturer
Department of Epidemiology
George Washington University School of Public Health
Interim Medical Director
BlueRock Care
Washington, DC
David J. Malebranche, MD, MPH
Board-Certified Internal Medicine Physician
HIV Specialist
Content based on an online CME program supported by educational grants from Gilead Sciences and ViiV Healthcare and produced in collaboration with PCE and HealthHIV.
Link to full program:
https://bit.ly/3263Q1s
In this episode, Dr. Gandhi discusses results from key studies reported at the virtual IDWeek 2020 conference, including new findings on transmission in different settings, symptom progression and clinical outcomes, detection of non-SARS-CoV-2 viruses during the pandemic, and treatment and prevention strategies.
Presenter:
Rajesh T. Gandhi, MD
Professor of Medicine
Department of Infectious Diseases
Harvard Medical School
Physician, Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts
Content based on a CME program supported by an independent educational grant from Gilead Sciences, Inc.
Link to full program:
https://bit.ly/35HxQS8
In this episode, Part 11 of an ongoing series, Sharon R. Lewin AO, FRACP, PhD, FAHMS, provides a brief update on the role of interferons in COVID-19. After the update, Dr. Lewin answers clinician questions on various aspects of COVID-19.
Presenter:
Sharon R. Lewin AO, FRACP, PhD, FAHMS
Director,
The Peter Doherty Institute for Infection and Immunity
Melbourne Laureate Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Diseases Physician
Alfred Hospital and Royal Melbourne Hospital
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Dr. Sherer discusses results from key studies reported at the 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2020 Virtual), including studies on long-term 2-drug and 3-drug antiretroviral therapy, newer 3-drug regimens in patients with baseline NRTI resistance, investigational HIV treatment approaches, and important comoribidities in patients with HIV, including COVID-19.
Presenter:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
University of Chicago
Chicago, Illinois
Content based on a CME program supported by independent educational grants from Gilead Sciences, Inc., Janssen Therapeutics, Division of Janssen Products, LP, and ViiV Healthcare.
Link to full program:
https://bit.ly/35nGqph
In this episode, Part 10 of an ongoing series, Wong Chen Seong, MBBS, MRCP(UK), FAMS, provides a brief update on COVID-19 and HIV. After the update, Dr. Wong answers clinician questions on various aspects of COVID-19.
Presenter:
Wong Chen Seong, MBBS, MRCP(UK), FAMS
Head, NCID Clinical HIV Programme
Deputy Director, National HIV Programme
National Centre for Infectious Diseases
Consultant
Department of Infectious Diseases
Tan Tock Seng Hospital
Programme Director
NHG Infectious Diseases Residency Programme
Adjunct Assistant Professor
Yong Loo Lin School of Medicine
National University of Singapore
Singapore
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Dr. Rath discusses results from key studies reported at the European Society of Clinical Microbiology and Infectious Diseases Conference on Corona Virus Disease (ECCVID), including studies on COVID-19 screening and diagnostics, vaccines, prevention strategies, social disparities, and therapeutics.
Presenter:
Barbara Rath, MD, PhD, HDR
Co-founder & Chair
The Vienna Vaccine Safety Initiative
Research Director
Université de Bourgogne Franche-Comté, France
Honorary Professor
Executive Board Member
ESGREV (Respiratory Virus Study Group for ESCMID)
Content based on CME program supported by an independent educational grant from Merck & Co., Inc.
Link to full program:
https://bit.ly/37e6Hcc
In this episode, Part 9 of an ongoing series, Lynora Saxinger, MD, FRCPC, CTropMed, provides a brief update on key concepts in COVID-19 immunity and the latest information on treatment strategies. After the update, Dr. Saxinger answers clinician questions on various aspects of COVID-19.
Presenter:
Lynora Saxinger, MD, FRCPC, CTropMed
Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency Coordination Centre
Associate Professor
Department of Medicine
Division of Infectious Diseases
University of Alberta
Edmonton, Albert
Canada
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Part 8 of an ongoing series, Paul E. Sax, MD, provides a brief update on current treatment options for COVID-19. After the update, Dr. Sax answers clinician questions on various aspects of COVID-19.
Presenter:
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, W. David Hardy, MD, discusses current guidelines and clinical trial data informing optimal selection of first-line antiretroviral therapy for HIV.
Presenter:
W. David Hardy, MD
Scientific and Medical Consultant
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to full program:
https://bit.ly/34fVILZ
In this episode, Part 7 of an ongoing 12-part COVID-19 series, Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS, provides a brief update on COVID-19 risk and prevention strategies among healthcare workers. After the update, Professor Leo answers clinician questions on various aspects of COVID-19.
Presenter:
Leo Yee-Sin, MBBS, MPH, MRCP, FRCP, FAMS
Professor
Lee Kong Chian School of Medicine
Saw Swee Hock School of Public Health
Nanyang Technological University
National University of Singapore
Senior Consultant
National Centre for Infectious Disease
Singapore
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Part 6 of an ongoing 12-part COVID-19 series, Jens D. Lundgren, MD, DMSc, provides a brief update on vaccine development and treatment strategies. After the update, Dr. Lundgren answers clinician questions on various aspects of COVID-19.
Note that this podcast was recorded on August 4, 2020. Some information may have changed since that time.
Presenter:
Jens D. Lundgren, MD, DMSc
Professor
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospitalet, University of Copenhagen
Copenhagen, Denmark
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Part 1 of an 4-part series, Dr. Joseph J. Eron, Jr., Professor Chloe Orkin, and Dr. Paul E. Sax, discuss key health challenges faced by aging patients with HIV and answer clinicians’ questions on HIV treatment considerations and on prevention, screening, and treatment of common age-related comorbidities.
Presenters:
Joseph J. Eron, Jr., MD
Professor of Medicine and Epidemiology
University of North Carolina
School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Paul E. Sax, MD
Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Content based on an online CME/CE/CPE-certified program supported by educational grants from Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and ViiV Healthcare.
Link to full program:
https://bit.ly/32JD145
In this episode, Dr. Stefan Zeuzem discusses results from key viral hepatitis studies reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver, including important findings from the following reports:
- Update on global progress toward HCV elimination goals
- SToP-C: HCV treatment-as-prevention in Australian prisons
- SHARED cohort: correlates of treatment failure with GLE/PIB or SOF/VEL/VOX
- Trio Health: retreating HCV with GLE/PIB or SOF/VEL/VOX after DAA failure
- Stop-NUC: discontinuation of long-term nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic HBV infection
- High-dose bulevirtide for chronic HBV/HDV coinfection
- Summary of select agents under early-phase investigation for HBV treatment
Presenter:
Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany
Content based on a CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/33nkRUI
In this episode, Part 5 of an ongoing 12-part COVID-19 series, David Heymann, BA, MD, DTM&H, provides a brief update on the epidemiology of SARS-CoV-2 and evidence-based interventions for reducing transmission,. After the update, Professor Heymann answers critical clinician questions on COVID-19 transmission and mitigation.
Presenter:
David Heymann, BA, MD, DTM&H
Professor, Infectious Disease Epidemiology,
London School of Hygiene & Tropical Medicine; and
Distinguished Fellow,
Centre on Universal Health at Chatham House, London
London, United Kingdom
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program: https://bit.ly/3eDoJF0
In this episode, Dr. Sherer discusses results from key studies reported at the International AIDS Society’s 2020 Virtual COVID-19 Conference, including studies evaluating characteristics and predictors of COVID-19 mortality, factors associated with remdesivir clinical outcomes, the effect of hydroxychloroquine coadministration on remdesivir safety and efficacy, the effect of race/ethnicity on clinical outcomes with remdesivir, and sofosbuvir/daclatasvir plus lopinavir/ritonavir for the treatment of severe COVID-19.
Presenter:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
University of Chicago
Chicago, Illinois
Content based on a CME program supported by an independent educational grant from Gilead Sciences.
Link to full program: https://bit.ly/2Q7GDp2
In this episode, Dr. Orkin discusses results from key studies reported at AIDS 2020: Virtual, with new data on the following hot topics: current ART in principal populations, including older patients and women who become pregnant; metabolic outcomes during ART; HIV and COVID-19; investigational ART strategies; and HIV prevention. The overview includes:
- The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF
- A pooled analysis of randomized trials evaluating a switch to BIC/FTC/TAF in patients 65 years of age or older with virologic suppression on their current ART
- A Kaiser Permanente study of BMI changes over time following ART initiation
- An analysis of the longitudinal prospective OPERA cohort that assessed weight change with switch from TDF to TAF
- Metabolic changes with switch from 3- or 4-drug TAF-based ART to 2-drug DTG/3TC in the TANGO study
- Updated findings from the Tsepamo birth surveillance study in Botswana evaluating the prevalence of neural tube defects by antiretroviral exposure during conception/pregnancy
- A retrospective study of COVID-19 in people with HIV presenting at 5 New York City Emergency Departments from March 2 to April 15, 2020
- An analysis of protocol-defined virologic failure in the P011 study comparing islatravir plus DOR vs DOR/3TC/TDF in treatment-naive adults
- A study evaluating the lenacapavir pharmacokinetic profile
- Results from the HPTN 083 trial investigating the efficacy and safety of long-acting injectable cabotegravir vs daily oral TDF/FTC for PrEP in MSM and TGW
Presenter:
Chloe Orkin, MBChB, FRCP, MD
Professor of HIV
Queen Mary, University of London
Consultant Physician
Lead for HIV Research
Barts Health NHS Trust
The Royal London Hospital
London, United Kingdom
Content based on a CME program supported by independent educational grants from Gilead Sciences, Merck Sharp & Dohme Corp., and ViiV Healthcare.
Link to full program: https://bit.ly/33YRz0t
In this episode, Part 4 of an ongoing 12-part COVID-19 series, Vikramjit Mukherjee, MD, provides a brief update on the latest incidence trends and a concise summary of updates to the US National Institutes of Health and the Infectious Diseases Society of America recommendations for managing COVID-19. After the update, Dr. Mukherjee answers critical clinician questions on COVID-19 transmission, diagnosis, and management.
Presenter:
Vikramjit Mukherjee, MD
Director, Medical Intensive Care Unit
Bellevue Hospital
Assistant Professor
Division of Pulmonary, Critical Care, and Sleep Medicine
NYU School of Medicine
New York, New York
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Christian B. Ramers, MD, MPH, and Sandra Springer, MD, discuss current evidence supporting the need for integrated addiction and infectious disease care and review the wide array of benefits that can be realized when these services are provided in tandem, ideally at the same clinic and by the same healthcare provider.
Presenters:
Christian B. Ramers, MD, MPH
Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California
Sandra Springer, MD
Associate Professor of Medicine
Division of Infectious Disease
Department of Internal Medicine
Yale School of Medicine
New Haven, Connecticut
Attending Physician
Section of Infectious Disease
Department of Internal Medicine
Veterans Administration Connecticut Healthcare Services
West Haven, Connecticut
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/2Zcdoqw
In this episode, Part 3 of an ongoing 12-part COVID-19 series, Sharon Lewin, AO, FRACP, PhD, FAAHMS, provides a brief update on the latest incidence trends and a concise guide to the management of mild and moderate disease. After the update, Dr. Lewin answers critical clinician questions on COVID-19 transmission, diagnosis, and management.
Presenter:
Sharon Lewin, AO, FRACP, PhD, FAAHMS
Director
The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
University of Melbourne
Consultant Infectious Disease Physician
Alfred Hospital and Royal Melbourne Hospital
Melbourne, Australia
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Part 2 of an ongoing 12-part COVID-19 series, Jens D. Lundgren, MD, DMSc, provides a brief update on the latest incidence trends, a concise guide to viral diagnostic testing, and new data on investigational treatment options. After the update, Dr. Lundgren answers critical clinician questions on COVID-19 transmission, diagnosis, and management.
Presenter:
Jens D. Lundgren, MD, DMSc
Professor
Director, Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital
University of Copenhagen
Copenhagen, Denmark
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0
In this episode, Dr. Kuritzkes and Dr. Ramers provide a case-based discussion addressing several age-related comorbidities among people with HIV, including bone loss, renal impairment, cardiovascular disease, mental health disorders, and neurocognitive disorders. Their discussion includes analysis of key data from the following HIV studies:
- DRIVE-AHEAD: Neuropsychiatric Events With First-line DOR/3TC/TDF vs EFV/FTC/TDF
- TANGO: Renal and Bone Changes With Switch to DTG/3TC
- SWORD-1/2: Renal and Bone Changes With Switch to DTG + RPV
- Study 1961: Quantitative Proteinuria by Baseline Regimen With Switch to BIC/FTC/TAF in Women
- Studies 1216 and 1160: Bone Changes With Switch to RPV/FTC/TAF
- NA-ACCORD: Increased MI Risk Among PWH
- D:A:D: Increased CVD Risk With Boosted PIs
- Danish HIV Cohort Study: Impact of Smoking on MI Risk
- D:A:D: Impact of Smoking on MI Risk
In addition, Dr. Kuritzkes and Dr. Ramers discuss relevant data and practical strategies for smoking cessation among people with HIV as well as risk factors, pathogenesis, and challenges in the clinical management of HIV-associated neurocognitive disorders.
Presenters:
Daniel R. Kuritzkes, MD
Chief, Division of Infectious Diseases
Brigham and Women’s Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Christian B. Ramers, MD, MPH
Associate Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California
Content based on an online CME program supported by an independent educational grant from ViiV Healthcare.
Link to downloadable slideset associated with this podcast: https://bit.ly/2MuoEHF
Link to full program:
https://bit.ly/3cFzy8o
In this episode, Dr. Gandhi discusses topline results from several studies investigating weight gain and metabolic outcomes with different antiretroviral therapy (ART) regimens among patients with HIV, including lipid level changes, cardiovascular disease risk, diabetes risk, and metabolic syndrome risk. The overview will include analyses from:
- The ADVANCE trial comparing initial ART with DTG plus FTC/TAF, DTG plus FTC/TDF, or EFV/FTC/TDF, including an examination of the influence of CYP2B6 polymorphisms on weight change during EFV-based therapy
- The NA-ACCORD study
- Evaluating patients with virologic suppression who switched from non–integrase inhibitor (INSTI)–based regimens to INSTI-based regimens
- Investigating the impact of initial ART regimen class on diabetes mellitus incidence
- A study investigating the association between resting metabolic rate, oxygen consumption, and dietary intake changes and body weight/composition changes following ART initiation
- A study evaluating differences in postpartum weight change with DTG-based vs EFV-based ART
In addition, Dr. Gandhi reviews new information on biomedical prevention of HIV infection, including results from several preclinical trials, a study investigating real-time urine-based testing for tenofovir levels, and the latest safety data from the phase III DISCOVER trial comparing FTC/TDF vs FTC/TAF for daily oral HIV pre-exposure prophylaxis (PrEP) among cis-gender men who have sex with men (MSM) and transgender women.
Presenter:
Monica Gandhi, MD, MPH
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Medical Director
Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California
Content based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.
Link to full program:
https://bit.ly/3bBjeoD
In this episode, Part 1 of an ongoing 12-part COVID-19 series, Vikramjit Mukherjee, MD, provides a brief update on the latest incidence trends, the role of serology in disease assessment, and newly published data from the ACTT-1 trial comparing remdesivir vs placebo for severe COVID-19 treatment. After the update, Dr. Mukherjee answers critical clinician questions on COVID-19 transmission, diagnosis, and management.
Presenter:
Vikramjit Mukherjee, MD
Director, Medical Intensive Care Unit
Bellevue Hospital
Assistant Professor
Division of Pulmonary, Critical Care, and Sleep Medicine
NYU School of Medicine
New York, New York
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program:
https://bit.ly/3eDoJF0